6	NULOJIX.xml:S1:4:1	O
ADVERSE	NULOJIX.xml:S1:6:7	O
REACTIONS	NULOJIX.xml:S1:14:9	O

The	NULOJIX.xml:S1:27:3	O
most	NULOJIX.xml:S1:31:4	O
serious	NULOJIX.xml:S1:36:7	O
adverse	NULOJIX.xml:S1:44:7	O
reactions	NULOJIX.xml:S1:52:9	O
reported	NULOJIX.xml:S1:62:8	O
with	NULOJIX.xml:S1:71:4	O
NULOJIX	NULOJIX.xml:S1:76:7	O
are	NULOJIX.xml:S1:84:3	O
:	NULOJIX.xml:S1:87:1	O

PTLD	NULOJIX.xml:S1:98:4	B-AdverseReaction
,	NULOJIX.xml:S1:102:1	O
predominantly	NULOJIX.xml:S1:104:13	O
CNS	NULOJIX.xml:S1:118:3	B-AdverseReaction
PTLD	NULOJIX.xml:S1:122:4	I-AdverseReaction
,	NULOJIX.xml:S1:126:1	O
and	NULOJIX.xml:S1:128:3	O
other	NULOJIX.xml:S1:132:5	O
malignancies	NULOJIX.xml:S1:138:12	B-AdverseReaction
[	NULOJIX.xml:S1:151:1	O
see	NULOJIX.xml:S1:152:3	O
Boxed	NULOJIX.xml:S1:158:5	O
Warning	NULOJIX.xml:S1:164:7	O
and	NULOJIX.xml:S1:174:3	O
Warnings	NULOJIX.xml:S1:180:8	O
and	NULOJIX.xml:S1:189:3	O
Precautions	NULOJIX.xml:S1:193:11	O
(	NULOJIX.xml:S1:205:1	O
5.1	NULOJIX.xml:S1:206:3	O
,	NULOJIX.xml:S1:211:1	O
5.3	NULOJIX.xml:S1:214:3	O
)	NULOJIX.xml:S1:217:1	O
]	NULOJIX.xml:S1:221:1	O

Serious	NULOJIX.xml:S1:230:7	B-Severity
infections	NULOJIX.xml:S1:238:10	B-AdverseReaction
,	NULOJIX.xml:S1:248:1	O
including	NULOJIX.xml:S1:250:9	O
JC	NULOJIX.xml:S1:260:2	B-AdverseReaction
virus	NULOJIX.xml:S1:263:5	I-AdverseReaction
-	NULOJIX.xml:S1:268:1	O
associated	NULOJIX.xml:S1:269:10	O
PML	NULOJIX.xml:S1:280:3	B-AdverseReaction
and	NULOJIX.xml:S1:284:3	O
polyoma	NULOJIX.xml:S1:288:7	B-AdverseReaction
virus	NULOJIX.xml:S1:296:5	I-AdverseReaction
nephropathy	NULOJIX.xml:S1:302:11	I-AdverseReaction
[	NULOJIX.xml:S1:314:1	O
see	NULOJIX.xml:S1:315:3	O
Warnings	NULOJIX.xml:S1:321:8	O
and	NULOJIX.xml:S1:330:3	O
Precautions	NULOJIX.xml:S1:334:11	O
(	NULOJIX.xml:S1:346:1	O
5.4	NULOJIX.xml:S1:347:3	O
,	NULOJIX.xml:S1:352:1	O
5.5	NULOJIX.xml:S1:355:3	O
,	NULOJIX.xml:S1:360:1	O
5.6	NULOJIX.xml:S1:363:3	O
)	NULOJIX.xml:S1:366:1	O
]	NULOJIX.xml:S1:370:1	O

EXCERPT	NULOJIX.xml:S1:379:7	O
:	NULOJIX.xml:S1:386:1	O
Most	NULOJIX.xml:S1:390:4	O
common	NULOJIX.xml:S1:395:6	O
adverse	NULOJIX.xml:S1:402:7	O
reactions	NULOJIX.xml:S1:410:9	O
(	NULOJIX.xml:S1:420:1	O
20%	NULOJIX.xml:S1:423:3	O
on	NULOJIX.xml:S1:427:2	O
NULOJIX	NULOJIX.xml:S1:430:7	O
treatment	NULOJIX.xml:S1:438:9	O
)	NULOJIX.xml:S1:447:1	O
are	NULOJIX.xml:S1:449:3	O
anemia	NULOJIX.xml:S1:453:6	B-AdverseReaction
,	NULOJIX.xml:S1:459:1	O
diarrhea	NULOJIX.xml:S1:461:8	B-AdverseReaction
,	NULOJIX.xml:S1:469:1	O
urinary	NULOJIX.xml:S1:471:7	B-AdverseReaction
tract	NULOJIX.xml:S1:479:5	I-AdverseReaction
infection	NULOJIX.xml:S1:485:9	I-AdverseReaction
,	NULOJIX.xml:S1:494:1	O
peripheral	NULOJIX.xml:S1:496:10	B-AdverseReaction
edema	NULOJIX.xml:S1:507:5	I-AdverseReaction
,	NULOJIX.xml:S1:512:1	O
constipation	NULOJIX.xml:S1:514:12	B-AdverseReaction
,	NULOJIX.xml:S1:526:1	O
hypertension	NULOJIX.xml:S1:528:12	B-AdverseReaction
,	NULOJIX.xml:S1:540:1	O
pyrexia	NULOJIX.xml:S1:542:7	B-AdverseReaction
,	NULOJIX.xml:S1:549:1	O
graft	NULOJIX.xml:S1:551:5	B-AdverseReaction
dysfunction	NULOJIX.xml:S1:557:11	I-AdverseReaction
,	NULOJIX.xml:S1:568:1	O
cough	NULOJIX.xml:S1:570:5	B-AdverseReaction
,	NULOJIX.xml:S1:575:1	O
nausea	NULOJIX.xml:S1:577:6	B-AdverseReaction
,	NULOJIX.xml:S1:583:1	O
vomiting	NULOJIX.xml:S1:585:8	B-AdverseReaction
,	NULOJIX.xml:S1:593:1	O
headache	NULOJIX.xml:S1:595:8	B-AdverseReaction
,	NULOJIX.xml:S1:603:1	O
hypokalemia	NULOJIX.xml:S1:605:11	B-AdverseReaction
,	NULOJIX.xml:S1:616:1	O
hyperkalemia	NULOJIX.xml:S1:618:12	B-AdverseReaction
,	NULOJIX.xml:S1:630:1	O
and	NULOJIX.xml:S1:632:3	O
leukopenia	NULOJIX.xml:S1:636:10	B-AdverseReaction
.	NULOJIX.xml:S1:646:1	O

(	NULOJIX.xml:S1:649:1	O
6.1	NULOJIX.xml:S1:650:3	O
)	NULOJIX.xml:S1:653:1	O

To	NULOJIX.xml:S1:663:2	O

report	NULOJIX.xml:S1:666:6	O
SUSPECTED	NULOJIX.xml:S1:673:9	O
ADVERSE	NULOJIX.xml:S1:683:7	O
REACTIONS	NULOJIX.xml:S1:691:9	O
,	NULOJIX.xml:S1:700:1	O
contact	NULOJIX.xml:S1:702:7	O
Bristol	NULOJIX.xml:S1:710:7	O
-	NULOJIX.xml:S1:717:1	O
Myers	NULOJIX.xml:S1:718:5	O
Squibb	NULOJIX.xml:S1:724:6	O
at	NULOJIX.xml:S1:731:2	O
1	NULOJIX.xml:S1:734:1	O
-	NULOJIX.xml:S1:735:1	O
800	NULOJIX.xml:S1:736:3	O
-	NULOJIX.xml:S1:739:1	O
721	NULOJIX.xml:S1:740:3	O
-	NULOJIX.xml:S1:743:1	O
5072	NULOJIX.xml:S1:744:4	O
or	NULOJIX.xml:S1:749:2	O
FDA	NULOJIX.xml:S1:752:3	O
at	NULOJIX.xml:S1:756:2	O
1	NULOJIX.xml:S1:759:1	O
-	NULOJIX.xml:S1:760:1	O
800	NULOJIX.xml:S1:761:3	O
-	NULOJIX.xml:S1:764:1	O
FDA	NULOJIX.xml:S1:765:3	O
-	NULOJIX.xml:S1:768:1	O
1088	NULOJIX.xml:S1:769:4	O
or	NULOJIX.xml:S1:774:2	O
www	NULOJIX.xml:S1:780:3	O
.	NULOJIX.xml:S1:783:1	O
fda	NULOJIX.xml:S1:784:3	O
.	NULOJIX.xml:S1:787:1	O
gov	NULOJIX.xml:S1:788:3	O
medwatch	NULOJIX.xml:S1:792:8	O
.	NULOJIX.xml:S1:804:1	O

6.1	NULOJIX.xml:S1:816:3	O

Clinical	NULOJIX.xml:S1:820:8	O
Studies	NULOJIX.xml:S1:829:7	O
Experience	NULOJIX.xml:S1:837:10	O

The	NULOJIX.xml:S1:851:3	O
data	NULOJIX.xml:S1:855:4	O
described	NULOJIX.xml:S1:860:9	O
below	NULOJIX.xml:S1:870:5	O
primarily	NULOJIX.xml:S1:876:9	O
derive	NULOJIX.xml:S1:886:6	O
from	NULOJIX.xml:S1:893:4	O
two	NULOJIX.xml:S1:898:3	O
randomized	NULOJIX.xml:S1:902:10	O
,	NULOJIX.xml:S1:912:1	O
active	NULOJIX.xml:S1:914:6	O
-	NULOJIX.xml:S1:920:1	O
controlled	NULOJIX.xml:S1:921:10	O
three	NULOJIX.xml:S1:932:5	O
-	NULOJIX.xml:S1:937:1	O
year	NULOJIX.xml:S1:938:4	O
trials	NULOJIX.xml:S1:943:6	O
of	NULOJIX.xml:S1:950:2	O
NULOJIX	NULOJIX.xml:S1:953:7	O
in	NULOJIX.xml:S1:961:2	O
de	NULOJIX.xml:S1:965:2	O
novo	NULOJIX.xml:S1:968:4	O
kidney	NULOJIX.xml:S1:974:6	O
transplant	NULOJIX.xml:S1:981:10	O
patients	NULOJIX.xml:S1:992:8	O
.	NULOJIX.xml:S1:1000:1	O

In	NULOJIX.xml:S1:1002:2	O
Study	NULOJIX.xml:S1:1005:5	O
1	NULOJIX.xml:S1:1011:1	O
and	NULOJIX.xml:S1:1013:3	O
Study	NULOJIX.xml:S1:1017:5	O
2	NULOJIX.xml:S1:1023:1	O
,	NULOJIX.xml:S1:1024:1	O
NULOJIX	NULOJIX.xml:S1:1026:7	O
was	NULOJIX.xml:S1:1034:3	O
studied	NULOJIX.xml:S1:1038:7	O
at	NULOJIX.xml:S1:1046:2	O
the	NULOJIX.xml:S1:1049:3	O
recommended	NULOJIX.xml:S1:1053:11	O
dose	NULOJIX.xml:S1:1065:4	O
and	NULOJIX.xml:S1:1070:3	O
frequency	NULOJIX.xml:S1:1074:9	O
[	NULOJIX.xml:S1:1084:1	O
see	NULOJIX.xml:S1:1085:3	O
Dosage	NULOJIX.xml:S1:1092:6	O
and	NULOJIX.xml:S1:1099:3	O
Administration	NULOJIX.xml:S1:1103:14	O
(	NULOJIX.xml:S1:1118:1	O
2.1	NULOJIX.xml:S1:1119:3	O
)	NULOJIX.xml:S1:1122:1	O
]	NULOJIX.xml:S1:1127:1	O
in	NULOJIX.xml:S1:1129:2	O
a	NULOJIX.xml:S1:1132:1	O
total	NULOJIX.xml:S1:1134:5	O
of	NULOJIX.xml:S1:1140:2	O
401	NULOJIX.xml:S1:1143:3	O
patients	NULOJIX.xml:S1:1147:8	O
compared	NULOJIX.xml:S1:1156:8	O
to	NULOJIX.xml:S1:1165:2	O
a	NULOJIX.xml:S1:1168:1	O
cyclosporine	NULOJIX.xml:S1:1170:12	O
control	NULOJIX.xml:S1:1183:7	O
regimen	NULOJIX.xml:S1:1191:7	O
in	NULOJIX.xml:S1:1199:2	O
a	NULOJIX.xml:S1:1202:1	O
total	NULOJIX.xml:S1:1204:5	O
of	NULOJIX.xml:S1:1210:2	O
405	NULOJIX.xml:S1:1213:3	O
patients	NULOJIX.xml:S1:1217:8	O
.	NULOJIX.xml:S1:1225:1	O

These	NULOJIX.xml:S1:1227:5	O
two	NULOJIX.xml:S1:1233:3	O
trials	NULOJIX.xml:S1:1237:6	O
also	NULOJIX.xml:S1:1244:4	O
included	NULOJIX.xml:S1:1249:8	O
a	NULOJIX.xml:S1:1258:1	O
total	NULOJIX.xml:S1:1260:5	O
of	NULOJIX.xml:S1:1266:2	O
403	NULOJIX.xml:S1:1269:3	O
patients	NULOJIX.xml:S1:1273:8	O
treated	NULOJIX.xml:S1:1282:7	O
with	NULOJIX.xml:S1:1290:4	O
a	NULOJIX.xml:S1:1295:1	O
NULOJIX	NULOJIX.xml:S1:1297:7	O
regimen	NULOJIX.xml:S1:1305:7	O
of	NULOJIX.xml:S1:1313:2	O
higher	NULOJIX.xml:S1:1316:6	O
cumulative	NULOJIX.xml:S1:1323:10	O
dose	NULOJIX.xml:S1:1334:4	O
and	NULOJIX.xml:S1:1339:3	O
more	NULOJIX.xml:S1:1343:4	O
frequent	NULOJIX.xml:S1:1348:8	O
dosing	NULOJIX.xml:S1:1357:6	O
than	NULOJIX.xml:S1:1364:4	O
recommended	NULOJIX.xml:S1:1369:11	O
[	NULOJIX.xml:S1:1381:1	O
see	NULOJIX.xml:S1:1382:3	O
Clinical	NULOJIX.xml:S1:1389:8	O
Studies	NULOJIX.xml:S1:1398:7	O
(	NULOJIX.xml:S1:1406:1	O
14.1	NULOJIX.xml:S1:1407:4	O
)	NULOJIX.xml:S1:1411:1	O
]	NULOJIX.xml:S1:1416:1	O
.	NULOJIX.xml:S1:1417:1	O

All	NULOJIX.xml:S1:1419:3	O
patients	NULOJIX.xml:S1:1423:8	O
also	NULOJIX.xml:S1:1432:4	O
received	NULOJIX.xml:S1:1437:8	O
basiliximab	NULOJIX.xml:S1:1446:11	O
induction	NULOJIX.xml:S1:1458:9	O
,	NULOJIX.xml:S1:1467:1	O
mycophenolate	NULOJIX.xml:S1:1469:13	O
mofetil	NULOJIX.xml:S1:1483:7	O
,	NULOJIX.xml:S1:1490:1	O
and	NULOJIX.xml:S1:1492:3	O
corticosteroids	NULOJIX.xml:S1:1496:15	O
.	NULOJIX.xml:S1:1511:1	O

Patients	NULOJIX.xml:S1:1513:8	O
were	NULOJIX.xml:S1:1522:4	O
treated	NULOJIX.xml:S1:1527:7	O
and	NULOJIX.xml:S1:1535:3	O
followed	NULOJIX.xml:S1:1539:8	O
for	NULOJIX.xml:S1:1548:3	O
3	NULOJIX.xml:S1:1552:1	O
years	NULOJIX.xml:S1:1554:5	O
.	NULOJIX.xml:S1:1559:1	O

CNS	NULOJIX.xml:S1:1565:3	B-AdverseReaction
PTLD	NULOJIX.xml:S1:1569:4	I-AdverseReaction
,	NULOJIX.xml:S1:1573:1	O
PML	NULOJIX.xml:S1:1575:3	B-AdverseReaction
,	NULOJIX.xml:S1:1578:1	O
and	NULOJIX.xml:S1:1580:3	O
other	NULOJIX.xml:S1:1584:5	O
CNS	NULOJIX.xml:S1:1590:3	B-AdverseReaction
infections	NULOJIX.xml:S1:1594:10	I-AdverseReaction
were	NULOJIX.xml:S1:1605:4	O
more	NULOJIX.xml:S1:1610:4	O
frequently	NULOJIX.xml:S1:1615:10	O
observed	NULOJIX.xml:S1:1626:8	O
in	NULOJIX.xml:S1:1635:2	O
association	NULOJIX.xml:S1:1638:11	O
with	NULOJIX.xml:S1:1650:4	O
a	NULOJIX.xml:S1:1655:1	O
NULOJIX	NULOJIX.xml:S1:1657:7	O
regimen	NULOJIX.xml:S1:1665:7	O
of	NULOJIX.xml:S1:1673:2	O
higher	NULOJIX.xml:S1:1676:6	O
cumulative	NULOJIX.xml:S1:1683:10	O
dose	NULOJIX.xml:S1:1694:4	O
and	NULOJIX.xml:S1:1699:3	O
more	NULOJIX.xml:S1:1703:4	O
frequent	NULOJIX.xml:S1:1708:8	O
dosing	NULOJIX.xml:S1:1717:6	O
compared	NULOJIX.xml:S1:1724:8	O
to	NULOJIX.xml:S1:1733:2	O
the	NULOJIX.xml:S1:1736:3	O
recommended	NULOJIX.xml:S1:1740:11	O
regimen	NULOJIX.xml:S1:1752:7	O
;	NULOJIX.xml:S1:1759:1	O
therefore	NULOJIX.xml:S1:1761:9	O
,	NULOJIX.xml:S1:1770:1	O
administration	NULOJIX.xml:S1:1772:14	O
of	NULOJIX.xml:S1:1787:2	O
higher	NULOJIX.xml:S1:1790:6	O
than	NULOJIX.xml:S1:1797:4	O
the	NULOJIX.xml:S1:1802:3	O
recommended	NULOJIX.xml:S1:1806:11	O
doses	NULOJIX.xml:S1:1818:5	O
and	NULOJIX.xml:S1:1824:3	O
or	NULOJIX.xml:S1:1828:2	O
more	NULOJIX.xml:S1:1831:4	O
frequent	NULOJIX.xml:S1:1836:8	O
dosing	NULOJIX.xml:S1:1845:6	O
of	NULOJIX.xml:S1:1852:2	O
NULOJIX	NULOJIX.xml:S1:1855:7	O
is	NULOJIX.xml:S1:1863:2	O
not	NULOJIX.xml:S1:1866:3	O
recommended	NULOJIX.xml:S1:1870:11	O
[	NULOJIX.xml:S1:1882:1	O
see	NULOJIX.xml:S1:1883:3	O
Dosage	NULOJIX.xml:S1:1890:6	O
and	NULOJIX.xml:S1:1897:3	O
Administration	NULOJIX.xml:S1:1901:14	O
(	NULOJIX.xml:S1:1916:1	O
2.1	NULOJIX.xml:S1:1917:3	O
)	NULOJIX.xml:S1:1920:1	O
]	NULOJIX.xml:S1:1925:1	O
.	NULOJIX.xml:S1:1926:1	O

The	NULOJIX.xml:S1:1932:3	O
average	NULOJIX.xml:S1:1936:7	O
age	NULOJIX.xml:S1:1944:3	O
of	NULOJIX.xml:S1:1948:2	O
patients	NULOJIX.xml:S1:1951:8	O
in	NULOJIX.xml:S1:1960:2	O
Studies	NULOJIX.xml:S1:1963:7	O
1	NULOJIX.xml:S1:1971:1	O
and	NULOJIX.xml:S1:1973:3	O
2	NULOJIX.xml:S1:1977:1	O
in	NULOJIX.xml:S1:1979:2	O
the	NULOJIX.xml:S1:1982:3	O
NULOJIX	NULOJIX.xml:S1:1986:7	O
recommended	NULOJIX.xml:S1:1994:11	O
dose	NULOJIX.xml:S1:2006:4	O
and	NULOJIX.xml:S1:2011:3	O
cyclosporine	NULOJIX.xml:S1:2015:12	O
control	NULOJIX.xml:S1:2028:7	O
regimens	NULOJIX.xml:S1:2036:8	O
was	NULOJIX.xml:S1:2045:3	O
49	NULOJIX.xml:S1:2049:2	O
years	NULOJIX.xml:S1:2052:5	O
,	NULOJIX.xml:S1:2057:1	O
ranging	NULOJIX.xml:S1:2059:7	O
from	NULOJIX.xml:S1:2067:4	O
18	NULOJIX.xml:S1:2072:2	O
to	NULOJIX.xml:S1:2075:2	O
79	NULOJIX.xml:S1:2078:2	O
years	NULOJIX.xml:S1:2081:5	O
.	NULOJIX.xml:S1:2086:1	O

Approximately	NULOJIX.xml:S1:2088:13	O
70%	NULOJIX.xml:S1:2102:3	O
of	NULOJIX.xml:S1:2106:2	O
patients	NULOJIX.xml:S1:2109:8	O
were	NULOJIX.xml:S1:2118:4	O
male	NULOJIX.xml:S1:2123:4	O
;	NULOJIX.xml:S1:2127:1	O
67%	NULOJIX.xml:S1:2129:3	O
were	NULOJIX.xml:S1:2133:4	O
white	NULOJIX.xml:S1:2138:5	O
,	NULOJIX.xml:S1:2143:1	O
11%	NULOJIX.xml:S1:2145:3	O
were	NULOJIX.xml:S1:2149:4	O
black	NULOJIX.xml:S1:2154:5	O
,	NULOJIX.xml:S1:2159:1	O
and	NULOJIX.xml:S1:2161:3	O
22%	NULOJIX.xml:S1:2165:3	O
other	NULOJIX.xml:S1:2169:5	O
races	NULOJIX.xml:S1:2175:5	O
.	NULOJIX.xml:S1:2180:1	O

About	NULOJIX.xml:S1:2182:5	O
25%	NULOJIX.xml:S1:2188:3	O
of	NULOJIX.xml:S1:2192:2	O
patients	NULOJIX.xml:S1:2195:8	O
were	NULOJIX.xml:S1:2204:4	O
from	NULOJIX.xml:S1:2209:4	O
the	NULOJIX.xml:S1:2214:3	O
United	NULOJIX.xml:S1:2218:6	O
States	NULOJIX.xml:S1:2225:6	O
and	NULOJIX.xml:S1:2232:3	O
75%	NULOJIX.xml:S1:2236:3	O
from	NULOJIX.xml:S1:2240:4	O
other	NULOJIX.xml:S1:2245:5	O
countries	NULOJIX.xml:S1:2251:9	O
.	NULOJIX.xml:S1:2260:1	O

Because	NULOJIX.xml:S1:2266:7	O
clinical	NULOJIX.xml:S1:2274:8	O
trials	NULOJIX.xml:S1:2283:6	O
are	NULOJIX.xml:S1:2290:3	O
conducted	NULOJIX.xml:S1:2294:9	O
under	NULOJIX.xml:S1:2304:5	O
widely	NULOJIX.xml:S1:2310:6	O
varying	NULOJIX.xml:S1:2317:7	O
conditions	NULOJIX.xml:S1:2325:10	O
,	NULOJIX.xml:S1:2335:1	O
the	NULOJIX.xml:S1:2337:3	O
adverse	NULOJIX.xml:S1:2341:7	O
reaction	NULOJIX.xml:S1:2349:8	O
rates	NULOJIX.xml:S1:2358:5	O
observed	NULOJIX.xml:S1:2364:8	O
cannot	NULOJIX.xml:S1:2373:6	O
be	NULOJIX.xml:S1:2380:2	O
directly	NULOJIX.xml:S1:2383:8	O
compared	NULOJIX.xml:S1:2392:8	O
to	NULOJIX.xml:S1:2401:2	O
rates	NULOJIX.xml:S1:2404:5	O
in	NULOJIX.xml:S1:2410:2	O
other	NULOJIX.xml:S1:2413:5	O
trials	NULOJIX.xml:S1:2419:6	O
and	NULOJIX.xml:S1:2426:3	O
may	NULOJIX.xml:S1:2430:3	O
not	NULOJIX.xml:S1:2434:3	O
reflect	NULOJIX.xml:S1:2438:7	O
the	NULOJIX.xml:S1:2446:3	O
rates	NULOJIX.xml:S1:2450:5	O
observed	NULOJIX.xml:S1:2456:8	O
in	NULOJIX.xml:S1:2465:2	O
clinical	NULOJIX.xml:S1:2468:8	O
practice	NULOJIX.xml:S1:2477:8	O
.	NULOJIX.xml:S1:2485:1	O

The	NULOJIX.xml:S1:2491:3	O
most	NULOJIX.xml:S1:2495:4	O
commonly	NULOJIX.xml:S1:2500:8	O
reported	NULOJIX.xml:S1:2509:8	O
adverse	NULOJIX.xml:S1:2518:7	O
reactions	NULOJIX.xml:S1:2526:9	O
occurring	NULOJIX.xml:S1:2536:9	O
in	NULOJIX.xml:S1:2546:2	O
20%	NULOJIX.xml:S1:2551:3	O
of	NULOJIX.xml:S1:2555:2	O
patients	NULOJIX.xml:S1:2558:8	O
treated	NULOJIX.xml:S1:2567:7	O
with	NULOJIX.xml:S1:2575:4	O
the	NULOJIX.xml:S1:2580:3	O
recommended	NULOJIX.xml:S1:2584:11	O
dose	NULOJIX.xml:S1:2596:4	O
and	NULOJIX.xml:S1:2601:3	O
frequency	NULOJIX.xml:S1:2605:9	O
of	NULOJIX.xml:S1:2615:2	O
NULOJIX	NULOJIX.xml:S1:2618:7	O
were	NULOJIX.xml:S1:2626:4	O
anemia	NULOJIX.xml:S1:2631:6	B-AdverseReaction
,	NULOJIX.xml:S1:2637:1	O
diarrhea	NULOJIX.xml:S1:2639:8	B-AdverseReaction
,	NULOJIX.xml:S1:2647:1	O
urinary	NULOJIX.xml:S1:2649:7	B-AdverseReaction
tract	NULOJIX.xml:S1:2657:5	I-AdverseReaction
infection	NULOJIX.xml:S1:2663:9	I-AdverseReaction
,	NULOJIX.xml:S1:2672:1	O
peripheral	NULOJIX.xml:S1:2674:10	B-AdverseReaction
edema	NULOJIX.xml:S1:2685:5	I-AdverseReaction
,	NULOJIX.xml:S1:2690:1	O
constipation	NULOJIX.xml:S1:2692:12	B-AdverseReaction
,	NULOJIX.xml:S1:2704:1	O
hypertension	NULOJIX.xml:S1:2706:12	B-AdverseReaction
,	NULOJIX.xml:S1:2718:1	O
pyrexia	NULOJIX.xml:S1:2720:7	B-AdverseReaction
,	NULOJIX.xml:S1:2727:1	O
graft	NULOJIX.xml:S1:2729:5	B-AdverseReaction
dysfunction	NULOJIX.xml:S1:2735:11	I-AdverseReaction
,	NULOJIX.xml:S1:2746:1	O
cough	NULOJIX.xml:S1:2748:5	B-AdverseReaction
,	NULOJIX.xml:S1:2753:1	O
nausea	NULOJIX.xml:S1:2755:6	B-AdverseReaction
,	NULOJIX.xml:S1:2761:1	O
vomiting	NULOJIX.xml:S1:2763:8	B-AdverseReaction
,	NULOJIX.xml:S1:2771:1	O
headache	NULOJIX.xml:S1:2773:8	B-AdverseReaction
,	NULOJIX.xml:S1:2781:1	O
hypokalemia	NULOJIX.xml:S1:2783:11	B-AdverseReaction
,	NULOJIX.xml:S1:2794:1	O
hyperkalemia	NULOJIX.xml:S1:2796:12	B-AdverseReaction
,	NULOJIX.xml:S1:2808:1	O
and	NULOJIX.xml:S1:2810:3	O
leukopenia	NULOJIX.xml:S1:2814:10	B-AdverseReaction
.	NULOJIX.xml:S1:2824:1	O

The	NULOJIX.xml:S1:2830:3	O
proportion	NULOJIX.xml:S1:2834:10	O
of	NULOJIX.xml:S1:2845:2	O
patients	NULOJIX.xml:S1:2848:8	O
who	NULOJIX.xml:S1:2857:3	O
discontinued	NULOJIX.xml:S1:2861:12	O
treatment	NULOJIX.xml:S1:2874:9	O
due	NULOJIX.xml:S1:2884:3	O
to	NULOJIX.xml:S1:2888:2	O
adverse	NULOJIX.xml:S1:2891:7	O
reactions	NULOJIX.xml:S1:2899:9	O
was	NULOJIX.xml:S1:2909:3	O
13%	NULOJIX.xml:S1:2913:3	O
for	NULOJIX.xml:S1:2917:3	O
the	NULOJIX.xml:S1:2921:3	O
recommended	NULOJIX.xml:S1:2925:11	O
NULOJIX	NULOJIX.xml:S1:2937:7	O
regimen	NULOJIX.xml:S1:2945:7	O
and	NULOJIX.xml:S1:2953:3	O
19%	NULOJIX.xml:S1:2957:3	O
for	NULOJIX.xml:S1:2961:3	O
the	NULOJIX.xml:S1:2965:3	O
cyclosporine	NULOJIX.xml:S1:2969:12	O
control	NULOJIX.xml:S1:2982:7	O
arm	NULOJIX.xml:S1:2990:3	O
through	NULOJIX.xml:S1:2994:7	O
three	NULOJIX.xml:S1:3002:5	O
years	NULOJIX.xml:S1:3008:5	O
of	NULOJIX.xml:S1:3014:2	O
treatment	NULOJIX.xml:S1:3017:9	O
.	NULOJIX.xml:S1:3026:1	O

The	NULOJIX.xml:S1:3028:3	O
most	NULOJIX.xml:S1:3032:4	O
common	NULOJIX.xml:S1:3037:6	O
adverse	NULOJIX.xml:S1:3044:7	O
reactions	NULOJIX.xml:S1:3052:9	O
leading	NULOJIX.xml:S1:3062:7	O
to	NULOJIX.xml:S1:3070:2	O
discontinuation	NULOJIX.xml:S1:3073:15	O
in	NULOJIX.xml:S1:3089:2	O
NULOJIX	NULOJIX.xml:S1:3092:7	O
-	NULOJIX.xml:S1:3099:1	O
treated	NULOJIX.xml:S1:3100:7	O
patients	NULOJIX.xml:S1:3108:8	O
were	NULOJIX.xml:S1:3117:4	O
cytomegalovirus	NULOJIX.xml:S1:3122:15	B-AdverseReaction
infection	NULOJIX.xml:S1:3138:9	I-AdverseReaction
(	NULOJIX.xml:S1:3148:1	O
1.5%	NULOJIX.xml:S1:3149:4	O
)	NULOJIX.xml:S1:3153:1	O
and	NULOJIX.xml:S1:3155:3	O
complications	NULOJIX.xml:S1:3159:13	B-AdverseReaction
of	NULOJIX.xml:S1:3173:2	I-AdverseReaction
transplanted	NULOJIX.xml:S1:3176:12	I-AdverseReaction
kidney	NULOJIX.xml:S1:3189:6	I-AdverseReaction
(	NULOJIX.xml:S1:3196:1	O
1.5%	NULOJIX.xml:S1:3197:4	O
)	NULOJIX.xml:S1:3201:1	O
.	NULOJIX.xml:S1:3202:1	O

Information	NULOJIX.xml:S1:3208:11	O
on	NULOJIX.xml:S1:3220:2	O
selected	NULOJIX.xml:S1:3223:8	O
significant	NULOJIX.xml:S1:3232:11	O
adverse	NULOJIX.xml:S1:3244:7	O
reactions	NULOJIX.xml:S1:3252:9	O
observed	NULOJIX.xml:S1:3262:8	O
during	NULOJIX.xml:S1:3271:6	O
clinical	NULOJIX.xml:S1:3278:8	O
trials	NULOJIX.xml:S1:3287:6	O
is	NULOJIX.xml:S1:3294:2	O
summarized	NULOJIX.xml:S1:3297:10	O
below	NULOJIX.xml:S1:3308:5	O
.	NULOJIX.xml:S1:3313:1	O

Post	NULOJIX.xml:S1:3321:4	O
-	NULOJIX.xml:S1:3325:1	O
Transplant	NULOJIX.xml:S1:3326:10	O
Lymphoproliferative	NULOJIX.xml:S1:3337:19	O
Disorder	NULOJIX.xml:S1:3357:8	O

Reported	NULOJIX.xml:S1:3369:8	O
cases	NULOJIX.xml:S1:3378:5	O
of	NULOJIX.xml:S1:3384:2	O
post	NULOJIX.xml:S1:3387:4	B-AdverseReaction
-	NULOJIX.xml:S1:3391:1	I-AdverseReaction
transplant	NULOJIX.xml:S1:3392:10	I-AdverseReaction
lymphoproliferative	NULOJIX.xml:S1:3403:19	I-AdverseReaction
disorder	NULOJIX.xml:S1:3423:8	I-AdverseReaction
(	NULOJIX.xml:S1:3432:1	O
PTLD	NULOJIX.xml:S1:3433:4	B-AdverseReaction
)	NULOJIX.xml:S1:3437:1	O
up	NULOJIX.xml:S1:3439:2	O
to	NULOJIX.xml:S1:3442:2	O
36	NULOJIX.xml:S1:3445:2	O
months	NULOJIX.xml:S1:3448:6	O
post	NULOJIX.xml:S1:3455:4	O
transplant	NULOJIX.xml:S1:3460:10	O
were	NULOJIX.xml:S1:3471:4	O
obtained	NULOJIX.xml:S1:3476:8	O
for	NULOJIX.xml:S1:3485:3	O
NULOJIX	NULOJIX.xml:S1:3489:7	O
by	NULOJIX.xml:S1:3497:2	O
pooling	NULOJIX.xml:S1:3500:7	O
both	NULOJIX.xml:S1:3508:4	O
dosage	NULOJIX.xml:S1:3513:6	O
regimens	NULOJIX.xml:S1:3520:8	O
of	NULOJIX.xml:S1:3529:2	O
NULOJIX	NULOJIX.xml:S1:3532:7	O
in	NULOJIX.xml:S1:3540:2	O
Studies	NULOJIX.xml:S1:3543:7	O
1	NULOJIX.xml:S1:3551:1	O
and	NULOJIX.xml:S1:3553:3	O
2	NULOJIX.xml:S1:3557:1	O
(	NULOJIX.xml:S1:3559:1	O
804	NULOJIX.xml:S1:3560:3	O
patients	NULOJIX.xml:S1:3564:8	O
)	NULOJIX.xml:S1:3572:1	O
with	NULOJIX.xml:S1:3574:4	O
data	NULOJIX.xml:S1:3579:4	O
from	NULOJIX.xml:S1:3584:4	O
a	NULOJIX.xml:S1:3589:1	O
third	NULOJIX.xml:S1:3591:5	O
study	NULOJIX.xml:S1:3597:5	O
in	NULOJIX.xml:S1:3603:2	O
kidney	NULOJIX.xml:S1:3606:6	O
transplantation	NULOJIX.xml:S1:3613:15	O
(	NULOJIX.xml:S1:3629:1	O
Study	NULOJIX.xml:S1:3630:5	O
3	NULOJIX.xml:S1:3636:1	O
,	NULOJIX.xml:S1:3637:1	O
145	NULOJIX.xml:S1:3639:3	O
patients	NULOJIX.xml:S1:3643:8	O
)	NULOJIX.xml:S1:3651:1	O
which	NULOJIX.xml:S1:3653:5	O
evaluated	NULOJIX.xml:S1:3659:9	O
two	NULOJIX.xml:S1:3669:3	O
NULOJIX	NULOJIX.xml:S1:3673:7	O
dosage	NULOJIX.xml:S1:3681:6	O
regimens	NULOJIX.xml:S1:3688:8	O
similar	NULOJIX.xml:S1:3697:7	O
,	NULOJIX.xml:S1:3704:1	O
but	NULOJIX.xml:S1:3706:3	O
slightly	NULOJIX.xml:S1:3710:8	O
different	NULOJIX.xml:S1:3719:9	O
,	NULOJIX.xml:S1:3728:1	O
from	NULOJIX.xml:S1:3730:4	O
those	NULOJIX.xml:S1:3735:5	O
of	NULOJIX.xml:S1:3741:2	O
Studies	NULOJIX.xml:S1:3744:7	O
1	NULOJIX.xml:S1:3752:1	O
and	NULOJIX.xml:S1:3754:3	O
2	NULOJIX.xml:S1:3758:1	O
(	NULOJIX.xml:S1:3760:1	O
see	NULOJIX.xml:S1:3761:3	O
Table	NULOJIX.xml:S1:3765:5	O
2	NULOJIX.xml:S1:3771:1	O
)	NULOJIX.xml:S1:3772:1	O
.	NULOJIX.xml:S1:3773:1	O

The	NULOJIX.xml:S1:3775:3	O
total	NULOJIX.xml:S1:3779:5	O
number	NULOJIX.xml:S1:3785:6	O
of	NULOJIX.xml:S1:3792:2	O
NULOJIX	NULOJIX.xml:S1:3795:7	O
patients	NULOJIX.xml:S1:3803:8	O
from	NULOJIX.xml:S1:3812:4	O
these	NULOJIX.xml:S1:3817:5	O
three	NULOJIX.xml:S1:3823:5	O
studies	NULOJIX.xml:S1:3829:7	O
(	NULOJIX.xml:S1:3837:1	O
949	NULOJIX.xml:S1:3838:3	O
)	NULOJIX.xml:S1:3841:1	O
was	NULOJIX.xml:S1:3843:3	O
compared	NULOJIX.xml:S1:3847:8	O
to	NULOJIX.xml:S1:3856:2	O
the	NULOJIX.xml:S1:3859:3	O
pooled	NULOJIX.xml:S1:3863:6	O
cyclosporine	NULOJIX.xml:S1:3870:12	O
control	NULOJIX.xml:S1:3883:7	O
groups	NULOJIX.xml:S1:3891:6	O
from	NULOJIX.xml:S1:3898:4	O
all	NULOJIX.xml:S1:3903:3	O
three	NULOJIX.xml:S1:3907:5	O
studies	NULOJIX.xml:S1:3913:7	O
(	NULOJIX.xml:S1:3921:1	O
476	NULOJIX.xml:S1:3922:3	O
patients	NULOJIX.xml:S1:3926:8	O
)	NULOJIX.xml:S1:3934:1	O
.	NULOJIX.xml:S1:3935:1	O

Among	NULOJIX.xml:S1:3941:5	O
401	NULOJIX.xml:S1:3947:3	O
patients	NULOJIX.xml:S1:3951:8	O
in	NULOJIX.xml:S1:3960:2	O
Studies	NULOJIX.xml:S1:3963:7	O
1	NULOJIX.xml:S1:3971:1	O
and	NULOJIX.xml:S1:3973:3	O
2	NULOJIX.xml:S1:3977:1	O
treated	NULOJIX.xml:S1:3979:7	O
with	NULOJIX.xml:S1:3987:4	O
the	NULOJIX.xml:S1:3992:3	O
recommended	NULOJIX.xml:S1:3996:11	O
regimen	NULOJIX.xml:S1:4008:7	O
of	NULOJIX.xml:S1:4016:2	O
NULOJIX	NULOJIX.xml:S1:4019:7	O
and	NULOJIX.xml:S1:4027:3	O
the	NULOJIX.xml:S1:4031:3	O
71	NULOJIX.xml:S1:4035:2	O
patients	NULOJIX.xml:S1:4038:8	O
in	NULOJIX.xml:S1:4047:2	O
Study	NULOJIX.xml:S1:4050:5	O
3	NULOJIX.xml:S1:4056:1	O
treated	NULOJIX.xml:S1:4058:7	O
with	NULOJIX.xml:S1:4066:4	O
a	NULOJIX.xml:S1:4071:1	O
very	NULOJIX.xml:S1:4073:4	O
similar	NULOJIX.xml:S1:4078:7	O
(	NULOJIX.xml:S1:4086:1	O
but	NULOJIX.xml:S1:4087:3	O
non	NULOJIX.xml:S1:4091:3	O
-	NULOJIX.xml:S1:4094:1	O
identical	NULOJIX.xml:S1:4095:9	O
)	NULOJIX.xml:S1:4104:1	O
NULOJIX	NULOJIX.xml:S1:4106:7	O
regimen	NULOJIX.xml:S1:4114:7	O
,	NULOJIX.xml:S1:4121:1	O
there	NULOJIX.xml:S1:4123:5	O
were	NULOJIX.xml:S1:4129:4	O
5	NULOJIX.xml:S1:4134:1	O
cases	NULOJIX.xml:S1:4136:5	O
of	NULOJIX.xml:S1:4142:2	O
PTLD	NULOJIX.xml:S1:4145:4	B-AdverseReaction
:	NULOJIX.xml:S1:4149:1	O
3	NULOJIX.xml:S1:4151:1	O
in	NULOJIX.xml:S1:4153:2	O
EBV	NULOJIX.xml:S1:4156:3	O
seropositive	NULOJIX.xml:S1:4160:12	O
patients	NULOJIX.xml:S1:4173:8	O
and	NULOJIX.xml:S1:4182:3	O
2	NULOJIX.xml:S1:4186:1	O
in	NULOJIX.xml:S1:4188:2	O
EBV	NULOJIX.xml:S1:4191:3	O
seronegative	NULOJIX.xml:S1:4195:12	O
patients	NULOJIX.xml:S1:4208:8	O
.	NULOJIX.xml:S1:4216:1	O

Two	NULOJIX.xml:S1:4218:3	O
of	NULOJIX.xml:S1:4222:2	O
the	NULOJIX.xml:S1:4225:3	O
5	NULOJIX.xml:S1:4229:1	O
cases	NULOJIX.xml:S1:4231:5	O
presented	NULOJIX.xml:S1:4237:9	O
with	NULOJIX.xml:S1:4247:4	O
CNS	NULOJIX.xml:S1:4252:3	O
involvement	NULOJIX.xml:S1:4256:11	O
.	NULOJIX.xml:S1:4267:1	O

Among	NULOJIX.xml:S1:4273:5	O
the	NULOJIX.xml:S1:4279:3	O
477	NULOJIX.xml:S1:4283:3	O
patients	NULOJIX.xml:S1:4287:8	O
in	NULOJIX.xml:S1:4296:2	O
Studies	NULOJIX.xml:S1:4299:7	O
1	NULOJIX.xml:S1:4307:1	O
,	NULOJIX.xml:S1:4308:1	O
2	NULOJIX.xml:S1:4310:1	O
,	NULOJIX.xml:S1:4311:1	O
and	NULOJIX.xml:S1:4313:3	O
3	NULOJIX.xml:S1:4317:1	O
treated	NULOJIX.xml:S1:4319:7	O
with	NULOJIX.xml:S1:4327:4	O
the	NULOJIX.xml:S1:4332:3	O
NULOJIX	NULOJIX.xml:S1:4336:7	O
regimen	NULOJIX.xml:S1:4344:7	O
of	NULOJIX.xml:S1:4352:2	O
higher	NULOJIX.xml:S1:4355:6	O
cumulative	NULOJIX.xml:S1:4362:10	O
dose	NULOJIX.xml:S1:4373:4	O
and	NULOJIX.xml:S1:4378:3	O
more	NULOJIX.xml:S1:4382:4	O
frequent	NULOJIX.xml:S1:4387:8	O
dosing	NULOJIX.xml:S1:4396:6	O
than	NULOJIX.xml:S1:4403:4	O
recommended	NULOJIX.xml:S1:4408:11	O
,	NULOJIX.xml:S1:4419:1	O
there	NULOJIX.xml:S1:4421:5	O
were	NULOJIX.xml:S1:4427:4	O
8	NULOJIX.xml:S1:4432:1	O
cases	NULOJIX.xml:S1:4434:5	O
of	NULOJIX.xml:S1:4440:2	O
PTLD	NULOJIX.xml:S1:4443:4	B-AdverseReaction
:	NULOJIX.xml:S1:4447:1	O
2	NULOJIX.xml:S1:4449:1	O
in	NULOJIX.xml:S1:4451:2	O
EBV	NULOJIX.xml:S1:4454:3	O
seropositive	NULOJIX.xml:S1:4458:12	O
patients	NULOJIX.xml:S1:4471:8	O
and	NULOJIX.xml:S1:4480:3	O
6	NULOJIX.xml:S1:4484:1	O
in	NULOJIX.xml:S1:4486:2	O
EBV	NULOJIX.xml:S1:4489:3	O
seronegative	NULOJIX.xml:S1:4493:12	O
or	NULOJIX.xml:S1:4506:2	O
serostatus	NULOJIX.xml:S1:4509:10	O
unknown	NULOJIX.xml:S1:4520:7	O
patients	NULOJIX.xml:S1:4528:8	O
.	NULOJIX.xml:S1:4536:1	O

Six	NULOJIX.xml:S1:4538:3	O
of	NULOJIX.xml:S1:4542:2	O
the	NULOJIX.xml:S1:4545:3	O
8	NULOJIX.xml:S1:4549:1	O
cases	NULOJIX.xml:S1:4551:5	O
presented	NULOJIX.xml:S1:4557:9	O
with	NULOJIX.xml:S1:4567:4	O
CNS	NULOJIX.xml:S1:4572:3	O
involvement	NULOJIX.xml:S1:4576:11	O
.	NULOJIX.xml:S1:4587:1	O

Therefore	NULOJIX.xml:S1:4589:9	O
,	NULOJIX.xml:S1:4598:1	O
administration	NULOJIX.xml:S1:4600:14	O
of	NULOJIX.xml:S1:4615:2	O
higher	NULOJIX.xml:S1:4618:6	O
than	NULOJIX.xml:S1:4625:4	O
the	NULOJIX.xml:S1:4630:3	O
recommended	NULOJIX.xml:S1:4634:11	O
doses	NULOJIX.xml:S1:4646:5	O
or	NULOJIX.xml:S1:4652:2	O
more	NULOJIX.xml:S1:4655:4	O
frequent	NULOJIX.xml:S1:4660:8	O
dosing	NULOJIX.xml:S1:4669:6	O
of	NULOJIX.xml:S1:4676:2	O
NULOJIX	NULOJIX.xml:S1:4679:7	O
is	NULOJIX.xml:S1:4687:2	O
not	NULOJIX.xml:S1:4690:3	O
recommended	NULOJIX.xml:S1:4694:11	O
.	NULOJIX.xml:S1:4705:1	O

[	NULOJIX.xml:S1:4707:1	O
See	NULOJIX.xml:S1:4708:3	O
Dosage	NULOJIX.xml:S1:4715:6	O
and	NULOJIX.xml:S1:4722:3	O
Administration	NULOJIX.xml:S1:4726:14	O
(	NULOJIX.xml:S1:4741:1	O
2.1	NULOJIX.xml:S1:4742:3	O
)	NULOJIX.xml:S1:4745:1	O
and	NULOJIX.xml:S1:4750:3	O
Warnings	NULOJIX.xml:S1:4757:8	O
and	NULOJIX.xml:S1:4766:3	O
Precautions	NULOJIX.xml:S1:4770:11	O
(	NULOJIX.xml:S1:4782:1	O
5.1	NULOJIX.xml:S1:4783:3	O
)	NULOJIX.xml:S1:4786:1	O
.	NULOJIX.xml:S1:4791:1	O
]	NULOJIX.xml:S1:4792:1	O

One	NULOJIX.xml:S1:4798:3	O
of	NULOJIX.xml:S1:4802:2	O
the	NULOJIX.xml:S1:4805:3	O
476	NULOJIX.xml:S1:4809:3	O
patients	NULOJIX.xml:S1:4813:8	O
treated	NULOJIX.xml:S1:4822:7	O
with	NULOJIX.xml:S1:4830:4	O
cyclosporine	NULOJIX.xml:S1:4835:12	O
developed	NULOJIX.xml:S1:4848:9	O
PTLD	NULOJIX.xml:S1:4858:4	B-AdverseReaction
,	NULOJIX.xml:S1:4862:1	O
without	NULOJIX.xml:S1:4864:7	O
CNS	NULOJIX.xml:S1:4872:3	O
involvement	NULOJIX.xml:S1:4876:11	O
.	NULOJIX.xml:S1:4887:1	O

All	NULOJIX.xml:S1:4893:3	O
cases	NULOJIX.xml:S1:4897:5	O
of	NULOJIX.xml:S1:4903:2	O
PTLD	NULOJIX.xml:S1:4906:4	B-AdverseReaction
reported	NULOJIX.xml:S1:4911:8	O
up	NULOJIX.xml:S1:4920:2	O
to	NULOJIX.xml:S1:4923:2	O
36	NULOJIX.xml:S1:4926:2	O
months	NULOJIX.xml:S1:4929:6	O
post	NULOJIX.xml:S1:4936:4	O
transplant	NULOJIX.xml:S1:4941:10	O
in	NULOJIX.xml:S1:4952:2	O
NULOJIX	NULOJIX.xml:S1:4955:7	O
-	NULOJIX.xml:S1:4962:1	O
or	NULOJIX.xml:S1:4964:2	O
cyclosporine	NULOJIX.xml:S1:4967:12	O
-	NULOJIX.xml:S1:4979:1	O
treated	NULOJIX.xml:S1:4980:7	O
patients	NULOJIX.xml:S1:4988:8	O
presented	NULOJIX.xml:S1:4997:9	O
within	NULOJIX.xml:S1:5007:6	O
18	NULOJIX.xml:S1:5014:2	O
months	NULOJIX.xml:S1:5017:6	O
of	NULOJIX.xml:S1:5024:2	O
transplantation	NULOJIX.xml:S1:5027:15	O
.	NULOJIX.xml:S1:5042:1	O

Overall	NULOJIX.xml:S1:5048:7	O
,	NULOJIX.xml:S1:5055:1	O
the	NULOJIX.xml:S1:5057:3	O
rate	NULOJIX.xml:S1:5061:4	O
of	NULOJIX.xml:S1:5066:2	O
PTLD	NULOJIX.xml:S1:5069:4	B-AdverseReaction
in	NULOJIX.xml:S1:5074:2	O
949	NULOJIX.xml:S1:5077:3	O
patients	NULOJIX.xml:S1:5081:8	O
treated	NULOJIX.xml:S1:5090:7	O
with	NULOJIX.xml:S1:5098:4	O
any	NULOJIX.xml:S1:5103:3	O
of	NULOJIX.xml:S1:5107:2	O
the	NULOJIX.xml:S1:5110:3	O
NULOJIX	NULOJIX.xml:S1:5114:7	O
regimens	NULOJIX.xml:S1:5122:8	O
was	NULOJIX.xml:S1:5131:3	O
9	NULOJIX.xml:S1:5135:1	O
-	NULOJIX.xml:S1:5136:1	O
fold	NULOJIX.xml:S1:5137:4	O
higher	NULOJIX.xml:S1:5142:6	O
in	NULOJIX.xml:S1:5149:2	O
those	NULOJIX.xml:S1:5152:5	O
who	NULOJIX.xml:S1:5158:3	O
were	NULOJIX.xml:S1:5162:4	O
EBV	NULOJIX.xml:S1:5167:3	O
seronegative	NULOJIX.xml:S1:5171:12	O
or	NULOJIX.xml:S1:5184:2	O
EBV	NULOJIX.xml:S1:5187:3	O
serostatus	NULOJIX.xml:S1:5191:10	O
unknown	NULOJIX.xml:S1:5202:7	O
(	NULOJIX.xml:S1:5210:1	O
8	NULOJIX.xml:S1:5211:1	O
139	NULOJIX.xml:S1:5213:3	O
)	NULOJIX.xml:S1:5216:1	O
compared	NULOJIX.xml:S1:5218:8	O
to	NULOJIX.xml:S1:5227:2	O
those	NULOJIX.xml:S1:5230:5	O
who	NULOJIX.xml:S1:5236:3	O
were	NULOJIX.xml:S1:5240:4	O
EBV	NULOJIX.xml:S1:5245:3	O
seropositive	NULOJIX.xml:S1:5249:12	O
(	NULOJIX.xml:S1:5262:1	O
5	NULOJIX.xml:S1:5263:1	O
810	NULOJIX.xml:S1:5265:3	O
patients	NULOJIX.xml:S1:5269:8	O
)	NULOJIX.xml:S1:5277:1	O
.	NULOJIX.xml:S1:5278:1	O

Therefore	NULOJIX.xml:S1:5280:9	O
NULOJIX	NULOJIX.xml:S1:5290:7	O
is	NULOJIX.xml:S1:5298:2	O
recommended	NULOJIX.xml:S1:5301:11	O
for	NULOJIX.xml:S1:5313:3	O
use	NULOJIX.xml:S1:5317:3	O
only	NULOJIX.xml:S1:5321:4	O
in	NULOJIX.xml:S1:5326:2	O
patients	NULOJIX.xml:S1:5329:8	O
who	NULOJIX.xml:S1:5338:3	O
are	NULOJIX.xml:S1:5342:3	O
EBV	NULOJIX.xml:S1:5346:3	O
seropositive	NULOJIX.xml:S1:5350:12	O
[	NULOJIX.xml:S1:5363:1	O
see	NULOJIX.xml:S1:5364:3	O
Boxed	NULOJIX.xml:S1:5371:5	O
Warning	NULOJIX.xml:S1:5377:7	O
and	NULOJIX.xml:S1:5388:3	O
Contraindications	NULOJIX.xml:S1:5395:17	O
(	NULOJIX.xml:S1:5413:1	O
4	NULOJIX.xml:S1:5414:1	O
)	NULOJIX.xml:S1:5415:1	O
]	NULOJIX.xml:S1:5420:1	O
.	NULOJIX.xml:S1:5421:1	O

Table	NULOJIX.xml:S1:5427:5	O
2	NULOJIX.xml:S1:5433:1	O
:	NULOJIX.xml:S1:5434:1	O
Summary	NULOJIX.xml:S1:5436:7	O
of	NULOJIX.xml:S1:5444:2	O
PTLD	NULOJIX.xml:S1:5447:4	B-AdverseReaction
Reported	NULOJIX.xml:S1:5452:8	O
in	NULOJIX.xml:S1:5461:2	O
Studies	NULOJIX.xml:S1:5464:7	O
1	NULOJIX.xml:S1:5472:1	O
,	NULOJIX.xml:S1:5473:1	O
2	NULOJIX.xml:S1:5475:1	O
,	NULOJIX.xml:S1:5476:1	O
and	NULOJIX.xml:S1:5478:3	O
3	NULOJIX.xml:S1:5482:1	O
Through	NULOJIX.xml:S1:5484:7	O
Three	NULOJIX.xml:S1:5492:5	O
Years	NULOJIX.xml:S1:5498:5	O
of	NULOJIX.xml:S1:5504:2	O
Treatment	NULOJIX.xml:S1:5507:9	O

NULOJIX	NULOJIX.xml:S1:5538:7	O
Non	NULOJIX.xml:S1:5549:3	O
-	NULOJIX.xml:S1:5552:1	O
Recommended	NULOJIX.xml:S1:5553:11	O
Regimen	NULOJIX.xml:S1:5568:7	O
(	NULOJIX.xml:S1:5580:1	O
N	NULOJIX.xml:S1:5581:1	O
477	NULOJIX.xml:S1:5583:3	O
)	NULOJIX.xml:S1:5586:1	O
NULOJIX	NULOJIX.xml:S1:5593:7	O
Recommended	NULOJIX.xml:S1:5604:11	O
Regimen	NULOJIX.xml:S1:5619:7	O
(	NULOJIX.xml:S1:5634:1	O
N	NULOJIX.xml:S1:5635:1	O
472	NULOJIX.xml:S1:5637:3	O
)	NULOJIX.xml:S1:5640:1	O
Cyclosporine	NULOJIX.xml:S1:5647:12	O
(	NULOJIX.xml:S1:5663:1	O
N	NULOJIX.xml:S1:5664:1	O
476	NULOJIX.xml:S1:5666:3	O
)	NULOJIX.xml:S1:5669:1	O

Trial	NULOJIX.xml:S1:5679:5	O
EBV	NULOJIX.xml:S1:5696:3	O
Positive	NULOJIX.xml:S1:5703:8	O
(	NULOJIX.xml:S1:5715:1	O
n	NULOJIX.xml:S1:5716:1	O
406	NULOJIX.xml:S1:5718:3	O
)	NULOJIX.xml:S1:5721:1	O
EBV	NULOJIX.xml:S1:5728:3	O
Negative	NULOJIX.xml:S1:5735:8	O
(	NULOJIX.xml:S1:5747:1	O
n	NULOJIX.xml:S1:5748:1	O
43	NULOJIX.xml:S1:5750:2	O
)	NULOJIX.xml:S1:5752:1	O
EBV	NULOJIX.xml:S1:5759:3	O
Unknown	NULOJIX.xml:S1:5766:7	O
(	NULOJIX.xml:S1:5777:1	O
n	NULOJIX.xml:S1:5778:1	O
28	NULOJIX.xml:S1:5780:2	O
)	NULOJIX.xml:S1:5782:1	O
EBV	NULOJIX.xml:S1:5789:3	O
Positive	NULOJIX.xml:S1:5796:8	O
(	NULOJIX.xml:S1:5808:1	O
n	NULOJIX.xml:S1:5809:1	O
404	NULOJIX.xml:S1:5811:3	O
)	NULOJIX.xml:S1:5814:1	O
EBV	NULOJIX.xml:S1:5821:3	O
Negative	NULOJIX.xml:S1:5828:8	O
(	NULOJIX.xml:S1:5840:1	O
n	NULOJIX.xml:S1:5841:1	O
48	NULOJIX.xml:S1:5843:2	O
)	NULOJIX.xml:S1:5845:1	O
EBV	NULOJIX.xml:S1:5852:3	O
Unknown	NULOJIX.xml:S1:5859:7	O
(	NULOJIX.xml:S1:5870:1	O
n	NULOJIX.xml:S1:5871:1	O
20	NULOJIX.xml:S1:5873:2	O
)	NULOJIX.xml:S1:5875:1	O
EBV	NULOJIX.xml:S1:5882:3	O
Positive	NULOJIX.xml:S1:5889:8	O
(	NULOJIX.xml:S1:5901:1	O
n	NULOJIX.xml:S1:5902:1	O
399	NULOJIX.xml:S1:5904:3	O
)	NULOJIX.xml:S1:5907:1	O
EBV	NULOJIX.xml:S1:5914:3	O
Negative	NULOJIX.xml:S1:5921:8	O
(	NULOJIX.xml:S1:5933:1	O
n	NULOJIX.xml:S1:5934:1	O
57	NULOJIX.xml:S1:5936:2	O
)	NULOJIX.xml:S1:5938:1	O
EBV	NULOJIX.xml:S1:5945:3	O
Unknown	NULOJIX.xml:S1:5952:7	O
(	NULOJIX.xml:S1:5963:1	O
n	NULOJIX.xml:S1:5964:1	O
20	NULOJIX.xml:S1:5966:2	O
)	NULOJIX.xml:S1:5968:1	O

Regimen	NULOJIX.xml:S1:5982:7	O

with	NULOJIX.xml:S1:5990:4	O
higher	NULOJIX.xml:S1:5995:6	O
cumulative	NULOJIX.xml:S1:6002:10	O
dose	NULOJIX.xml:S1:6013:4	O
and	NULOJIX.xml:S1:6018:3	O
more	NULOJIX.xml:S1:6022:4	O
frequent	NULOJIX.xml:S1:6027:8	O
dosing	NULOJIX.xml:S1:6036:6	O
than	NULOJIX.xml:S1:6043:4	O
the	NULOJIX.xml:S1:6048:3	O
recommended	NULOJIX.xml:S1:6052:11	O
NULOJIX	NULOJIX.xml:S1:6064:7	O
regimen	NULOJIX.xml:S1:6072:7	O
.	NULOJIX.xml:S1:6079:1	O

In	NULOJIX.xml:S1:6086:2	O
Studies	NULOJIX.xml:S1:6089:7	O
1	NULOJIX.xml:S1:6097:1	O
and	NULOJIX.xml:S1:6099:3	O
2	NULOJIX.xml:S1:6103:1	O
the	NULOJIX.xml:S1:6105:3	O
NULOJIX	NULOJIX.xml:S1:6109:7	O
regimen	NULOJIX.xml:S1:6117:7	O
is	NULOJIX.xml:S1:6125:2	O
identical	NULOJIX.xml:S1:6128:9	O
to	NULOJIX.xml:S1:6138:2	O
the	NULOJIX.xml:S1:6141:3	O
recommended	NULOJIX.xml:S1:6145:11	O
regimen	NULOJIX.xml:S1:6157:7	O
,	NULOJIX.xml:S1:6164:1	O
but	NULOJIX.xml:S1:6166:3	O
is	NULOJIX.xml:S1:6170:2	O
slightly	NULOJIX.xml:S1:6173:8	O
different	NULOJIX.xml:S1:6182:9	O
in	NULOJIX.xml:S1:6192:2	O
Study	NULOJIX.xml:S1:6195:5	O
3	NULOJIX.xml:S1:6201:1	O
.	NULOJIX.xml:S1:6202:1	O

Study	NULOJIX.xml:S1:6212:5	O

1	NULOJIX.xml:S1:6218:1	O

CNS	NULOJIX.xml:S1:6232:3	B-AdverseReaction
PTLD	NULOJIX.xml:S1:6236:4	I-AdverseReaction
1	NULOJIX.xml:S1:6249:1	O
1	NULOJIX.xml:S1:6261:1	O

Non	NULOJIX.xml:S1:6355:3	B-AdverseReaction
-	NULOJIX.xml:S1:6358:1	I-AdverseReaction
CNSPTLD	NULOJIX.xml:S1:6359:7	I-AdverseReaction
1	NULOJIX.xml:S1:6384:1	O
2	NULOJIX.xml:S1:6407:1	O
1	NULOJIX.xml:S1:6453:1	O

Study	NULOJIX.xml:S1:6478:5	O
2	NULOJIX.xml:S1:6484:1	O

CNS	NULOJIX.xml:S1:6498:3	B-AdverseReaction
PTLD	NULOJIX.xml:S1:6502:4	I-AdverseReaction
1	NULOJIX.xml:S1:6515:1	O
1	NULOJIX.xml:S1:6527:1	O
1	NULOJIX.xml:S1:6550:1	O
1	NULOJIX.xml:S1:6562:1	O

Non	NULOJIX.xml:S1:6621:3	B-AdverseReaction
-	NULOJIX.xml:S1:6624:1	I-AdverseReaction
CNSPTLD	NULOJIX.xml:S1:6625:7	I-AdverseReaction
1	NULOJIX.xml:S1:6685:1	O

Study	NULOJIX.xml:S1:6744:5	O
3	NULOJIX.xml:S1:6750:1	O

CNS	NULOJIX.xml:S1:6764:3	B-AdverseReaction
PTLD	NULOJIX.xml:S1:6768:4	I-AdverseReaction
2	NULOJIX.xml:S1:6793:1	O

Non	NULOJIX.xml:S1:6887:3	B-AdverseReaction
-	NULOJIX.xml:S1:6890:1	I-AdverseReaction
CNSPTLD	NULOJIX.xml:S1:6891:7	I-AdverseReaction
1	NULOJIX.xml:S1:6927:1	O

Total	NULOJIX.xml:S1:7010:5	O
(	NULOJIX.xml:S1:7016:1	O
)	NULOJIX.xml:S1:7018:1	O
2	NULOJIX.xml:S1:7027:1	O
(	NULOJIX.xml:S1:7029:1	O
0.5	NULOJIX.xml:S1:7030:3	O
)	NULOJIX.xml:S1:7033:1	O
5	NULOJIX.xml:S1:7039:1	O
(	NULOJIX.xml:S1:7041:1	O
11.6	NULOJIX.xml:S1:7042:4	O
)	NULOJIX.xml:S1:7046:1	O
1	NULOJIX.xml:S1:7051:1	O
(	NULOJIX.xml:S1:7053:1	O
3.6	NULOJIX.xml:S1:7054:3	O
)	NULOJIX.xml:S1:7057:1	O
3	NULOJIX.xml:S1:7063:1	O
(	NULOJIX.xml:S1:7065:1	O
0.7	NULOJIX.xml:S1:7066:3	O
)	NULOJIX.xml:S1:7069:1	O
2	NULOJIX.xml:S1:7075:1	O
(	NULOJIX.xml:S1:7077:1	O
4.1	NULOJIX.xml:S1:7078:3	O
)	NULOJIX.xml:S1:7081:1	O
0	NULOJIX.xml:S1:7086:1	O
0	NULOJIX.xml:S1:7098:1	O
1	NULOJIX.xml:S1:7110:1	O
(	NULOJIX.xml:S1:7112:1	O
1.8	NULOJIX.xml:S1:7113:3	O
)	NULOJIX.xml:S1:7116:1	O
0	NULOJIX.xml:S1:7121:1	O

EBV	NULOJIX.xml:S1:7152:3	O
Seropositive	NULOJIX.xml:S1:7156:12	O
Subpopulation	NULOJIX.xml:S1:7169:13	O

Among	NULOJIX.xml:S1:7186:5	O
the	NULOJIX.xml:S1:7192:3	O
806	NULOJIX.xml:S1:7196:3	O
EBV	NULOJIX.xml:S1:7200:3	O
seropositive	NULOJIX.xml:S1:7204:12	O
patients	NULOJIX.xml:S1:7217:8	O
with	NULOJIX.xml:S1:7226:4	O
known	NULOJIX.xml:S1:7231:5	O
CMV	NULOJIX.xml:S1:7237:3	O
serostatus	NULOJIX.xml:S1:7241:10	O
treated	NULOJIX.xml:S1:7252:7	O
with	NULOJIX.xml:S1:7260:4	O
either	NULOJIX.xml:S1:7265:6	O
NULOJIX	NULOJIX.xml:S1:7272:7	O
regimen	NULOJIX.xml:S1:7280:7	O
in	NULOJIX.xml:S1:7288:2	O
Studies	NULOJIX.xml:S1:7291:7	O
1	NULOJIX.xml:S1:7299:1	O
,	NULOJIX.xml:S1:7300:1	O
2	NULOJIX.xml:S1:7302:1	O
,	NULOJIX.xml:S1:7303:1	O
and	NULOJIX.xml:S1:7305:3	O
3	NULOJIX.xml:S1:7309:1	O
,	NULOJIX.xml:S1:7310:1	O
two	NULOJIX.xml:S1:7312:3	O
percent	NULOJIX.xml:S1:7316:7	O
(	NULOJIX.xml:S1:7324:1	O
2%	NULOJIX.xml:S1:7325:2	O
;	NULOJIX.xml:S1:7327:1	O
4	NULOJIX.xml:S1:7329:1	O
210	NULOJIX.xml:S1:7331:3	O
)	NULOJIX.xml:S1:7334:1	O
of	NULOJIX.xml:S1:7336:2	O
CMV	NULOJIX.xml:S1:7339:3	O
seronegative	NULOJIX.xml:S1:7343:12	O
patients	NULOJIX.xml:S1:7356:8	O
developed	NULOJIX.xml:S1:7365:9	O
PTLD	NULOJIX.xml:S1:7375:4	B-AdverseReaction
compared	NULOJIX.xml:S1:7380:8	O
to	NULOJIX.xml:S1:7389:2	O
0.2%	NULOJIX.xml:S1:7392:4	O
(	NULOJIX.xml:S1:7397:1	O
1	NULOJIX.xml:S1:7398:1	O
596	NULOJIX.xml:S1:7400:3	O
)	NULOJIX.xml:S1:7403:1	O
of	NULOJIX.xml:S1:7405:2	O
CMV	NULOJIX.xml:S1:7408:3	O
seropositive	NULOJIX.xml:S1:7412:12	O
patients	NULOJIX.xml:S1:7425:8	O
.	NULOJIX.xml:S1:7433:1	O

Among	NULOJIX.xml:S1:7435:5	O
the	NULOJIX.xml:S1:7441:3	O
404	NULOJIX.xml:S1:7445:3	O
EBV	NULOJIX.xml:S1:7449:3	O
seropositive	NULOJIX.xml:S1:7453:12	O
recipients	NULOJIX.xml:S1:7466:10	O
treated	NULOJIX.xml:S1:7477:7	O
with	NULOJIX.xml:S1:7485:4	O
the	NULOJIX.xml:S1:7490:3	O
recommended	NULOJIX.xml:S1:7494:11	O
dosage	NULOJIX.xml:S1:7506:6	O
regimen	NULOJIX.xml:S1:7513:7	O
of	NULOJIX.xml:S1:7521:2	O
NULOJIX	NULOJIX.xml:S1:7524:7	O
,	NULOJIX.xml:S1:7531:1	O
three	NULOJIX.xml:S1:7533:5	O
PTLD	NULOJIX.xml:S1:7539:4	B-AdverseReaction
cases	NULOJIX.xml:S1:7544:5	O
were	NULOJIX.xml:S1:7550:4	O
detected	NULOJIX.xml:S1:7555:8	O
among	NULOJIX.xml:S1:7564:5	O
99	NULOJIX.xml:S1:7570:2	O
CMV	NULOJIX.xml:S1:7573:3	O
seronegative	NULOJIX.xml:S1:7577:12	O
patients	NULOJIX.xml:S1:7590:8	O
(	NULOJIX.xml:S1:7599:1	O
3%	NULOJIX.xml:S1:7600:2	O
)	NULOJIX.xml:S1:7602:1	O
and	NULOJIX.xml:S1:7604:3	O
there	NULOJIX.xml:S1:7608:5	O
was	NULOJIX.xml:S1:7614:3	O
no	NULOJIX.xml:S1:7618:2	O
case	NULOJIX.xml:S1:7621:4	O
detected	NULOJIX.xml:S1:7626:8	O
among	NULOJIX.xml:S1:7635:5	O
303	NULOJIX.xml:S1:7641:3	O
CMV	NULOJIX.xml:S1:7645:3	O
seropositive	NULOJIX.xml:S1:7649:12	O
patients	NULOJIX.xml:S1:7662:8	O
.	NULOJIX.xml:S1:7670:1	O

The	NULOJIX.xml:S1:7672:3	O
clinical	NULOJIX.xml:S1:7676:8	O
significance	NULOJIX.xml:S1:7685:12	O
of	NULOJIX.xml:S1:7698:2	O
CMV	NULOJIX.xml:S1:7701:3	O
serology	NULOJIX.xml:S1:7705:8	O
as	NULOJIX.xml:S1:7714:2	O
a	NULOJIX.xml:S1:7717:1	O
risk	NULOJIX.xml:S1:7719:4	O
factor	NULOJIX.xml:S1:7724:6	O
for	NULOJIX.xml:S1:7731:3	O
PTLD	NULOJIX.xml:S1:7735:4	B-AdverseReaction
remains	NULOJIX.xml:S1:7740:7	O
to	NULOJIX.xml:S1:7748:2	O
be	NULOJIX.xml:S1:7751:2	O
determined	NULOJIX.xml:S1:7754:10	O
;	NULOJIX.xml:S1:7764:1	O
however	NULOJIX.xml:S1:7766:7	O
,	NULOJIX.xml:S1:7773:1	O
these	NULOJIX.xml:S1:7775:5	O
findings	NULOJIX.xml:S1:7781:8	O
should	NULOJIX.xml:S1:7790:6	O
be	NULOJIX.xml:S1:7797:2	O
considered	NULOJIX.xml:S1:7800:10	O
when	NULOJIX.xml:S1:7811:4	O
prescribing	NULOJIX.xml:S1:7816:11	O
NULOJIX	NULOJIX.xml:S1:7828:7	O
[	NULOJIX.xml:S1:7836:1	O
see	NULOJIX.xml:S1:7837:3	O
Warnings	NULOJIX.xml:S1:7844:8	O
and	NULOJIX.xml:S1:7853:3	O
Precautions	NULOJIX.xml:S1:7857:11	O
(	NULOJIX.xml:S1:7869:1	O
5.1	NULOJIX.xml:S1:7870:3	O
)	NULOJIX.xml:S1:7873:1	O
]	NULOJIX.xml:S1:7878:1	O
.	NULOJIX.xml:S1:7879:1	O

Other	NULOJIX.xml:S1:7887:5	O
Malignancies	NULOJIX.xml:S1:7893:12	O

Malignancies	NULOJIX.xml:S1:7909:12	B-AdverseReaction
,	NULOJIX.xml:S1:7921:1	O
excluding	NULOJIX.xml:S1:7923:9	B-Negation
non	NULOJIX.xml:S1:7933:3	B-AdverseReaction
-	NULOJIX.xml:S1:7936:1	I-AdverseReaction
melanoma	NULOJIX.xml:S1:7937:8	I-AdverseReaction
skin	NULOJIX.xml:S1:7946:4	I-AdverseReaction
cancer	NULOJIX.xml:S1:7951:6	I-AdverseReaction
and	NULOJIX.xml:S1:7958:3	O
PTLD	NULOJIX.xml:S1:7962:4	B-AdverseReaction
,	NULOJIX.xml:S1:7966:1	O
were	NULOJIX.xml:S1:7968:4	O
reported	NULOJIX.xml:S1:7973:8	O
in	NULOJIX.xml:S1:7982:2	O
Study	NULOJIX.xml:S1:7985:5	O
1	NULOJIX.xml:S1:7991:1	O
and	NULOJIX.xml:S1:7993:3	O
Study	NULOJIX.xml:S1:7997:5	O
2	NULOJIX.xml:S1:8003:1	O
in	NULOJIX.xml:S1:8005:2	O
3.5%	NULOJIX.xml:S1:8008:4	O
(	NULOJIX.xml:S1:8013:1	O
14	NULOJIX.xml:S1:8014:2	O
401	NULOJIX.xml:S1:8017:3	O
)	NULOJIX.xml:S1:8020:1	O
of	NULOJIX.xml:S1:8022:2	O
patients	NULOJIX.xml:S1:8025:8	O
treated	NULOJIX.xml:S1:8034:7	O
with	NULOJIX.xml:S1:8042:4	O
the	NULOJIX.xml:S1:8047:3	O
recommended	NULOJIX.xml:S1:8051:11	O
NULOJIX	NULOJIX.xml:S1:8063:7	O
regimen	NULOJIX.xml:S1:8071:7	O
and	NULOJIX.xml:S1:8079:3	O
3.7%	NULOJIX.xml:S1:8083:4	O
(	NULOJIX.xml:S1:8088:1	O
15	NULOJIX.xml:S1:8089:2	O
405	NULOJIX.xml:S1:8092:3	O
)	NULOJIX.xml:S1:8095:1	O
of	NULOJIX.xml:S1:8097:2	O
patients	NULOJIX.xml:S1:8100:8	O
treated	NULOJIX.xml:S1:8109:7	O
with	NULOJIX.xml:S1:8117:4	O
the	NULOJIX.xml:S1:8122:3	O
cyclosporine	NULOJIX.xml:S1:8126:12	O
control	NULOJIX.xml:S1:8139:7	O
regimen	NULOJIX.xml:S1:8147:7	O
.	NULOJIX.xml:S1:8154:1	O

Non	NULOJIX.xml:S1:8156:3	B-AdverseReaction
-	NULOJIX.xml:S1:8159:1	I-AdverseReaction
melanoma	NULOJIX.xml:S1:8160:8	I-AdverseReaction
skin	NULOJIX.xml:S1:8169:4	I-AdverseReaction
cancer	NULOJIX.xml:S1:8174:6	I-AdverseReaction
was	NULOJIX.xml:S1:8181:3	O
reported	NULOJIX.xml:S1:8185:8	O
in	NULOJIX.xml:S1:8194:2	O
1.5%	NULOJIX.xml:S1:8197:4	O
(	NULOJIX.xml:S1:8202:1	O
6	NULOJIX.xml:S1:8203:1	O
401	NULOJIX.xml:S1:8205:3	O
)	NULOJIX.xml:S1:8208:1	O
of	NULOJIX.xml:S1:8210:2	O
patients	NULOJIX.xml:S1:8213:8	O
treated	NULOJIX.xml:S1:8222:7	O
with	NULOJIX.xml:S1:8230:4	O
the	NULOJIX.xml:S1:8235:3	O
recommended	NULOJIX.xml:S1:8239:11	O
NULOJIX	NULOJIX.xml:S1:8251:7	O
regimen	NULOJIX.xml:S1:8259:7	O
and	NULOJIX.xml:S1:8267:3	O
in	NULOJIX.xml:S1:8271:2	O
3.7%	NULOJIX.xml:S1:8274:4	O
(	NULOJIX.xml:S1:8279:1	O
15	NULOJIX.xml:S1:8280:2	O
405	NULOJIX.xml:S1:8283:3	O
)	NULOJIX.xml:S1:8286:1	O
of	NULOJIX.xml:S1:8288:2	O
patients	NULOJIX.xml:S1:8291:8	O
treated	NULOJIX.xml:S1:8300:7	O
with	NULOJIX.xml:S1:8308:4	O
cyclosporine	NULOJIX.xml:S1:8313:12	O
[	NULOJIX.xml:S1:8326:1	O
see	NULOJIX.xml:S1:8327:3	O
Warnings	NULOJIX.xml:S1:8334:8	O
and	NULOJIX.xml:S1:8343:3	O
Precautions	NULOJIX.xml:S1:8347:11	O
(	NULOJIX.xml:S1:8359:1	O
5.3	NULOJIX.xml:S1:8360:3	O
)	NULOJIX.xml:S1:8363:1	O
]	NULOJIX.xml:S1:8368:1	O
.	NULOJIX.xml:S1:8369:1	O

Progressive	NULOJIX.xml:S1:8377:11	O
Multifocal	NULOJIX.xml:S1:8389:10	O
Leukoencephalopathy	NULOJIX.xml:S1:8400:19	O

Two	NULOJIX.xml:S1:8423:3	O
fatal	NULOJIX.xml:S1:8427:5	B-AdverseReaction
cases	NULOJIX.xml:S1:8433:5	O
of	NULOJIX.xml:S1:8439:2	O
progressive	NULOJIX.xml:S1:8442:11	B-AdverseReaction
multifocal	NULOJIX.xml:S1:8454:10	I-AdverseReaction
leukoencephalopathy	NULOJIX.xml:S1:8465:19	I-AdverseReaction
(	NULOJIX.xml:S1:8485:1	O
PML	NULOJIX.xml:S1:8486:3	B-AdverseReaction
)	NULOJIX.xml:S1:8489:1	O
have	NULOJIX.xml:S1:8491:4	O
been	NULOJIX.xml:S1:8496:4	O
reported	NULOJIX.xml:S1:8501:8	O
among	NULOJIX.xml:S1:8510:5	O
1096	NULOJIX.xml:S1:8516:4	O
patients	NULOJIX.xml:S1:8521:8	O
treated	NULOJIX.xml:S1:8530:7	O
with	NULOJIX.xml:S1:8538:4	O
a	NULOJIX.xml:S1:8543:1	O
NULOJIX	NULOJIX.xml:S1:8545:7	O
-	NULOJIX.xml:S1:8552:1	O
containing	NULOJIX.xml:S1:8553:10	O
regimen	NULOJIX.xml:S1:8564:7	O
:	NULOJIX.xml:S1:8571:1	O
one	NULOJIX.xml:S1:8573:3	O
patient	NULOJIX.xml:S1:8577:7	O
in	NULOJIX.xml:S1:8585:2	O
clinical	NULOJIX.xml:S1:8588:8	O
trials	NULOJIX.xml:S1:8597:6	O
of	NULOJIX.xml:S1:8604:2	O
kidney	NULOJIX.xml:S1:8607:6	O
transplant	NULOJIX.xml:S1:8614:10	O
(	NULOJIX.xml:S1:8625:1	O
Studies	NULOJIX.xml:S1:8626:7	O
1	NULOJIX.xml:S1:8634:1	O
,	NULOJIX.xml:S1:8635:1	O
2	NULOJIX.xml:S1:8637:1	O
,	NULOJIX.xml:S1:8638:1	O
and	NULOJIX.xml:S1:8640:3	O
3	NULOJIX.xml:S1:8644:1	O
described	NULOJIX.xml:S1:8646:9	O
above	NULOJIX.xml:S1:8656:5	O
)	NULOJIX.xml:S1:8661:1	O
and	NULOJIX.xml:S1:8663:3	O
one	NULOJIX.xml:S1:8667:3	O
patient	NULOJIX.xml:S1:8671:7	O
in	NULOJIX.xml:S1:8679:2	O
a	NULOJIX.xml:S1:8682:1	O
trial	NULOJIX.xml:S1:8684:5	O
of	NULOJIX.xml:S1:8690:2	O
liver	NULOJIX.xml:S1:8693:5	O
transplant	NULOJIX.xml:S1:8699:10	O
(	NULOJIX.xml:S1:8710:1	O
trial	NULOJIX.xml:S1:8711:5	O
of	NULOJIX.xml:S1:8717:2	O
250	NULOJIX.xml:S1:8720:3	O
patients	NULOJIX.xml:S1:8724:8	O
)	NULOJIX.xml:S1:8732:1	O
.	NULOJIX.xml:S1:8733:1	O

No	NULOJIX.xml:S1:8735:2	B-Negation
cases	NULOJIX.xml:S1:8738:5	O
of	NULOJIX.xml:S1:8744:2	O
PML	NULOJIX.xml:S1:8747:3	B-AdverseReaction
were	NULOJIX.xml:S1:8751:4	O
reported	NULOJIX.xml:S1:8756:8	O
in	NULOJIX.xml:S1:8765:2	O
patients	NULOJIX.xml:S1:8768:8	O
treated	NULOJIX.xml:S1:8777:7	O
with	NULOJIX.xml:S1:8785:4	O
the	NULOJIX.xml:S1:8790:3	O
recommended	NULOJIX.xml:S1:8794:11	O
NULOJIX	NULOJIX.xml:S1:8806:7	O
regimen	NULOJIX.xml:S1:8814:7	O
or	NULOJIX.xml:S1:8822:2	O
the	NULOJIX.xml:S1:8825:3	O
control	NULOJIX.xml:S1:8829:7	O
regimen	NULOJIX.xml:S1:8837:7	O
in	NULOJIX.xml:S1:8845:2	O
these	NULOJIX.xml:S1:8848:5	O
trials	NULOJIX.xml:S1:8854:6	O
.	NULOJIX.xml:S1:8860:1	O

The	NULOJIX.xml:S1:8866:3	O
kidney	NULOJIX.xml:S1:8870:6	O
transplant	NULOJIX.xml:S1:8877:10	O
recipient	NULOJIX.xml:S1:8888:9	O
was	NULOJIX.xml:S1:8898:3	O
treated	NULOJIX.xml:S1:8902:7	O
with	NULOJIX.xml:S1:8910:4	O
the	NULOJIX.xml:S1:8915:3	O
NULOJIX	NULOJIX.xml:S1:8919:7	O
regimen	NULOJIX.xml:S1:8927:7	O
of	NULOJIX.xml:S1:8935:2	O
higher	NULOJIX.xml:S1:8938:6	O
cumulative	NULOJIX.xml:S1:8945:10	O
dose	NULOJIX.xml:S1:8956:4	O
and	NULOJIX.xml:S1:8961:3	O
more	NULOJIX.xml:S1:8965:4	O
frequent	NULOJIX.xml:S1:8970:8	O
dosing	NULOJIX.xml:S1:8979:6	O
than	NULOJIX.xml:S1:8986:4	O
recommended	NULOJIX.xml:S1:8991:11	O
,	NULOJIX.xml:S1:9002:1	O
mycophenolate	NULOJIX.xml:S1:9004:13	O
mofetil	NULOJIX.xml:S1:9018:7	O
(	NULOJIX.xml:S1:9026:1	O
MMF	NULOJIX.xml:S1:9027:3	O
)	NULOJIX.xml:S1:9030:1	O
,	NULOJIX.xml:S1:9031:1	O
and	NULOJIX.xml:S1:9033:3	O
corticosteroids	NULOJIX.xml:S1:9037:15	O
for	NULOJIX.xml:S1:9053:3	O
2	NULOJIX.xml:S1:9057:1	O
years	NULOJIX.xml:S1:9059:5	O
.	NULOJIX.xml:S1:9064:1	O

The	NULOJIX.xml:S1:9066:3	O
liver	NULOJIX.xml:S1:9070:5	O
transplant	NULOJIX.xml:S1:9076:10	O
recipient	NULOJIX.xml:S1:9087:9	O
was	NULOJIX.xml:S1:9097:3	O
treated	NULOJIX.xml:S1:9101:7	O
with	NULOJIX.xml:S1:9109:4	O
6	NULOJIX.xml:S1:9114:1	O
months	NULOJIX.xml:S1:9116:6	O
of	NULOJIX.xml:S1:9123:2	O
a	NULOJIX.xml:S1:9126:1	O
NULOJIX	NULOJIX.xml:S1:9128:7	O
dosage	NULOJIX.xml:S1:9136:6	O
regimen	NULOJIX.xml:S1:9143:7	O
that	NULOJIX.xml:S1:9151:4	O
was	NULOJIX.xml:S1:9156:3	O
more	NULOJIX.xml:S1:9160:4	O
intensive	NULOJIX.xml:S1:9165:9	O
than	NULOJIX.xml:S1:9175:4	O
that	NULOJIX.xml:S1:9180:4	O
studied	NULOJIX.xml:S1:9185:7	O
in	NULOJIX.xml:S1:9193:2	O
kidney	NULOJIX.xml:S1:9196:6	O
transplant	NULOJIX.xml:S1:9203:10	O
recipients	NULOJIX.xml:S1:9214:10	O
,	NULOJIX.xml:S1:9224:1	O
MMF	NULOJIX.xml:S1:9226:3	O
at	NULOJIX.xml:S1:9230:2	O
doses	NULOJIX.xml:S1:9233:5	O
higher	NULOJIX.xml:S1:9239:6	O
than	NULOJIX.xml:S1:9246:4	O
the	NULOJIX.xml:S1:9251:3	O
recommended	NULOJIX.xml:S1:9255:11	O
dose	NULOJIX.xml:S1:9267:4	O
,	NULOJIX.xml:S1:9271:1	O
and	NULOJIX.xml:S1:9273:3	O
corticosteroids	NULOJIX.xml:S1:9277:15	O
[	NULOJIX.xml:S1:9293:1	O
see	NULOJIX.xml:S1:9294:3	O
Warnings	NULOJIX.xml:S1:9301:8	O
and	NULOJIX.xml:S1:9310:3	O
Precautions	NULOJIX.xml:S1:9314:11	O
(	NULOJIX.xml:S1:9326:1	O
5.4	NULOJIX.xml:S1:9327:3	O
)	NULOJIX.xml:S1:9330:1	O
]	NULOJIX.xml:S1:9335:1	O
.	NULOJIX.xml:S1:9336:1	O

Bacterial	NULOJIX.xml:S1:9344:9	O
,	NULOJIX.xml:S1:9353:1	O
Mycobacterial	NULOJIX.xml:S1:9355:13	O
,	NULOJIX.xml:S1:9368:1	O
Viral	NULOJIX.xml:S1:9370:5	O
,	NULOJIX.xml:S1:9375:1	O
and	NULOJIX.xml:S1:9377:3	O
Fungal	NULOJIX.xml:S1:9381:6	O
Infections	NULOJIX.xml:S1:9388:10	O

Adverse	NULOJIX.xml:S1:9402:7	O
reactions	NULOJIX.xml:S1:9410:9	O
of	NULOJIX.xml:S1:9420:2	O
infectious	NULOJIX.xml:S1:9423:10	B-AdverseReaction
etiology	NULOJIX.xml:S1:9434:8	I-AdverseReaction
were	NULOJIX.xml:S1:9443:4	O
reported	NULOJIX.xml:S1:9448:8	O
based	NULOJIX.xml:S1:9457:5	O
on	NULOJIX.xml:S1:9463:2	O
clinical	NULOJIX.xml:S1:9466:8	O
assessment	NULOJIX.xml:S1:9475:10	O
by	NULOJIX.xml:S1:9486:2	O
physicians	NULOJIX.xml:S1:9489:10	O
.	NULOJIX.xml:S1:9499:1	O

The	NULOJIX.xml:S1:9501:3	O
causative	NULOJIX.xml:S1:9505:9	O
organisms	NULOJIX.xml:S1:9515:9	O
for	NULOJIX.xml:S1:9525:3	O
these	NULOJIX.xml:S1:9529:5	O
reactions	NULOJIX.xml:S1:9535:9	O
are	NULOJIX.xml:S1:9545:3	O
identified	NULOJIX.xml:S1:9549:10	O
when	NULOJIX.xml:S1:9560:4	O
provided	NULOJIX.xml:S1:9565:8	O
by	NULOJIX.xml:S1:9574:2	O
the	NULOJIX.xml:S1:9577:3	O
physician	NULOJIX.xml:S1:9581:9	O
.	NULOJIX.xml:S1:9590:1	O

The	NULOJIX.xml:S1:9592:3	O
overall	NULOJIX.xml:S1:9596:7	O
number	NULOJIX.xml:S1:9604:6	O
of	NULOJIX.xml:S1:9611:2	O
infections	NULOJIX.xml:S1:9614:10	B-AdverseReaction
,	NULOJIX.xml:S1:9624:1	O
serious	NULOJIX.xml:S1:9626:7	B-Severity
infections	NULOJIX.xml:S1:9634:10	B-AdverseReaction
,	NULOJIX.xml:S1:9644:1	O
and	NULOJIX.xml:S1:9646:3	O
select	NULOJIX.xml:S1:9650:6	O
infections	NULOJIX.xml:S1:9657:10	B-AdverseReaction
with	NULOJIX.xml:S1:9668:4	O
identified	NULOJIX.xml:S1:9673:10	O
etiology	NULOJIX.xml:S1:9684:8	O
reported	NULOJIX.xml:S1:9693:8	O
in	NULOJIX.xml:S1:9702:2	O
patients	NULOJIX.xml:S1:9705:8	O
treated	NULOJIX.xml:S1:9714:7	O
with	NULOJIX.xml:S1:9722:4	O
the	NULOJIX.xml:S1:9727:3	O
NULOJIX	NULOJIX.xml:S1:9731:7	O
recommended	NULOJIX.xml:S1:9739:11	O
regimen	NULOJIX.xml:S1:9751:7	O
or	NULOJIX.xml:S1:9759:2	O
the	NULOJIX.xml:S1:9762:3	O
cyclosporine	NULOJIX.xml:S1:9766:12	O
control	NULOJIX.xml:S1:9779:7	O
in	NULOJIX.xml:S1:9787:2	O
Studies	NULOJIX.xml:S1:9790:7	O
1	NULOJIX.xml:S1:9798:1	O
and	NULOJIX.xml:S1:9800:3	O
2	NULOJIX.xml:S1:9804:1	O
are	NULOJIX.xml:S1:9806:3	O
shown	NULOJIX.xml:S1:9810:5	O
in	NULOJIX.xml:S1:9816:2	O
Table	NULOJIX.xml:S1:9819:5	O
3	NULOJIX.xml:S1:9825:1	O
.	NULOJIX.xml:S1:9826:1	O

Fungal	NULOJIX.xml:S1:9828:6	B-AdverseReaction
infections	NULOJIX.xml:S1:9835:10	I-AdverseReaction
were	NULOJIX.xml:S1:9846:4	O
reported	NULOJIX.xml:S1:9851:8	O
in	NULOJIX.xml:S1:9860:2	O
18%	NULOJIX.xml:S1:9863:3	O
of	NULOJIX.xml:S1:9867:2	O
patients	NULOJIX.xml:S1:9870:8	O
receiving	NULOJIX.xml:S1:9879:9	O
NULOJIX	NULOJIX.xml:S1:9889:7	O
compared	NULOJIX.xml:S1:9897:8	O
to	NULOJIX.xml:S1:9906:2	O
22%	NULOJIX.xml:S1:9909:3	O
receiving	NULOJIX.xml:S1:9913:9	O
cyclosporine	NULOJIX.xml:S1:9923:12	O
,	NULOJIX.xml:S1:9935:1	O
primarily	NULOJIX.xml:S1:9937:9	O
due	NULOJIX.xml:S1:9947:3	O
to	NULOJIX.xml:S1:9951:2	O
skin	NULOJIX.xml:S1:9954:4	B-AdverseReaction
and	NULOJIX.xml:S1:9959:3	O
mucocutaneous	NULOJIX.xml:S1:9963:13	B-AdverseReaction
fungal	NULOJIX.xml:S1:9977:6	I-AdverseReaction
infections	NULOJIX.xml:S1:9984:10	I-AdverseReaction
.	NULOJIX.xml:S1:9994:1	O

Tuberculosis	NULOJIX.xml:S1:9996:12	B-AdverseReaction
and	NULOJIX.xml:S1:10009:3	O
herpes	NULOJIX.xml:S1:10013:6	B-AdverseReaction
infections	NULOJIX.xml:S1:10020:10	I-AdverseReaction
were	NULOJIX.xml:S1:10031:4	O
reported	NULOJIX.xml:S1:10036:8	O
more	NULOJIX.xml:S1:10045:4	O
frequently	NULOJIX.xml:S1:10050:10	O
in	NULOJIX.xml:S1:10061:2	O
patients	NULOJIX.xml:S1:10064:8	O
receiving	NULOJIX.xml:S1:10073:9	O
NULOJIX	NULOJIX.xml:S1:10083:7	O
than	NULOJIX.xml:S1:10091:4	O
cyclosporine	NULOJIX.xml:S1:10096:12	O
.	NULOJIX.xml:S1:10108:1	O

Of	NULOJIX.xml:S1:10110:2	O
the	NULOJIX.xml:S1:10113:3	O
patients	NULOJIX.xml:S1:10117:8	O
who	NULOJIX.xml:S1:10126:3	O
developed	NULOJIX.xml:S1:10130:9	O
tuberculosis	NULOJIX.xml:S1:10140:12	B-AdverseReaction
through	NULOJIX.xml:S1:10153:7	O
3	NULOJIX.xml:S1:10161:1	O
years	NULOJIX.xml:S1:10163:5	O
,	NULOJIX.xml:S1:10168:1	O
all	NULOJIX.xml:S1:10170:3	O
but	NULOJIX.xml:S1:10174:3	O
one	NULOJIX.xml:S1:10178:3	O
NULOJIX	NULOJIX.xml:S1:10182:7	O
patient	NULOJIX.xml:S1:10190:7	O
lived	NULOJIX.xml:S1:10198:5	O
in	NULOJIX.xml:S1:10204:2	O
countries	NULOJIX.xml:S1:10207:9	O
with	NULOJIX.xml:S1:10217:4	O
a	NULOJIX.xml:S1:10222:1	O
high	NULOJIX.xml:S1:10224:4	O
prevalence	NULOJIX.xml:S1:10229:10	O
of	NULOJIX.xml:S1:10240:2	O
tuberculosis	NULOJIX.xml:S1:10243:12	O
[	NULOJIX.xml:S1:10256:1	O
see	NULOJIX.xml:S1:10257:3	O
Warnings	NULOJIX.xml:S1:10264:8	O
and	NULOJIX.xml:S1:10273:3	O
Precautions	NULOJIX.xml:S1:10277:11	O
(	NULOJIX.xml:S1:10289:1	O
5.5	NULOJIX.xml:S1:10290:3	O
)	NULOJIX.xml:S1:10293:1	O
]	NULOJIX.xml:S1:10298:1	O
.	NULOJIX.xml:S1:10299:1	O

Table	NULOJIX.xml:S1:10305:5	O
3	NULOJIX.xml:S1:10311:1	O
:	NULOJIX.xml:S1:10312:1	O
Overall	NULOJIX.xml:S1:10314:7	O
Infections	NULOJIX.xml:S1:10322:10	B-AdverseReaction
and	NULOJIX.xml:S1:10333:3	O
Select	NULOJIX.xml:S1:10337:6	O
Infections	NULOJIX.xml:S1:10344:10	B-AdverseReaction
with	NULOJIX.xml:S1:10355:4	O
Identified	NULOJIX.xml:S1:10360:10	O
Etiology	NULOJIX.xml:S1:10371:8	O
by	NULOJIX.xml:S1:10380:2	O
Treatment	NULOJIX.xml:S1:10383:9	O
Group	NULOJIX.xml:S1:10393:5	O
following	NULOJIX.xml:S1:10399:9	O
One	NULOJIX.xml:S1:10409:3	O
and	NULOJIX.xml:S1:10413:3	O
Three	NULOJIX.xml:S1:10417:5	O
Years	NULOJIX.xml:S1:10423:5	O
of	NULOJIX.xml:S1:10429:2	O
Treatment	NULOJIX.xml:S1:10432:9	O
in	NULOJIX.xml:S1:10442:2	O
Studies	NULOJIX.xml:S1:10445:7	O
1	NULOJIX.xml:S1:10453:1	O
and	NULOJIX.xml:S1:10455:3	O
2	NULOJIX.xml:S1:10459:1	O

Up	NULOJIX.xml:S1:10496:2	O
to	NULOJIX.xml:S1:10499:2	O
Year	NULOJIX.xml:S1:10502:4	O
1	NULOJIX.xml:S1:10507:1	O
Up	NULOJIX.xml:S1:10516:2	O
to	NULOJIX.xml:S1:10519:2	O
Year	NULOJIX.xml:S1:10522:4	O
3	NULOJIX.xml:S1:10527:1	O

NULOJIX	NULOJIX.xml:S1:10571:7	O
Recommended	NULOJIX.xml:S1:10582:11	O
Regimen	NULOJIX.xml:S1:10597:7	O
N	NULOJIX.xml:S1:10608:1	O
401	NULOJIX.xml:S1:10610:3	O
n	NULOJIX.xml:S1:10617:1	O
(	NULOJIX.xml:S1:10619:1	O
)	NULOJIX.xml:S1:10621:1	O
Cyclosporine	NULOJIX.xml:S1:10628:12	O
N	NULOJIX.xml:S1:10644:1	O
405	NULOJIX.xml:S1:10646:3	O
n	NULOJIX.xml:S1:10653:1	O
(	NULOJIX.xml:S1:10655:1	O
)	NULOJIX.xml:S1:10657:1	O
NULOJIX	NULOJIX.xml:S1:10664:7	O
Recommended	NULOJIX.xml:S1:10675:11	O
Regimen	NULOJIX.xml:S1:10690:7	O
N	NULOJIX.xml:S1:10701:1	O
401	NULOJIX.xml:S1:10703:3	O
n	NULOJIX.xml:S1:10710:1	O
(	NULOJIX.xml:S1:10712:1	O
)	NULOJIX.xml:S1:10714:1	O
Cyclosporine	NULOJIX.xml:S1:10721:12	O
N	NULOJIX.xml:S1:10737:1	O
405	NULOJIX.xml:S1:10739:3	O
n	NULOJIX.xml:S1:10746:1	O
(	NULOJIX.xml:S1:10748:1	O
)	NULOJIX.xml:S1:10750:1	O

Studies	NULOJIX.xml:S1:10764:7	O

1	NULOJIX.xml:S1:10772:1	O
and	NULOJIX.xml:S1:10774:3	O
2	NULOJIX.xml:S1:10778:1	O
were	NULOJIX.xml:S1:10780:4	O
not	NULOJIX.xml:S1:10785:3	O
designed	NULOJIX.xml:S1:10789:8	O
to	NULOJIX.xml:S1:10798:2	O
support	NULOJIX.xml:S1:10801:7	O
comparative	NULOJIX.xml:S1:10809:11	O
claims	NULOJIX.xml:S1:10821:6	O
for	NULOJIX.xml:S1:10828:3	O
NULOJIX	NULOJIX.xml:S1:10832:7	O
for	NULOJIX.xml:S1:10840:3	O
the	NULOJIX.xml:S1:10844:3	O
adverse	NULOJIX.xml:S1:10848:7	O
reactions	NULOJIX.xml:S1:10856:9	O
reported	NULOJIX.xml:S1:10866:8	O
in	NULOJIX.xml:S1:10875:2	O
this	NULOJIX.xml:S1:10878:4	O
table	NULOJIX.xml:S1:10883:5	O
.	NULOJIX.xml:S1:10888:1	O

Median	NULOJIX.xml:S1:10895:6	O
exposure	NULOJIX.xml:S1:10902:8	O
in	NULOJIX.xml:S1:10911:2	O
days	NULOJIX.xml:S1:10914:4	O
for	NULOJIX.xml:S1:10919:3	O
pooled	NULOJIX.xml:S1:10923:6	O
studies	NULOJIX.xml:S1:10930:7	O
:	NULOJIX.xml:S1:10937:1	O
1203	NULOJIX.xml:S1:10939:4	O
for	NULOJIX.xml:S1:10944:3	O
NULOJIX	NULOJIX.xml:S1:10948:7	O
recommended	NULOJIX.xml:S1:10956:11	O
regimen	NULOJIX.xml:S1:10968:7	O
and	NULOJIX.xml:S1:10976:3	O
1163	NULOJIX.xml:S1:10980:4	O
for	NULOJIX.xml:S1:10985:3	O
cyclosporine	NULOJIX.xml:S1:10989:12	O
in	NULOJIX.xml:S1:11002:2	O
Studies	NULOJIX.xml:S1:11005:7	O
1	NULOJIX.xml:S1:11013:1	O
and	NULOJIX.xml:S1:11015:3	O
2	NULOJIX.xml:S1:11019:1	O
.	NULOJIX.xml:S1:11020:1	O
?	NULOJIX.xml:S1:11023:1	O

All	NULOJIX.xml:S1:11028:3	O
infections	NULOJIX.xml:S1:11032:10	B-AdverseReaction
include	NULOJIX.xml:S1:11043:7	O
bacterial	NULOJIX.xml:S1:11051:9	I-AdverseReaction
,	NULOJIX.xml:S1:11060:1	O
viral	NULOJIX.xml:S1:11062:5	I-AdverseReaction
,	NULOJIX.xml:S1:11067:1	O
fungal	NULOJIX.xml:S1:11069:6	I-AdverseReaction
,	NULOJIX.xml:S1:11075:1	O
and	NULOJIX.xml:S1:11077:3	O
other	NULOJIX.xml:S1:11081:5	O
organisms	NULOJIX.xml:S1:11087:9	O
.	NULOJIX.xml:S1:11096:1	O

For	NULOJIX.xml:S1:11098:3	O
infectious	NULOJIX.xml:S1:11102:10	B-AdverseReaction
adverse	NULOJIX.xml:S1:11113:7	I-AdverseReaction
reactions	NULOJIX.xml:S1:11121:9	I-AdverseReaction
,	NULOJIX.xml:S1:11130:1	O
the	NULOJIX.xml:S1:11132:3	O
causative	NULOJIX.xml:S1:11136:9	O
organism	NULOJIX.xml:S1:11146:8	O
is	NULOJIX.xml:S1:11155:2	O
reported	NULOJIX.xml:S1:11158:8	O
if	NULOJIX.xml:S1:11167:2	O
specified	NULOJIX.xml:S1:11170:9	O
by	NULOJIX.xml:S1:11180:2	O
the	NULOJIX.xml:S1:11183:3	O
physician	NULOJIX.xml:S1:11187:9	O
in	NULOJIX.xml:S1:11197:2	O
the	NULOJIX.xml:S1:11200:3	O
clinical	NULOJIX.xml:S1:11204:8	O
trials	NULOJIX.xml:S1:11213:6	O
.	NULOJIX.xml:S1:11219:1	O

S	NULOJIX.xml:S1:11222:1	O
A	NULOJIX.xml:S1:11227:1	O
medically	NULOJIX.xml:S1:11229:9	O
important	NULOJIX.xml:S1:11239:9	O
event	NULOJIX.xml:S1:11249:5	O
that	NULOJIX.xml:S1:11255:4	O
may	NULOJIX.xml:S1:11260:3	O
be	NULOJIX.xml:S1:11264:2	O
life	NULOJIX.xml:S1:11267:4	O
-	NULOJIX.xml:S1:11271:1	O
threatening	NULOJIX.xml:S1:11272:11	O
or	NULOJIX.xml:S1:11284:2	O
result	NULOJIX.xml:S1:11287:6	O
in	NULOJIX.xml:S1:11294:2	O
death	NULOJIX.xml:S1:11297:5	B-AdverseReaction
or	NULOJIX.xml:S1:11303:2	O
hospitalization	NULOJIX.xml:S1:11306:15	O
or	NULOJIX.xml:S1:11322:2	O
prolongation	NULOJIX.xml:S1:11325:12	O
of	NULOJIX.xml:S1:11338:2	O
existing	NULOJIX.xml:S1:11341:8	O
hospitalization	NULOJIX.xml:S1:11350:15	O
.	NULOJIX.xml:S1:11365:1	O

Infections	NULOJIX.xml:S1:11367:10	B-AdverseReaction
not	NULOJIX.xml:S1:11378:3	O
meeting	NULOJIX.xml:S1:11382:7	O
these	NULOJIX.xml:S1:11390:5	O
criteria	NULOJIX.xml:S1:11396:8	O
are	NULOJIX.xml:S1:11405:3	O
considered	NULOJIX.xml:S1:11409:10	O
non	NULOJIX.xml:S1:11420:3	O
-	NULOJIX.xml:S1:11423:1	O
serious	NULOJIX.xml:S1:11424:7	O
.	NULOJIX.xml:S1:11431:1	O

BK	NULOJIX.xml:S1:11439:2	B-AdverseReaction
virus	NULOJIX.xml:S1:11442:5	I-AdverseReaction
-	NULOJIX.xml:S1:11447:1	I-AdverseReaction
associated	NULOJIX.xml:S1:11448:10	I-AdverseReaction
nephropathy	NULOJIX.xml:S1:11459:11	I-AdverseReaction
was	NULOJIX.xml:S1:11471:3	O
reported	NULOJIX.xml:S1:11475:8	O
in	NULOJIX.xml:S1:11484:2	O
6	NULOJIX.xml:S1:11487:1	O
NULOJIX	NULOJIX.xml:S1:11489:7	O
patients	NULOJIX.xml:S1:11497:8	O
(	NULOJIX.xml:S1:11506:1	O
4	NULOJIX.xml:S1:11507:1	O
of	NULOJIX.xml:S1:11509:2	O
which	NULOJIX.xml:S1:11512:5	O
resulted	NULOJIX.xml:S1:11518:8	O
in	NULOJIX.xml:S1:11527:2	O
graft	NULOJIX.xml:S1:11530:5	O
loss	NULOJIX.xml:S1:11536:4	O
)	NULOJIX.xml:S1:11540:1	O
and	NULOJIX.xml:S1:11542:3	O
6	NULOJIX.xml:S1:11546:1	O
cyclosporine	NULOJIX.xml:S1:11548:12	O
patients	NULOJIX.xml:S1:11561:8	O
(	NULOJIX.xml:S1:11570:1	O
none	NULOJIX.xml:S1:11571:4	O
of	NULOJIX.xml:S1:11576:2	O
which	NULOJIX.xml:S1:11579:5	O
resulted	NULOJIX.xml:S1:11585:8	O
in	NULOJIX.xml:S1:11594:2	O
graft	NULOJIX.xml:S1:11597:5	O
loss	NULOJIX.xml:S1:11603:4	O
)	NULOJIX.xml:S1:11607:1	O
by	NULOJIX.xml:S1:11609:2	O
Year	NULOJIX.xml:S1:11612:4	O
3	NULOJIX.xml:S1:11617:1	O
.	NULOJIX.xml:S1:11618:1	O

Most	NULOJIX.xml:S1:11626:4	O
herpes	NULOJIX.xml:S1:11631:6	B-AdverseReaction
infections	NULOJIX.xml:S1:11638:10	I-AdverseReaction
were	NULOJIX.xml:S1:11649:4	O
non	NULOJIX.xml:S1:11654:3	B-Severity
-	NULOJIX.xml:S1:11657:1	I-Severity
serious	NULOJIX.xml:S1:11658:7	I-Severity
and	NULOJIX.xml:S1:11666:3	O
1	NULOJIX.xml:S1:11670:1	O
led	NULOJIX.xml:S1:11672:3	O
to	NULOJIX.xml:S1:11676:2	O
treatment	NULOJIX.xml:S1:11679:9	O
discontinuation	NULOJIX.xml:S1:11689:15	O
.	NULOJIX.xml:S1:11704:1	O

All	NULOJIX.xml:S1:11714:3	O

infections	NULOJIX.xml:S1:11718:10	B-AdverseReaction
?	NULOJIX.xml:S1:11728:1	O

287	NULOJIX.xml:S1:11744:3	O
(	NULOJIX.xml:S1:11748:1	O
72	NULOJIX.xml:S1:11749:2	O
)	NULOJIX.xml:S1:11751:1	O
299	NULOJIX.xml:S1:11764:3	O
(	NULOJIX.xml:S1:11768:1	O
74	NULOJIX.xml:S1:11769:2	O
)	NULOJIX.xml:S1:11771:1	O
329	NULOJIX.xml:S1:11784:3	O
(	NULOJIX.xml:S1:11788:1	O
82	NULOJIX.xml:S1:11789:2	O
)	NULOJIX.xml:S1:11791:1	O
327	NULOJIX.xml:S1:11804:3	O
(	NULOJIX.xml:S1:11808:1	O
81	NULOJIX.xml:S1:11809:2	O
)	NULOJIX.xml:S1:11811:1	O

Serious	NULOJIX.xml:S1:11830:7	B-Severity
infectionsS	NULOJIX.xml:S1:11838:11	B-AdverseReaction
98	NULOJIX.xml:S1:11857:2	O
(	NULOJIX.xml:S1:11860:1	O
24	NULOJIX.xml:S1:11861:2	O
)	NULOJIX.xml:S1:11863:1	O
113	NULOJIX.xml:S1:11877:3	O
(	NULOJIX.xml:S1:11881:1	O
28	NULOJIX.xml:S1:11882:2	O
)	NULOJIX.xml:S1:11884:1	O
144	NULOJIX.xml:S1:11897:3	O
(	NULOJIX.xml:S1:11901:1	O
36	NULOJIX.xml:S1:11902:2	O
)	NULOJIX.xml:S1:11904:1	O
157	NULOJIX.xml:S1:11917:3	O
(	NULOJIX.xml:S1:11921:1	O
39	NULOJIX.xml:S1:11922:2	O
)	NULOJIX.xml:S1:11924:1	O

CMV	NULOJIX.xml:S1:11940:3	I-AdverseReaction
44	NULOJIX.xml:S1:11970:2	O
(	NULOJIX.xml:S1:11973:1	O
11	NULOJIX.xml:S1:11974:2	O
)	NULOJIX.xml:S1:11976:1	O
52	NULOJIX.xml:S1:11990:2	O
(	NULOJIX.xml:S1:11993:1	O
13	NULOJIX.xml:S1:11994:2	O
)	NULOJIX.xml:S1:11996:1	O
53	NULOJIX.xml:S1:12010:2	O
(	NULOJIX.xml:S1:12013:1	O
13	NULOJIX.xml:S1:12014:2	O
)	NULOJIX.xml:S1:12016:1	O
56	NULOJIX.xml:S1:12030:2	O
(	NULOJIX.xml:S1:12033:1	O
14	NULOJIX.xml:S1:12034:2	O
)	NULOJIX.xml:S1:12036:1	O

Polyoma	NULOJIX.xml:S1:12053:7	I-AdverseReaction
virus	NULOJIX.xml:S1:12061:5	I-AdverseReaction
10	NULOJIX.xml:S1:12083:2	O
(	NULOJIX.xml:S1:12086:1	O
3	NULOJIX.xml:S1:12087:1	O
)	NULOJIX.xml:S1:12088:1	O
23	NULOJIX.xml:S1:12103:2	O
(	NULOJIX.xml:S1:12106:1	O
6	NULOJIX.xml:S1:12107:1	O
)	NULOJIX.xml:S1:12108:1	O
17	NULOJIX.xml:S1:12123:2	O
(	NULOJIX.xml:S1:12126:1	O
4	NULOJIX.xml:S1:12127:1	O
)	NULOJIX.xml:S1:12128:1	O
27	NULOJIX.xml:S1:12143:2	O
(	NULOJIX.xml:S1:12146:1	O
7	NULOJIX.xml:S1:12147:1	O
)	NULOJIX.xml:S1:12148:1	O

Herpes	NULOJIX.xml:S1:12166:6	I-AdverseReaction
27	NULOJIX.xml:S1:12196:2	O
(	NULOJIX.xml:S1:12199:1	O
7	NULOJIX.xml:S1:12200:1	O
)	NULOJIX.xml:S1:12201:1	O
26	NULOJIX.xml:S1:12216:2	O
(	NULOJIX.xml:S1:12219:1	O
6	NULOJIX.xml:S1:12220:1	O
)	NULOJIX.xml:S1:12221:1	O
55	NULOJIX.xml:S1:12236:2	O
(	NULOJIX.xml:S1:12239:1	O
14	NULOJIX.xml:S1:12240:2	O
)	NULOJIX.xml:S1:12242:1	O
46	NULOJIX.xml:S1:12256:2	O
(	NULOJIX.xml:S1:12259:1	O
11	NULOJIX.xml:S1:12260:2	O
)	NULOJIX.xml:S1:12262:1	O

Tuberculosis	NULOJIX.xml:S1:12279:12	B-AdverseReaction
2	NULOJIX.xml:S1:12309:1	O
(	NULOJIX.xml:S1:12311:1	O
1	NULOJIX.xml:S1:12312:1	O
)	NULOJIX.xml:S1:12313:1	O
1	NULOJIX.xml:S1:12329:1	O
(	NULOJIX.xml:S1:12331:1	O
1	NULOJIX.xml:S1:12333:1	O
)	NULOJIX.xml:S1:12334:1	O
6	NULOJIX.xml:S1:12349:1	O
(	NULOJIX.xml:S1:12351:1	O
2	NULOJIX.xml:S1:12352:1	O
)	NULOJIX.xml:S1:12353:1	O
1	NULOJIX.xml:S1:12369:1	O
(	NULOJIX.xml:S1:12371:1	O
1	NULOJIX.xml:S1:12373:1	O
)	NULOJIX.xml:S1:12374:1	O

Infections	NULOJIX.xml:S1:12403:10	O
Reported	NULOJIX.xml:S1:12414:8	O
in	NULOJIX.xml:S1:12423:2	O
the	NULOJIX.xml:S1:12426:3	O
CNS	NULOJIX.xml:S1:12430:3	O

Following	NULOJIX.xml:S1:12437:9	O
three	NULOJIX.xml:S1:12447:5	O
years	NULOJIX.xml:S1:12453:5	O
of	NULOJIX.xml:S1:12459:2	O
treatment	NULOJIX.xml:S1:12462:9	O
in	NULOJIX.xml:S1:12472:2	O
Studies	NULOJIX.xml:S1:12475:7	O
1	NULOJIX.xml:S1:12483:1	O
and	NULOJIX.xml:S1:12485:3	O
2	NULOJIX.xml:S1:12489:1	O
,	NULOJIX.xml:S1:12490:1	O
cryptococcal	NULOJIX.xml:S1:12492:12	B-AdverseReaction
meningitis	NULOJIX.xml:S1:12505:10	I-AdverseReaction
was	NULOJIX.xml:S1:12516:3	O
reported	NULOJIX.xml:S1:12520:8	O
in	NULOJIX.xml:S1:12529:2	O
one	NULOJIX.xml:S1:12532:3	O
patient	NULOJIX.xml:S1:12536:7	O
out	NULOJIX.xml:S1:12544:3	O
of	NULOJIX.xml:S1:12548:2	O
401	NULOJIX.xml:S1:12551:3	O
patients	NULOJIX.xml:S1:12555:8	O
treated	NULOJIX.xml:S1:12564:7	O
with	NULOJIX.xml:S1:12572:4	O
the	NULOJIX.xml:S1:12577:3	O
NULOJIX	NULOJIX.xml:S1:12581:7	O
recommended	NULOJIX.xml:S1:12589:11	O
regimen	NULOJIX.xml:S1:12601:7	O
(	NULOJIX.xml:S1:12609:1	O
0.2%	NULOJIX.xml:S1:12610:4	O
)	NULOJIX.xml:S1:12614:1	O
and	NULOJIX.xml:S1:12616:3	O
one	NULOJIX.xml:S1:12620:3	O
patient	NULOJIX.xml:S1:12624:7	O
out	NULOJIX.xml:S1:12632:3	O
of	NULOJIX.xml:S1:12636:2	O
the	NULOJIX.xml:S1:12639:3	O
405	NULOJIX.xml:S1:12643:3	O
treated	NULOJIX.xml:S1:12647:7	O
with	NULOJIX.xml:S1:12655:4	O
the	NULOJIX.xml:S1:12660:3	O
cyclosporine	NULOJIX.xml:S1:12664:12	O
control	NULOJIX.xml:S1:12677:7	O
(	NULOJIX.xml:S1:12685:1	O
0.2%	NULOJIX.xml:S1:12686:4	O
)	NULOJIX.xml:S1:12690:1	O
.	NULOJIX.xml:S1:12691:1	O

Six	NULOJIX.xml:S1:12697:3	O
patients	NULOJIX.xml:S1:12701:8	O
out	NULOJIX.xml:S1:12710:3	O
of	NULOJIX.xml:S1:12714:2	O
the	NULOJIX.xml:S1:12717:3	O
403	NULOJIX.xml:S1:12721:3	O
who	NULOJIX.xml:S1:12725:3	O
were	NULOJIX.xml:S1:12729:4	O
treated	NULOJIX.xml:S1:12734:7	O
with	NULOJIX.xml:S1:12742:4	O
the	NULOJIX.xml:S1:12747:3	O
NULOJIX	NULOJIX.xml:S1:12751:7	O
regimen	NULOJIX.xml:S1:12759:7	O
of	NULOJIX.xml:S1:12767:2	O
higher	NULOJIX.xml:S1:12770:6	O
cumulative	NULOJIX.xml:S1:12777:10	O
dose	NULOJIX.xml:S1:12788:4	O
and	NULOJIX.xml:S1:12793:3	O
more	NULOJIX.xml:S1:12797:4	O
frequent	NULOJIX.xml:S1:12802:8	O
dosing	NULOJIX.xml:S1:12811:6	O
than	NULOJIX.xml:S1:12818:4	O
recommended	NULOJIX.xml:S1:12823:11	O
in	NULOJIX.xml:S1:12835:2	O
Studies	NULOJIX.xml:S1:12838:7	O
1	NULOJIX.xml:S1:12846:1	O
and	NULOJIX.xml:S1:12848:3	O
2	NULOJIX.xml:S1:12852:1	O
(	NULOJIX.xml:S1:12854:1	O
1.5%	NULOJIX.xml:S1:12855:4	O
)	NULOJIX.xml:S1:12859:1	O
were	NULOJIX.xml:S1:12861:4	O
reported	NULOJIX.xml:S1:12866:8	O
to	NULOJIX.xml:S1:12875:2	O
have	NULOJIX.xml:S1:12878:4	O
developed	NULOJIX.xml:S1:12883:9	O
CNS	NULOJIX.xml:S1:12893:3	B-AdverseReaction
infections	NULOJIX.xml:S1:12897:10	I-AdverseReaction
,	NULOJIX.xml:S1:12907:1	O
including	NULOJIX.xml:S1:12909:9	O
2	NULOJIX.xml:S1:12919:1	O
cases	NULOJIX.xml:S1:12921:5	O
of	NULOJIX.xml:S1:12927:2	O
cryptococcal	NULOJIX.xml:S1:12930:12	B-AdverseReaction
meningitis	NULOJIX.xml:S1:12943:10	I-AdverseReaction
,	NULOJIX.xml:S1:12953:1	O
one	NULOJIX.xml:S1:12955:3	O
case	NULOJIX.xml:S1:12959:4	O
of	NULOJIX.xml:S1:12964:2	O
Chagas	NULOJIX.xml:S1:12967:6	B-AdverseReaction
encephalitis	NULOJIX.xml:S1:12974:12	I-AdverseReaction
with	NULOJIX.xml:S1:12987:4	O
cryptococcal	NULOJIX.xml:S1:12992:12	B-AdverseReaction
meningitis	NULOJIX.xml:S1:13005:10	I-AdverseReaction
,	NULOJIX.xml:S1:13015:1	O
one	NULOJIX.xml:S1:13017:3	O
case	NULOJIX.xml:S1:13021:4	O
of	NULOJIX.xml:S1:13026:2	O
cerebral	NULOJIX.xml:S1:13029:8	B-AdverseReaction
aspergillosis	NULOJIX.xml:S1:13038:13	I-AdverseReaction
,	NULOJIX.xml:S1:13051:1	O
one	NULOJIX.xml:S1:13053:3	O
case	NULOJIX.xml:S1:13057:4	O
of	NULOJIX.xml:S1:13062:2	O
West	NULOJIX.xml:S1:13065:4	B-AdverseReaction
Nile	NULOJIX.xml:S1:13070:4	I-AdverseReaction
encephalitis	NULOJIX.xml:S1:13075:12	I-AdverseReaction
,	NULOJIX.xml:S1:13087:1	O
and	NULOJIX.xml:S1:13089:3	O
one	NULOJIX.xml:S1:13093:3	O
case	NULOJIX.xml:S1:13097:4	O
of	NULOJIX.xml:S1:13102:2	O
PML	NULOJIX.xml:S1:13105:3	B-AdverseReaction
(	NULOJIX.xml:S1:13109:1	O
discussed	NULOJIX.xml:S1:13110:9	O
above	NULOJIX.xml:S1:13120:5	O
)	NULOJIX.xml:S1:13125:1	O
.	NULOJIX.xml:S1:13126:1	O

Infusion	NULOJIX.xml:S1:13134:8	O
Reactions	NULOJIX.xml:S1:13143:9	O

There	NULOJIX.xml:S1:13156:5	O
were	NULOJIX.xml:S1:13162:4	O
no	NULOJIX.xml:S1:13167:2	B-Negation
reports	NULOJIX.xml:S1:13170:7	O
of	NULOJIX.xml:S1:13178:2	O
anaphylaxis	NULOJIX.xml:S1:13181:11	B-AdverseReaction
or	NULOJIX.xml:S1:13193:2	O
drug	NULOJIX.xml:S1:13196:4	B-AdverseReaction
hypersensitivity	NULOJIX.xml:S1:13201:16	I-AdverseReaction
in	NULOJIX.xml:S1:13218:2	O
patients	NULOJIX.xml:S1:13221:8	O
treated	NULOJIX.xml:S1:13230:7	O
with	NULOJIX.xml:S1:13238:4	O
NULOJIX	NULOJIX.xml:S1:13243:7	O
in	NULOJIX.xml:S1:13251:2	O
Studies	NULOJIX.xml:S1:13254:7	O
1	NULOJIX.xml:S1:13262:1	O
and	NULOJIX.xml:S1:13264:3	O
2	NULOJIX.xml:S1:13268:1	O
through	NULOJIX.xml:S1:13270:7	O
three	NULOJIX.xml:S1:13278:5	O
years	NULOJIX.xml:S1:13284:5	O
.	NULOJIX.xml:S1:13289:1	O

Infusion	NULOJIX.xml:S1:13295:8	B-AdverseReaction
-	NULOJIX.xml:S1:13303:1	I-AdverseReaction
related	NULOJIX.xml:S1:13304:7	I-AdverseReaction
reactions	NULOJIX.xml:S1:13312:9	I-AdverseReaction
within	NULOJIX.xml:S1:13322:6	O
one	NULOJIX.xml:S1:13329:3	O
hour	NULOJIX.xml:S1:13333:4	O
of	NULOJIX.xml:S1:13338:2	O
infusion	NULOJIX.xml:S1:13341:8	O
were	NULOJIX.xml:S1:13350:4	O
reported	NULOJIX.xml:S1:13355:8	O
in	NULOJIX.xml:S1:13364:2	O
5%	NULOJIX.xml:S1:13367:2	O
of	NULOJIX.xml:S1:13370:2	O
patients	NULOJIX.xml:S1:13373:8	O
treated	NULOJIX.xml:S1:13382:7	O
with	NULOJIX.xml:S1:13390:4	O
the	NULOJIX.xml:S1:13395:3	O
recommended	NULOJIX.xml:S1:13399:11	O
dose	NULOJIX.xml:S1:13411:4	O
of	NULOJIX.xml:S1:13416:2	O
NULOJIX	NULOJIX.xml:S1:13419:7	O
,	NULOJIX.xml:S1:13426:1	O
similar	NULOJIX.xml:S1:13428:7	O
to	NULOJIX.xml:S1:13436:2	O
the	NULOJIX.xml:S1:13439:3	O
placebo	NULOJIX.xml:S1:13443:7	O
rate	NULOJIX.xml:S1:13451:4	O
.	NULOJIX.xml:S1:13455:1	O

No	NULOJIX.xml:S1:13457:2	O
serious	NULOJIX.xml:S1:13460:7	O
events	NULOJIX.xml:S1:13468:6	O
were	NULOJIX.xml:S1:13475:4	O
reported	NULOJIX.xml:S1:13480:8	O
through	NULOJIX.xml:S1:13489:7	O
Year	NULOJIX.xml:S1:13497:4	O
3	NULOJIX.xml:S1:13502:1	O
.	NULOJIX.xml:S1:13503:1	O

The	NULOJIX.xml:S1:13505:3	O
most	NULOJIX.xml:S1:13509:4	O
frequent	NULOJIX.xml:S1:13514:8	O
reactions	NULOJIX.xml:S1:13523:9	O
were	NULOJIX.xml:S1:13533:4	O
hypotension	NULOJIX.xml:S1:13538:11	B-AdverseReaction
and	NULOJIX.xml:S1:13550:3	O
hypertension	NULOJIX.xml:S1:13554:12	B-AdverseReaction
.	NULOJIX.xml:S1:13566:1	O

Proteinuria	NULOJIX.xml:S1:13574:11	O

At	NULOJIX.xml:S1:13589:2	O
Month	NULOJIX.xml:S1:13592:5	O
1	NULOJIX.xml:S1:13598:1	O
after	NULOJIX.xml:S1:13600:5	O
transplantation	NULOJIX.xml:S1:13606:15	O
in	NULOJIX.xml:S1:13622:2	O
Studies	NULOJIX.xml:S1:13625:7	O
1	NULOJIX.xml:S1:13633:1	O
and	NULOJIX.xml:S1:13635:3	O
2	NULOJIX.xml:S1:13639:1	O
,	NULOJIX.xml:S1:13640:1	O
the	NULOJIX.xml:S1:13642:3	O
frequency	NULOJIX.xml:S1:13646:9	O
of	NULOJIX.xml:S1:13656:2	O
2	NULOJIX.xml:S1:13659:1	B-Severity
proteinuria	NULOJIX.xml:S1:13662:11	B-AdverseReaction
on	NULOJIX.xml:S1:13674:2	O
urine	NULOJIX.xml:S1:13677:5	O
dipstick	NULOJIX.xml:S1:13683:8	O
in	NULOJIX.xml:S1:13692:2	O
patients	NULOJIX.xml:S1:13695:8	O
treated	NULOJIX.xml:S1:13704:7	O
with	NULOJIX.xml:S1:13712:4	O
the	NULOJIX.xml:S1:13717:3	O
NULOJIX	NULOJIX.xml:S1:13721:7	O
recommended	NULOJIX.xml:S1:13729:11	O
regimen	NULOJIX.xml:S1:13741:7	O
was	NULOJIX.xml:S1:13749:3	O
33%	NULOJIX.xml:S1:13753:3	O
(	NULOJIX.xml:S1:13757:1	O
130	NULOJIX.xml:S1:13758:3	O
390	NULOJIX.xml:S1:13762:3	O
)	NULOJIX.xml:S1:13765:1	O
and	NULOJIX.xml:S1:13767:3	O
28%	NULOJIX.xml:S1:13771:3	O
(	NULOJIX.xml:S1:13775:1	O
107	NULOJIX.xml:S1:13776:3	O
384	NULOJIX.xml:S1:13780:3	O
)	NULOJIX.xml:S1:13783:1	O
in	NULOJIX.xml:S1:13785:2	O
patients	NULOJIX.xml:S1:13788:8	O
treated	NULOJIX.xml:S1:13797:7	O
with	NULOJIX.xml:S1:13805:4	O
the	NULOJIX.xml:S1:13810:3	O
cyclosporine	NULOJIX.xml:S1:13814:12	O
control	NULOJIX.xml:S1:13827:7	O
regimen	NULOJIX.xml:S1:13835:7	O
.	NULOJIX.xml:S1:13842:1	O

The	NULOJIX.xml:S1:13844:3	O
frequency	NULOJIX.xml:S1:13848:9	O
of	NULOJIX.xml:S1:13858:2	O
2	NULOJIX.xml:S1:13861:1	B-Severity
proteinuria	NULOJIX.xml:S1:13864:11	B-AdverseReaction
was	NULOJIX.xml:S1:13876:3	O
similar	NULOJIX.xml:S1:13880:7	O
between	NULOJIX.xml:S1:13888:7	O
the	NULOJIX.xml:S1:13896:3	O
two	NULOJIX.xml:S1:13900:3	O
treatment	NULOJIX.xml:S1:13904:9	O
groups	NULOJIX.xml:S1:13914:6	O
between	NULOJIX.xml:S1:13921:7	O
one	NULOJIX.xml:S1:13929:3	O
and	NULOJIX.xml:S1:13933:3	O
three	NULOJIX.xml:S1:13937:5	O
years	NULOJIX.xml:S1:13943:5	O
after	NULOJIX.xml:S1:13949:5	O
transplantation	NULOJIX.xml:S1:13955:15	O
(	NULOJIX.xml:S1:13971:1	O
10%	NULOJIX.xml:S1:13973:3	O
in	NULOJIX.xml:S1:13977:2	O
both	NULOJIX.xml:S1:13980:4	O
studies	NULOJIX.xml:S1:13985:7	O
)	NULOJIX.xml:S1:13992:1	O
.	NULOJIX.xml:S1:13993:1	O

There	NULOJIX.xml:S1:13995:5	O
were	NULOJIX.xml:S1:14001:4	O
no	NULOJIX.xml:S1:14006:2	O
differences	NULOJIX.xml:S1:14009:11	O
in	NULOJIX.xml:S1:14021:2	O
the	NULOJIX.xml:S1:14024:3	O
occurrence	NULOJIX.xml:S1:14028:10	O
of	NULOJIX.xml:S1:14039:2	O
3	NULOJIX.xml:S1:14042:1	B-Severity
proteinuria	NULOJIX.xml:S1:14045:11	B-AdverseReaction
(	NULOJIX.xml:S1:14057:1	O
4%	NULOJIX.xml:S1:14059:2	O
in	NULOJIX.xml:S1:14062:2	O
both	NULOJIX.xml:S1:14065:4	O
studies	NULOJIX.xml:S1:14070:7	O
)	NULOJIX.xml:S1:14077:1	O
at	NULOJIX.xml:S1:14079:2	O
any	NULOJIX.xml:S1:14082:3	O
time	NULOJIX.xml:S1:14086:4	O
point	NULOJIX.xml:S1:14091:5	O
,	NULOJIX.xml:S1:14096:1	O
and	NULOJIX.xml:S1:14098:3	O
no	NULOJIX.xml:S1:14102:2	B-Negation
patients	NULOJIX.xml:S1:14105:8	O
experienced	NULOJIX.xml:S1:14114:11	O
4	NULOJIX.xml:S1:14126:1	B-Severity
proteinuria	NULOJIX.xml:S1:14129:11	B-AdverseReaction
.	NULOJIX.xml:S1:14140:1	O

The	NULOJIX.xml:S1:14142:3	O
clinical	NULOJIX.xml:S1:14146:8	O
significance	NULOJIX.xml:S1:14155:12	O
of	NULOJIX.xml:S1:14168:2	O
this	NULOJIX.xml:S1:14171:4	O
increase	NULOJIX.xml:S1:14176:8	O
in	NULOJIX.xml:S1:14185:2	O
early	NULOJIX.xml:S1:14188:5	B-AdverseReaction
proteinuria	NULOJIX.xml:S1:14194:11	I-AdverseReaction
is	NULOJIX.xml:S1:14206:2	O
unknown	NULOJIX.xml:S1:14209:7	O
.	NULOJIX.xml:S1:14216:1	O

Immunogenicity	NULOJIX.xml:S1:14224:14	O

Antibodies	NULOJIX.xml:S1:14242:10	O
directed	NULOJIX.xml:S1:14253:8	O
against	NULOJIX.xml:S1:14262:7	O
the	NULOJIX.xml:S1:14270:3	O
belatacept	NULOJIX.xml:S1:14274:10	O
molecule	NULOJIX.xml:S1:14285:8	O
were	NULOJIX.xml:S1:14294:4	O
assessed	NULOJIX.xml:S1:14299:8	O
in	NULOJIX.xml:S1:14308:2	O
398	NULOJIX.xml:S1:14311:3	O
patients	NULOJIX.xml:S1:14315:8	O
treated	NULOJIX.xml:S1:14324:7	O
with	NULOJIX.xml:S1:14332:4	O
the	NULOJIX.xml:S1:14337:3	O
NULOJIX	NULOJIX.xml:S1:14341:7	O
recommended	NULOJIX.xml:S1:14349:11	O
regimen	NULOJIX.xml:S1:14361:7	O
in	NULOJIX.xml:S1:14369:2	O
Studies	NULOJIX.xml:S1:14372:7	O
1	NULOJIX.xml:S1:14380:1	O
and	NULOJIX.xml:S1:14382:3	O
2	NULOJIX.xml:S1:14386:1	O
(	NULOJIX.xml:S1:14388:1	O
212	NULOJIX.xml:S1:14389:3	O
of	NULOJIX.xml:S1:14393:2	O
these	NULOJIX.xml:S1:14396:5	O
patients	NULOJIX.xml:S1:14402:8	O
were	NULOJIX.xml:S1:14411:4	O
treated	NULOJIX.xml:S1:14416:7	O
for	NULOJIX.xml:S1:14424:3	O
at	NULOJIX.xml:S1:14428:2	O
least	NULOJIX.xml:S1:14431:5	O
2	NULOJIX.xml:S1:14437:1	O
years	NULOJIX.xml:S1:14439:5	O
)	NULOJIX.xml:S1:14444:1	O
.	NULOJIX.xml:S1:14445:1	O

Of	NULOJIX.xml:S1:14447:2	O
the	NULOJIX.xml:S1:14450:3	O
372	NULOJIX.xml:S1:14454:3	O
patients	NULOJIX.xml:S1:14458:8	O
with	NULOJIX.xml:S1:14467:4	O
immunogenicity	NULOJIX.xml:S1:14472:14	O
assessment	NULOJIX.xml:S1:14487:10	O
at	NULOJIX.xml:S1:14498:2	O
baseline	NULOJIX.xml:S1:14501:8	O
(	NULOJIX.xml:S1:14510:1	O
prior	NULOJIX.xml:S1:14511:5	O
to	NULOJIX.xml:S1:14517:2	O
receiving	NULOJIX.xml:S1:14520:9	O
belatacept	NULOJIX.xml:S1:14530:10	O
treatment	NULOJIX.xml:S1:14541:9	O
)	NULOJIX.xml:S1:14550:1	O
,	NULOJIX.xml:S1:14551:1	O
29	NULOJIX.xml:S1:14553:2	O
patients	NULOJIX.xml:S1:14556:8	O
tested	NULOJIX.xml:S1:14565:6	O
positive	NULOJIX.xml:S1:14572:8	O
for	NULOJIX.xml:S1:14581:3	O
anti	NULOJIX.xml:S1:14585:4	O
-	NULOJIX.xml:S1:14589:1	O
belatacept	NULOJIX.xml:S1:14590:10	O
antibodies	NULOJIX.xml:S1:14601:10	O
;	NULOJIX.xml:S1:14611:1	O
13	NULOJIX.xml:S1:14613:2	O
of	NULOJIX.xml:S1:14616:2	O
these	NULOJIX.xml:S1:14619:5	O
patients	NULOJIX.xml:S1:14625:8	O
had	NULOJIX.xml:S1:14634:3	O
antibodies	NULOJIX.xml:S1:14638:10	O
to	NULOJIX.xml:S1:14649:2	O
the	NULOJIX.xml:S1:14652:3	O
modified	NULOJIX.xml:S1:14656:8	O
cytotoxic	NULOJIX.xml:S1:14665:9	O
T	NULOJIX.xml:S1:14675:1	O
-	NULOJIX.xml:S1:14676:1	O
lymphocyte	NULOJIX.xml:S1:14677:10	O
-	NULOJIX.xml:S1:14687:1	O
associated	NULOJIX.xml:S1:14688:10	O
antigen	NULOJIX.xml:S1:14699:7	O
4	NULOJIX.xml:S1:14707:1	O
(	NULOJIX.xml:S1:14709:1	O
CTLA	NULOJIX.xml:S1:14710:4	O
-	NULOJIX.xml:S1:14714:1	O
4	NULOJIX.xml:S1:14715:1	O
)	NULOJIX.xml:S1:14716:1	O
.	NULOJIX.xml:S1:14717:1	O

Anti	NULOJIX.xml:S1:14719:4	O
-	NULOJIX.xml:S1:14723:1	O
belatacept	NULOJIX.xml:S1:14724:10	O
antibody	NULOJIX.xml:S1:14735:8	O
titers	NULOJIX.xml:S1:14744:6	O
did	NULOJIX.xml:S1:14751:3	O
not	NULOJIX.xml:S1:14755:3	O
increase	NULOJIX.xml:S1:14759:8	O
during	NULOJIX.xml:S1:14768:6	O
treatment	NULOJIX.xml:S1:14775:9	O
in	NULOJIX.xml:S1:14785:2	O
these	NULOJIX.xml:S1:14788:5	O
29	NULOJIX.xml:S1:14794:2	O
patients	NULOJIX.xml:S1:14797:8	O
.	NULOJIX.xml:S1:14805:1	O

Eight	NULOJIX.xml:S1:14811:5	O
(	NULOJIX.xml:S1:14817:1	O
2%	NULOJIX.xml:S1:14818:2	O
)	NULOJIX.xml:S1:14820:1	O
patients	NULOJIX.xml:S1:14822:8	O
developed	NULOJIX.xml:S1:14831:9	O
antibodies	NULOJIX.xml:S1:14841:10	O
during	NULOJIX.xml:S1:14852:6	O
treatment	NULOJIX.xml:S1:14859:9	O
with	NULOJIX.xml:S1:14869:4	O
the	NULOJIX.xml:S1:14874:3	O
NULOJIX	NULOJIX.xml:S1:14878:7	O
recommended	NULOJIX.xml:S1:14886:11	O
regimen	NULOJIX.xml:S1:14898:7	O
.	NULOJIX.xml:S1:14905:1	O

In	NULOJIX.xml:S1:14907:2	O
the	NULOJIX.xml:S1:14910:3	O
patients	NULOJIX.xml:S1:14914:8	O
who	NULOJIX.xml:S1:14923:3	O
developed	NULOJIX.xml:S1:14927:9	O
antibodies	NULOJIX.xml:S1:14937:10	O
during	NULOJIX.xml:S1:14948:6	O
treatment	NULOJIX.xml:S1:14955:9	O
,	NULOJIX.xml:S1:14964:1	O
the	NULOJIX.xml:S1:14966:3	O
median	NULOJIX.xml:S1:14970:6	O
titer	NULOJIX.xml:S1:14977:5	O
(	NULOJIX.xml:S1:14983:1	O
by	NULOJIX.xml:S1:14984:2	O
dilution	NULOJIX.xml:S1:14987:8	O
method	NULOJIX.xml:S1:14996:6	O
)	NULOJIX.xml:S1:15002:1	O
was	NULOJIX.xml:S1:15004:3	O
8	NULOJIX.xml:S1:15008:1	O
,	NULOJIX.xml:S1:15009:1	O
with	NULOJIX.xml:S1:15011:4	O
a	NULOJIX.xml:S1:15016:1	O
range	NULOJIX.xml:S1:15018:5	O
of	NULOJIX.xml:S1:15024:2	O
5	NULOJIX.xml:S1:15027:1	O
to	NULOJIX.xml:S1:15029:2	O
80	NULOJIX.xml:S1:15032:2	O
.	NULOJIX.xml:S1:15034:1	O

Of	NULOJIX.xml:S1:15036:2	O
56	NULOJIX.xml:S1:15039:2	O
patients	NULOJIX.xml:S1:15042:8	O
who	NULOJIX.xml:S1:15051:3	O
tested	NULOJIX.xml:S1:15055:6	O
negative	NULOJIX.xml:S1:15062:8	O
for	NULOJIX.xml:S1:15071:3	O
antibodies	NULOJIX.xml:S1:15075:10	O
during	NULOJIX.xml:S1:15086:6	O
treatment	NULOJIX.xml:S1:15093:9	O
and	NULOJIX.xml:S1:15103:3	O
reassessed	NULOJIX.xml:S1:15107:10	O
approximately	NULOJIX.xml:S1:15118:13	O
7	NULOJIX.xml:S1:15132:1	O
half	NULOJIX.xml:S1:15134:4	O
-	NULOJIX.xml:S1:15138:1	O
lives	NULOJIX.xml:S1:15139:5	O
after	NULOJIX.xml:S1:15145:5	O
discontinuation	NULOJIX.xml:S1:15151:15	O
of	NULOJIX.xml:S1:15167:2	O
NULOJIX	NULOJIX.xml:S1:15170:7	O
,	NULOJIX.xml:S1:15177:1	O
1	NULOJIX.xml:S1:15179:1	O
tested	NULOJIX.xml:S1:15181:6	O
antibody	NULOJIX.xml:S1:15188:8	O
positive	NULOJIX.xml:S1:15197:8	O
.	NULOJIX.xml:S1:15205:1	O

Anti	NULOJIX.xml:S1:15207:4	O
-	NULOJIX.xml:S1:15211:1	O
belatacept	NULOJIX.xml:S1:15212:10	O
antibody	NULOJIX.xml:S1:15223:8	O
development	NULOJIX.xml:S1:15232:11	O
was	NULOJIX.xml:S1:15244:3	O
not	NULOJIX.xml:S1:15248:3	O
associated	NULOJIX.xml:S1:15252:10	O
with	NULOJIX.xml:S1:15263:4	O
altered	NULOJIX.xml:S1:15268:7	O
clearance	NULOJIX.xml:S1:15276:9	O
of	NULOJIX.xml:S1:15286:2	O
belatacept	NULOJIX.xml:S1:15289:10	O
.	NULOJIX.xml:S1:15299:1	O

Samples	NULOJIX.xml:S1:15305:7	O
from	NULOJIX.xml:S1:15313:4	O
6	NULOJIX.xml:S1:15318:1	O
patients	NULOJIX.xml:S1:15320:8	O
with	NULOJIX.xml:S1:15329:4	O
confirmed	NULOJIX.xml:S1:15334:9	O
binding	NULOJIX.xml:S1:15344:7	O
activity	NULOJIX.xml:S1:15352:8	O
to	NULOJIX.xml:S1:15361:2	O
the	NULOJIX.xml:S1:15364:3	O
modified	NULOJIX.xml:S1:15368:8	O
cytotoxic	NULOJIX.xml:S1:15377:9	O
T	NULOJIX.xml:S1:15387:1	O
-	NULOJIX.xml:S1:15388:1	O
lymphocyte	NULOJIX.xml:S1:15389:10	O
-	NULOJIX.xml:S1:15399:1	O
associated	NULOJIX.xml:S1:15400:10	O
antigen	NULOJIX.xml:S1:15411:7	O
4	NULOJIX.xml:S1:15419:1	O
(	NULOJIX.xml:S1:15421:1	O
CTLA	NULOJIX.xml:S1:15422:4	O
-	NULOJIX.xml:S1:15426:1	O
4	NULOJIX.xml:S1:15427:1	O
)	NULOJIX.xml:S1:15428:1	O
region	NULOJIX.xml:S1:15430:6	O
of	NULOJIX.xml:S1:15437:2	O
the	NULOJIX.xml:S1:15440:3	O
belatacept	NULOJIX.xml:S1:15444:10	O
molecule	NULOJIX.xml:S1:15455:8	O
were	NULOJIX.xml:S1:15464:4	O
assessed	NULOJIX.xml:S1:15469:8	O
by	NULOJIX.xml:S1:15478:2	O
an	NULOJIX.xml:S1:15481:2	O
in	NULOJIX.xml:S1:15485:2	O
vitro	NULOJIX.xml:S1:15488:5	O
bioassay	NULOJIX.xml:S1:15495:8	O
for	NULOJIX.xml:S1:15504:3	O
the	NULOJIX.xml:S1:15508:3	O
presence	NULOJIX.xml:S1:15512:8	O
of	NULOJIX.xml:S1:15521:2	O
neutralizing	NULOJIX.xml:S1:15524:12	O
antibodies	NULOJIX.xml:S1:15537:10	O
.	NULOJIX.xml:S1:15547:1	O

Three	NULOJIX.xml:S1:15549:5	O
of	NULOJIX.xml:S1:15555:2	O
these	NULOJIX.xml:S1:15558:5	O
6	NULOJIX.xml:S1:15564:1	O
patients	NULOJIX.xml:S1:15566:8	O
tested	NULOJIX.xml:S1:15575:6	O
positive	NULOJIX.xml:S1:15582:8	O
for	NULOJIX.xml:S1:15591:3	O
neutralizing	NULOJIX.xml:S1:15595:12	O
antibodies	NULOJIX.xml:S1:15608:10	O
.	NULOJIX.xml:S1:15618:1	O

However	NULOJIX.xml:S1:15620:7	O
,	NULOJIX.xml:S1:15627:1	O
the	NULOJIX.xml:S1:15629:3	O
development	NULOJIX.xml:S1:15633:11	O
of	NULOJIX.xml:S1:15645:2	O
neutralizing	NULOJIX.xml:S1:15648:12	O
antibodies	NULOJIX.xml:S1:15661:10	O
may	NULOJIX.xml:S1:15672:3	O
be	NULOJIX.xml:S1:15676:2	O
underreported	NULOJIX.xml:S1:15679:13	O
due	NULOJIX.xml:S1:15693:3	O
to	NULOJIX.xml:S1:15697:2	O
lack	NULOJIX.xml:S1:15700:4	O
of	NULOJIX.xml:S1:15705:2	O
assay	NULOJIX.xml:S1:15708:5	O
sensitivity	NULOJIX.xml:S1:15714:11	O
.	NULOJIX.xml:S1:15725:1	O

The	NULOJIX.xml:S1:15731:3	O
clinical	NULOJIX.xml:S1:15735:8	O
impact	NULOJIX.xml:S1:15744:6	O
of	NULOJIX.xml:S1:15751:2	O
anti	NULOJIX.xml:S1:15754:4	O
-	NULOJIX.xml:S1:15758:1	O
belatacept	NULOJIX.xml:S1:15759:10	O
antibodies	NULOJIX.xml:S1:15770:10	O
(	NULOJIX.xml:S1:15781:1	O
including	NULOJIX.xml:S1:15782:9	O
neutralizing	NULOJIX.xml:S1:15792:12	O
anti	NULOJIX.xml:S1:15805:4	O
-	NULOJIX.xml:S1:15809:1	O
belatacept	NULOJIX.xml:S1:15810:10	O
antibodies	NULOJIX.xml:S1:15821:10	O
)	NULOJIX.xml:S1:15831:1	O
could	NULOJIX.xml:S1:15833:5	O
not	NULOJIX.xml:S1:15839:3	O
be	NULOJIX.xml:S1:15843:2	O
determined	NULOJIX.xml:S1:15846:10	O
in	NULOJIX.xml:S1:15857:2	O
the	NULOJIX.xml:S1:15860:3	O
studies	NULOJIX.xml:S1:15864:7	O
.	NULOJIX.xml:S1:15871:1	O

The	NULOJIX.xml:S1:15877:3	O
data	NULOJIX.xml:S1:15881:4	O
reflect	NULOJIX.xml:S1:15886:7	O
the	NULOJIX.xml:S1:15894:3	O
percentage	NULOJIX.xml:S1:15898:10	O
of	NULOJIX.xml:S1:15909:2	O
patients	NULOJIX.xml:S1:15912:8	O
whose	NULOJIX.xml:S1:15921:5	O
test	NULOJIX.xml:S1:15927:4	O
results	NULOJIX.xml:S1:15932:7	O
were	NULOJIX.xml:S1:15940:4	O
positive	NULOJIX.xml:S1:15945:8	O
for	NULOJIX.xml:S1:15954:3	O
antibodies	NULOJIX.xml:S1:15958:10	O
to	NULOJIX.xml:S1:15969:2	O
belatacept	NULOJIX.xml:S1:15972:10	O
in	NULOJIX.xml:S1:15983:2	O
specific	NULOJIX.xml:S1:15986:8	O
assays	NULOJIX.xml:S1:15995:6	O
.	NULOJIX.xml:S1:16001:1	O

The	NULOJIX.xml:S1:16003:3	O
observed	NULOJIX.xml:S1:16007:8	O
incidence	NULOJIX.xml:S1:16016:9	O
of	NULOJIX.xml:S1:16026:2	O
antibody	NULOJIX.xml:S1:16029:8	O
(	NULOJIX.xml:S1:16038:1	O
including	NULOJIX.xml:S1:16039:9	O
neutralizing	NULOJIX.xml:S1:16049:12	O
antibody	NULOJIX.xml:S1:16062:8	O
)	NULOJIX.xml:S1:16070:1	O
positivity	NULOJIX.xml:S1:16072:10	O
in	NULOJIX.xml:S1:16083:2	O
an	NULOJIX.xml:S1:16086:2	O
assay	NULOJIX.xml:S1:16089:5	O
may	NULOJIX.xml:S1:16095:3	O
be	NULOJIX.xml:S1:16099:2	O
influenced	NULOJIX.xml:S1:16102:10	O
by	NULOJIX.xml:S1:16113:2	O
several	NULOJIX.xml:S1:16116:7	O
factors	NULOJIX.xml:S1:16124:7	O
including	NULOJIX.xml:S1:16132:9	O
assay	NULOJIX.xml:S1:16142:5	O
sensitivity	NULOJIX.xml:S1:16148:11	O
and	NULOJIX.xml:S1:16160:3	O
specificity	NULOJIX.xml:S1:16164:11	O
,	NULOJIX.xml:S1:16175:1	O
assay	NULOJIX.xml:S1:16177:5	O
methodology	NULOJIX.xml:S1:16183:11	O
,	NULOJIX.xml:S1:16194:1	O
sample	NULOJIX.xml:S1:16196:6	O
handling	NULOJIX.xml:S1:16203:8	O
,	NULOJIX.xml:S1:16211:1	O
timing	NULOJIX.xml:S1:16213:6	O
of	NULOJIX.xml:S1:16220:2	O
sample	NULOJIX.xml:S1:16223:6	O
collection	NULOJIX.xml:S1:16230:10	O
,	NULOJIX.xml:S1:16240:1	O
concomitant	NULOJIX.xml:S1:16242:11	O
medications	NULOJIX.xml:S1:16254:11	O
,	NULOJIX.xml:S1:16265:1	O
and	NULOJIX.xml:S1:16267:3	O
underlying	NULOJIX.xml:S1:16271:10	O
disease	NULOJIX.xml:S1:16282:7	O
.	NULOJIX.xml:S1:16289:1	O

For	NULOJIX.xml:S1:16291:3	O
these	NULOJIX.xml:S1:16295:5	O
reasons	NULOJIX.xml:S1:16301:7	O
,	NULOJIX.xml:S1:16308:1	O
comparison	NULOJIX.xml:S1:16310:10	O
of	NULOJIX.xml:S1:16321:2	O
the	NULOJIX.xml:S1:16324:3	O
incidence	NULOJIX.xml:S1:16328:9	O
of	NULOJIX.xml:S1:16338:2	O
antibodies	NULOJIX.xml:S1:16341:10	O
to	NULOJIX.xml:S1:16352:2	O
belatacept	NULOJIX.xml:S1:16355:10	O
with	NULOJIX.xml:S1:16366:4	O
the	NULOJIX.xml:S1:16371:3	O
incidence	NULOJIX.xml:S1:16375:9	O
of	NULOJIX.xml:S1:16385:2	O
antibodies	NULOJIX.xml:S1:16388:10	O
to	NULOJIX.xml:S1:16399:2	O
other	NULOJIX.xml:S1:16402:5	O
products	NULOJIX.xml:S1:16408:8	O
may	NULOJIX.xml:S1:16417:3	O
be	NULOJIX.xml:S1:16421:2	O
misleading	NULOJIX.xml:S1:16424:10	O
.	NULOJIX.xml:S1:16434:1	O

New	NULOJIX.xml:S1:16442:3	O
-	NULOJIX.xml:S1:16445:1	O
Onset	NULOJIX.xml:S1:16446:5	O
Diabetes	NULOJIX.xml:S1:16452:8	O
After	NULOJIX.xml:S1:16461:5	O
Transplantation	NULOJIX.xml:S1:16467:15	O

The	NULOJIX.xml:S1:16486:3	O
incidence	NULOJIX.xml:S1:16490:9	O
of	NULOJIX.xml:S1:16500:2	O
new	NULOJIX.xml:S1:16503:3	B-AdverseReaction
-	NULOJIX.xml:S1:16506:1	I-AdverseReaction
onset	NULOJIX.xml:S1:16507:5	I-AdverseReaction
diabetes	NULOJIX.xml:S1:16513:8	I-AdverseReaction
after	NULOJIX.xml:S1:16522:5	I-AdverseReaction
transplantation	NULOJIX.xml:S1:16528:15	I-AdverseReaction
(	NULOJIX.xml:S1:16544:1	O
NODAT	NULOJIX.xml:S1:16545:5	B-AdverseReaction
)	NULOJIX.xml:S1:16550:1	O
was	NULOJIX.xml:S1:16552:3	O
defined	NULOJIX.xml:S1:16556:7	O
in	NULOJIX.xml:S1:16564:2	O
Studies	NULOJIX.xml:S1:16567:7	O
1	NULOJIX.xml:S1:16575:1	O
and	NULOJIX.xml:S1:16577:3	O
2	NULOJIX.xml:S1:16581:1	O
as	NULOJIX.xml:S1:16583:2	O
use	NULOJIX.xml:S1:16586:3	O
of	NULOJIX.xml:S1:16590:2	O
an	NULOJIX.xml:S1:16593:2	O
antidiabetic	NULOJIX.xml:S1:16596:12	O
agent	NULOJIX.xml:S1:16609:5	O
for	NULOJIX.xml:S1:16615:3	O
30	NULOJIX.xml:S1:16621:2	O
days	NULOJIX.xml:S1:16624:4	O
or	NULOJIX.xml:S1:16629:2	O
2	NULOJIX.xml:S1:16634:1	O
fasting	NULOJIX.xml:S1:16636:7	O
plasma	NULOJIX.xml:S1:16644:6	O
glucose	NULOJIX.xml:S1:16651:7	O
values	NULOJIX.xml:S1:16659:6	O
126	NULOJIX.xml:S1:16668:3	O
mg	NULOJIX.xml:S1:16672:2	O
dL	NULOJIX.xml:S1:16675:2	O
(	NULOJIX.xml:S1:16678:1	O
7.0	NULOJIX.xml:S1:16679:3	O
mmol	NULOJIX.xml:S1:16683:4	O
L	NULOJIX.xml:S1:16688:1	O
)	NULOJIX.xml:S1:16689:1	O
post	NULOJIX.xml:S1:16691:4	O
-	NULOJIX.xml:S1:16695:1	O
transplantation	NULOJIX.xml:S1:16696:15	O
.	NULOJIX.xml:S1:16711:1	O

Of	NULOJIX.xml:S1:16713:2	O
the	NULOJIX.xml:S1:16716:3	O
patients	NULOJIX.xml:S1:16720:8	O
treated	NULOJIX.xml:S1:16729:7	O
with	NULOJIX.xml:S1:16737:4	O
the	NULOJIX.xml:S1:16742:3	O
NULOJIX	NULOJIX.xml:S1:16746:7	O
recommended	NULOJIX.xml:S1:16754:11	O
regimen	NULOJIX.xml:S1:16766:7	O
,	NULOJIX.xml:S1:16773:1	O
5%	NULOJIX.xml:S1:16775:2	O
(	NULOJIX.xml:S1:16778:1	O
14	NULOJIX.xml:S1:16779:2	O
304	NULOJIX.xml:S1:16782:3	O
)	NULOJIX.xml:S1:16785:1	O
developed	NULOJIX.xml:S1:16787:9	O
NODAT	NULOJIX.xml:S1:16797:5	B-AdverseReaction
by	NULOJIX.xml:S1:16803:2	O
the	NULOJIX.xml:S1:16806:3	O
end	NULOJIX.xml:S1:16810:3	O
of	NULOJIX.xml:S1:16814:2	O
one	NULOJIX.xml:S1:16817:3	O
year	NULOJIX.xml:S1:16821:4	O
compared	NULOJIX.xml:S1:16826:8	O
to	NULOJIX.xml:S1:16835:2	O
10%	NULOJIX.xml:S1:16838:3	O
(	NULOJIX.xml:S1:16842:1	O
27	NULOJIX.xml:S1:16843:2	O
280	NULOJIX.xml:S1:16846:3	O
)	NULOJIX.xml:S1:16849:1	O
of	NULOJIX.xml:S1:16851:2	O
patients	NULOJIX.xml:S1:16854:8	O
on	NULOJIX.xml:S1:16863:2	O
the	NULOJIX.xml:S1:16866:3	O
cyclosporine	NULOJIX.xml:S1:16870:12	O
control	NULOJIX.xml:S1:16883:7	O
regimen	NULOJIX.xml:S1:16891:7	O
.	NULOJIX.xml:S1:16898:1	O

However	NULOJIX.xml:S1:16900:7	O
,	NULOJIX.xml:S1:16907:1	O
by	NULOJIX.xml:S1:16909:2	O
the	NULOJIX.xml:S1:16912:3	O
end	NULOJIX.xml:S1:16916:3	O
of	NULOJIX.xml:S1:16920:2	O
the	NULOJIX.xml:S1:16923:3	O
third	NULOJIX.xml:S1:16927:5	O
year	NULOJIX.xml:S1:16933:4	O
,	NULOJIX.xml:S1:16937:1	O
the	NULOJIX.xml:S1:16939:3	O
cumulative	NULOJIX.xml:S1:16943:10	O
incidence	NULOJIX.xml:S1:16954:9	O
of	NULOJIX.xml:S1:16964:2	O
NODAT	NULOJIX.xml:S1:16967:5	B-AdverseReaction
was	NULOJIX.xml:S1:16973:3	O
8%	NULOJIX.xml:S1:16977:2	O
(	NULOJIX.xml:S1:16980:1	O
24	NULOJIX.xml:S1:16981:2	O
304	NULOJIX.xml:S1:16984:3	O
)	NULOJIX.xml:S1:16987:1	O
in	NULOJIX.xml:S1:16989:2	O
patients	NULOJIX.xml:S1:16992:8	O
treated	NULOJIX.xml:S1:17001:7	O
with	NULOJIX.xml:S1:17009:4	O
the	NULOJIX.xml:S1:17014:3	O
NULOJIX	NULOJIX.xml:S1:17018:7	O
recommended	NULOJIX.xml:S1:17026:11	O
regimen	NULOJIX.xml:S1:17038:7	O
and	NULOJIX.xml:S1:17046:3	O
10%	NULOJIX.xml:S1:17050:3	O
(	NULOJIX.xml:S1:17054:1	O
29	NULOJIX.xml:S1:17055:2	O
280	NULOJIX.xml:S1:17058:3	O
)	NULOJIX.xml:S1:17061:1	O
in	NULOJIX.xml:S1:17063:2	O
patients	NULOJIX.xml:S1:17066:8	O
treated	NULOJIX.xml:S1:17075:7	O
with	NULOJIX.xml:S1:17083:4	O
the	NULOJIX.xml:S1:17088:3	O
cyclosporine	NULOJIX.xml:S1:17092:12	O
regimen	NULOJIX.xml:S1:17105:7	O
.	NULOJIX.xml:S1:17112:1	O

Hypertension	NULOJIX.xml:S1:17120:12	O

Blood	NULOJIX.xml:S1:17136:5	O
pressure	NULOJIX.xml:S1:17142:8	O
and	NULOJIX.xml:S1:17151:3	O
use	NULOJIX.xml:S1:17155:3	O
of	NULOJIX.xml:S1:17159:2	O
antihypertensive	NULOJIX.xml:S1:17162:16	O
medications	NULOJIX.xml:S1:17179:11	O
were	NULOJIX.xml:S1:17191:4	O
reported	NULOJIX.xml:S1:17196:8	O
in	NULOJIX.xml:S1:17205:2	O
Studies	NULOJIX.xml:S1:17208:7	O
1	NULOJIX.xml:S1:17216:1	O
and	NULOJIX.xml:S1:17218:3	O
2	NULOJIX.xml:S1:17222:1	O
.	NULOJIX.xml:S1:17223:1	O

By	NULOJIX.xml:S1:17225:2	O
Year	NULOJIX.xml:S1:17228:4	O
3	NULOJIX.xml:S1:17233:1	O
,	NULOJIX.xml:S1:17234:1	O
one	NULOJIX.xml:S1:17236:3	O
or	NULOJIX.xml:S1:17240:2	O
more	NULOJIX.xml:S1:17243:4	O
antihypertensive	NULOJIX.xml:S1:17248:16	O
medications	NULOJIX.xml:S1:17265:11	O
were	NULOJIX.xml:S1:17277:4	O
used	NULOJIX.xml:S1:17282:4	O
in	NULOJIX.xml:S1:17287:2	O
85%	NULOJIX.xml:S1:17290:3	O
of	NULOJIX.xml:S1:17294:2	O
NULOJIX	NULOJIX.xml:S1:17297:7	O
-	NULOJIX.xml:S1:17304:1	O
treated	NULOJIX.xml:S1:17305:7	O
patients	NULOJIX.xml:S1:17313:8	O
and	NULOJIX.xml:S1:17322:3	O
92%	NULOJIX.xml:S1:17326:3	O
of	NULOJIX.xml:S1:17330:2	O
cyclosporine	NULOJIX.xml:S1:17333:12	O
-	NULOJIX.xml:S1:17345:1	O
treated	NULOJIX.xml:S1:17346:7	O
patients	NULOJIX.xml:S1:17354:8	O
.	NULOJIX.xml:S1:17362:1	O

At	NULOJIX.xml:S1:17364:2	O
one	NULOJIX.xml:S1:17367:3	O
year	NULOJIX.xml:S1:17371:4	O
after	NULOJIX.xml:S1:17376:5	O
transplantation	NULOJIX.xml:S1:17382:15	O
,	NULOJIX.xml:S1:17397:1	O
systolic	NULOJIX.xml:S1:17399:8	O
blood	NULOJIX.xml:S1:17408:5	O
pressures	NULOJIX.xml:S1:17414:9	O
were	NULOJIX.xml:S1:17424:4	O
8	NULOJIX.xml:S1:17429:1	O
mmHg	NULOJIX.xml:S1:17431:4	O
lower	NULOJIX.xml:S1:17436:5	O
and	NULOJIX.xml:S1:17442:3	O
diastolic	NULOJIX.xml:S1:17446:9	O
blood	NULOJIX.xml:S1:17456:5	O
pressures	NULOJIX.xml:S1:17462:9	O
were	NULOJIX.xml:S1:17472:4	O
3	NULOJIX.xml:S1:17477:1	O
mmHg	NULOJIX.xml:S1:17479:4	O
lower	NULOJIX.xml:S1:17484:5	O
in	NULOJIX.xml:S1:17490:2	O
patients	NULOJIX.xml:S1:17493:8	O
treated	NULOJIX.xml:S1:17502:7	O
with	NULOJIX.xml:S1:17510:4	O
the	NULOJIX.xml:S1:17515:3	O
NULOJIX	NULOJIX.xml:S1:17519:7	O
recommended	NULOJIX.xml:S1:17527:11	O
regimen	NULOJIX.xml:S1:17539:7	O
compared	NULOJIX.xml:S1:17547:8	O
to	NULOJIX.xml:S1:17556:2	O
the	NULOJIX.xml:S1:17559:3	O
cyclosporine	NULOJIX.xml:S1:17563:12	O
control	NULOJIX.xml:S1:17576:7	O
regimen	NULOJIX.xml:S1:17584:7	O
.	NULOJIX.xml:S1:17591:1	O

At	NULOJIX.xml:S1:17593:2	O
three	NULOJIX.xml:S1:17596:5	O
years	NULOJIX.xml:S1:17602:5	O
after	NULOJIX.xml:S1:17608:5	O
transplantation	NULOJIX.xml:S1:17614:15	O
,	NULOJIX.xml:S1:17629:1	O
systolic	NULOJIX.xml:S1:17631:8	O
blood	NULOJIX.xml:S1:17640:5	O
pressures	NULOJIX.xml:S1:17646:9	O
were	NULOJIX.xml:S1:17656:4	O
6	NULOJIX.xml:S1:17661:1	O
mmHg	NULOJIX.xml:S1:17663:4	O
lower	NULOJIX.xml:S1:17668:5	O
and	NULOJIX.xml:S1:17674:3	O
diastolic	NULOJIX.xml:S1:17678:9	O
blood	NULOJIX.xml:S1:17688:5	O
pressures	NULOJIX.xml:S1:17694:9	O
were	NULOJIX.xml:S1:17704:4	O
3	NULOJIX.xml:S1:17709:1	O
mmHg	NULOJIX.xml:S1:17711:4	O
lower	NULOJIX.xml:S1:17716:5	O
in	NULOJIX.xml:S1:17722:2	O
NULOJIX	NULOJIX.xml:S1:17725:7	O
-	NULOJIX.xml:S1:17732:1	O
treated	NULOJIX.xml:S1:17733:7	O
patients	NULOJIX.xml:S1:17741:8	O
compared	NULOJIX.xml:S1:17750:8	O
to	NULOJIX.xml:S1:17759:2	O
cyclosporine	NULOJIX.xml:S1:17762:12	O
-	NULOJIX.xml:S1:17774:1	O
treated	NULOJIX.xml:S1:17775:7	O
patients	NULOJIX.xml:S1:17783:8	O
.	NULOJIX.xml:S1:17791:1	O

Hypertension	NULOJIX.xml:S1:17793:12	B-AdverseReaction
was	NULOJIX.xml:S1:17806:3	O
reported	NULOJIX.xml:S1:17810:8	O
as	NULOJIX.xml:S1:17819:2	O
an	NULOJIX.xml:S1:17822:2	O
adverse	NULOJIX.xml:S1:17825:7	O
reaction	NULOJIX.xml:S1:17833:8	O
in	NULOJIX.xml:S1:17842:2	O
32%	NULOJIX.xml:S1:17845:3	O
of	NULOJIX.xml:S1:17849:2	O
NULOJIX	NULOJIX.xml:S1:17852:7	O
-	NULOJIX.xml:S1:17859:1	O
treated	NULOJIX.xml:S1:17860:7	O
patients	NULOJIX.xml:S1:17868:8	O
and	NULOJIX.xml:S1:17877:3	O
37%	NULOJIX.xml:S1:17881:3	O
of	NULOJIX.xml:S1:17885:2	O
cyclosporine	NULOJIX.xml:S1:17888:12	O
-	NULOJIX.xml:S1:17900:1	O
treated	NULOJIX.xml:S1:17901:7	O
patients	NULOJIX.xml:S1:17909:8	O
(	NULOJIX.xml:S1:17918:1	O
see	NULOJIX.xml:S1:17919:3	O
Table	NULOJIX.xml:S1:17923:5	O
4	NULOJIX.xml:S1:17929:1	O
)	NULOJIX.xml:S1:17930:1	O
.	NULOJIX.xml:S1:17931:1	O

Dyslipidemia	NULOJIX.xml:S1:17939:12	O

Mean	NULOJIX.xml:S1:17955:4	O
values	NULOJIX.xml:S1:17960:6	O
of	NULOJIX.xml:S1:17967:2	O
total	NULOJIX.xml:S1:17970:5	O
cholesterol	NULOJIX.xml:S1:17976:11	O
,	NULOJIX.xml:S1:17987:1	O
HDL	NULOJIX.xml:S1:17989:3	O
,	NULOJIX.xml:S1:17992:1	O
LDL	NULOJIX.xml:S1:17994:3	O
,	NULOJIX.xml:S1:17997:1	O
and	NULOJIX.xml:S1:17999:3	O
triglycerides	NULOJIX.xml:S1:18003:13	O
were	NULOJIX.xml:S1:18017:4	O
reported	NULOJIX.xml:S1:18022:8	O
in	NULOJIX.xml:S1:18031:2	O
Studies	NULOJIX.xml:S1:18034:7	O
1	NULOJIX.xml:S1:18042:1	O
and	NULOJIX.xml:S1:18044:3	O
2	NULOJIX.xml:S1:18048:1	O
.	NULOJIX.xml:S1:18049:1	O

At	NULOJIX.xml:S1:18051:2	O
one	NULOJIX.xml:S1:18054:3	O
year	NULOJIX.xml:S1:18058:4	O
after	NULOJIX.xml:S1:18063:5	O
transplantation	NULOJIX.xml:S1:18069:15	O
these	NULOJIX.xml:S1:18085:5	O
values	NULOJIX.xml:S1:18091:6	O
were	NULOJIX.xml:S1:18098:4	O
183	NULOJIX.xml:S1:18103:3	O
mg	NULOJIX.xml:S1:18107:2	O
dL	NULOJIX.xml:S1:18110:2	O
,	NULOJIX.xml:S1:18112:1	O
50	NULOJIX.xml:S1:18114:2	O
mg	NULOJIX.xml:S1:18117:2	O
dL	NULOJIX.xml:S1:18120:2	O
,	NULOJIX.xml:S1:18122:1	O
102	NULOJIX.xml:S1:18124:3	O
mg	NULOJIX.xml:S1:18128:2	O
dL	NULOJIX.xml:S1:18131:2	O
,	NULOJIX.xml:S1:18133:1	O
and	NULOJIX.xml:S1:18135:3	O
151	NULOJIX.xml:S1:18139:3	O
mg	NULOJIX.xml:S1:18143:2	O
dL	NULOJIX.xml:S1:18146:2	O
,	NULOJIX.xml:S1:18148:1	O
respectively	NULOJIX.xml:S1:18150:12	O
,	NULOJIX.xml:S1:18162:1	O
in	NULOJIX.xml:S1:18164:2	O
401	NULOJIX.xml:S1:18167:3	O
patients	NULOJIX.xml:S1:18171:8	O
treated	NULOJIX.xml:S1:18180:7	O
with	NULOJIX.xml:S1:18188:4	O
the	NULOJIX.xml:S1:18193:3	O
NULOJIX	NULOJIX.xml:S1:18197:7	O
recommended	NULOJIX.xml:S1:18205:11	O
regimen	NULOJIX.xml:S1:18217:7	O
and	NULOJIX.xml:S1:18225:3	O
196	NULOJIX.xml:S1:18229:3	O
mg	NULOJIX.xml:S1:18233:2	O
dL	NULOJIX.xml:S1:18236:2	O
,	NULOJIX.xml:S1:18238:1	O
48	NULOJIX.xml:S1:18240:2	O
mg	NULOJIX.xml:S1:18243:2	O
dL	NULOJIX.xml:S1:18246:2	O
,	NULOJIX.xml:S1:18248:1	O
108	NULOJIX.xml:S1:18250:3	O
mg	NULOJIX.xml:S1:18254:2	O
dL	NULOJIX.xml:S1:18257:2	O
,	NULOJIX.xml:S1:18259:1	O
and	NULOJIX.xml:S1:18261:3	O
195	NULOJIX.xml:S1:18265:3	O
mg	NULOJIX.xml:S1:18269:2	O
dL	NULOJIX.xml:S1:18272:2	O
,	NULOJIX.xml:S1:18274:1	O
respectively	NULOJIX.xml:S1:18276:12	O
,	NULOJIX.xml:S1:18288:1	O
in	NULOJIX.xml:S1:18290:2	O
405	NULOJIX.xml:S1:18293:3	O
patients	NULOJIX.xml:S1:18297:8	O
treated	NULOJIX.xml:S1:18306:7	O
with	NULOJIX.xml:S1:18314:4	O
the	NULOJIX.xml:S1:18319:3	O
cyclosporine	NULOJIX.xml:S1:18323:12	O
control	NULOJIX.xml:S1:18336:7	O
regimen	NULOJIX.xml:S1:18344:7	O
.	NULOJIX.xml:S1:18351:1	O

At	NULOJIX.xml:S1:18353:2	O
three	NULOJIX.xml:S1:18356:5	O
years	NULOJIX.xml:S1:18362:5	O
after	NULOJIX.xml:S1:18368:5	O
transplantation	NULOJIX.xml:S1:18374:15	O
,	NULOJIX.xml:S1:18389:1	O
the	NULOJIX.xml:S1:18391:3	O
total	NULOJIX.xml:S1:18395:5	O
cholesterol	NULOJIX.xml:S1:18401:11	O
,	NULOJIX.xml:S1:18412:1	O
HDL	NULOJIX.xml:S1:18414:3	O
,	NULOJIX.xml:S1:18417:1	O
LDL	NULOJIX.xml:S1:18419:3	O
,	NULOJIX.xml:S1:18422:1	O
and	NULOJIX.xml:S1:18424:3	O
triglycerides	NULOJIX.xml:S1:18428:13	O
were	NULOJIX.xml:S1:18442:4	O
176	NULOJIX.xml:S1:18447:3	O
mg	NULOJIX.xml:S1:18451:2	O
dL	NULOJIX.xml:S1:18454:2	O
,	NULOJIX.xml:S1:18456:1	O
49	NULOJIX.xml:S1:18458:2	O
mg	NULOJIX.xml:S1:18461:2	O
dL	NULOJIX.xml:S1:18464:2	O
,	NULOJIX.xml:S1:18466:1	O
100	NULOJIX.xml:S1:18468:3	O
mg	NULOJIX.xml:S1:18472:2	O
dL	NULOJIX.xml:S1:18475:2	O
,	NULOJIX.xml:S1:18477:1	O
and	NULOJIX.xml:S1:18479:3	O
141	NULOJIX.xml:S1:18483:3	O
mg	NULOJIX.xml:S1:18487:2	O
dL	NULOJIX.xml:S1:18490:2	O
,	NULOJIX.xml:S1:18492:1	O
respectively	NULOJIX.xml:S1:18494:12	O
,	NULOJIX.xml:S1:18506:1	O
in	NULOJIX.xml:S1:18508:2	O
NULOJIX	NULOJIX.xml:S1:18511:7	O
-	NULOJIX.xml:S1:18518:1	O
treated	NULOJIX.xml:S1:18519:7	O
patients	NULOJIX.xml:S1:18527:8	O
compared	NULOJIX.xml:S1:18536:8	O
to	NULOJIX.xml:S1:18545:2	O
193	NULOJIX.xml:S1:18548:3	O
mg	NULOJIX.xml:S1:18552:2	O
dL	NULOJIX.xml:S1:18555:2	O
,	NULOJIX.xml:S1:18557:1	O
48	NULOJIX.xml:S1:18559:2	O
mg	NULOJIX.xml:S1:18562:2	O
dL	NULOJIX.xml:S1:18565:2	O
,	NULOJIX.xml:S1:18567:1	O
106	NULOJIX.xml:S1:18569:3	O
mg	NULOJIX.xml:S1:18573:2	O
dL	NULOJIX.xml:S1:18576:2	O
,	NULOJIX.xml:S1:18578:1	O
and	NULOJIX.xml:S1:18580:3	O
180	NULOJIX.xml:S1:18584:3	O
mg	NULOJIX.xml:S1:18588:2	O
dL	NULOJIX.xml:S1:18591:2	O
in	NULOJIX.xml:S1:18594:2	O
cyclosporine	NULOJIX.xml:S1:18597:12	O
-	NULOJIX.xml:S1:18609:1	O
treated	NULOJIX.xml:S1:18610:7	O
patients	NULOJIX.xml:S1:18618:8	O
.	NULOJIX.xml:S1:18626:1	O

The	NULOJIX.xml:S1:18632:3	O
clinical	NULOJIX.xml:S1:18636:8	O
significance	NULOJIX.xml:S1:18645:12	O
of	NULOJIX.xml:S1:18658:2	O
the	NULOJIX.xml:S1:18661:3	O
lower	NULOJIX.xml:S1:18665:5	O
mean	NULOJIX.xml:S1:18671:4	O
triglyceride	NULOJIX.xml:S1:18676:12	O
values	NULOJIX.xml:S1:18689:6	O
in	NULOJIX.xml:S1:18696:2	O
NULOJIX	NULOJIX.xml:S1:18699:7	O
-	NULOJIX.xml:S1:18706:1	O
treated	NULOJIX.xml:S1:18707:7	O
patients	NULOJIX.xml:S1:18715:8	O
at	NULOJIX.xml:S1:18724:2	O
one	NULOJIX.xml:S1:18727:3	O
and	NULOJIX.xml:S1:18731:3	O
three	NULOJIX.xml:S1:18735:5	O
years	NULOJIX.xml:S1:18741:5	O
is	NULOJIX.xml:S1:18747:2	O
unknown	NULOJIX.xml:S1:18750:7	O
.	NULOJIX.xml:S1:18757:1	O

Other	NULOJIX.xml:S1:18765:5	O
Adverse	NULOJIX.xml:S1:18771:7	O
Reactions	NULOJIX.xml:S1:18779:9	O

Adverse	NULOJIX.xml:S1:18792:7	O
reactions	NULOJIX.xml:S1:18800:9	O
that	NULOJIX.xml:S1:18810:4	O
occurred	NULOJIX.xml:S1:18815:8	O
at	NULOJIX.xml:S1:18824:2	O
a	NULOJIX.xml:S1:18827:1	O
frequency	NULOJIX.xml:S1:18829:9	O
of	NULOJIX.xml:S1:18839:2	O
10%	NULOJIX.xml:S1:18844:3	O
in	NULOJIX.xml:S1:18848:2	O
patients	NULOJIX.xml:S1:18851:8	O
treated	NULOJIX.xml:S1:18860:7	O
with	NULOJIX.xml:S1:18868:4	O
the	NULOJIX.xml:S1:18873:3	O
NULOJIX	NULOJIX.xml:S1:18877:7	O
recommended	NULOJIX.xml:S1:18885:11	O
regimen	NULOJIX.xml:S1:18897:7	O
or	NULOJIX.xml:S1:18905:2	O
cyclosporine	NULOJIX.xml:S1:18908:12	O
control	NULOJIX.xml:S1:18921:7	O
regimen	NULOJIX.xml:S1:18929:7	O
in	NULOJIX.xml:S1:18937:2	O
Studies	NULOJIX.xml:S1:18940:7	O
1	NULOJIX.xml:S1:18948:1	O
and	NULOJIX.xml:S1:18950:3	O
2	NULOJIX.xml:S1:18954:1	O
through	NULOJIX.xml:S1:18956:7	O
three	NULOJIX.xml:S1:18964:5	O
years	NULOJIX.xml:S1:18970:5	O
are	NULOJIX.xml:S1:18976:3	O
summarized	NULOJIX.xml:S1:18980:10	O
by	NULOJIX.xml:S1:18991:2	O
preferred	NULOJIX.xml:S1:18994:9	O
term	NULOJIX.xml:S1:19004:4	O
in	NULOJIX.xml:S1:19009:2	O
decreasing	NULOJIX.xml:S1:19012:10	O
order	NULOJIX.xml:S1:19023:5	O
of	NULOJIX.xml:S1:19029:2	O
frequency	NULOJIX.xml:S1:19032:9	O
within	NULOJIX.xml:S1:19042:6	O
Table	NULOJIX.xml:S1:19049:5	O
4	NULOJIX.xml:S1:19055:1	O
.	NULOJIX.xml:S1:19056:1	O

Table	NULOJIX.xml:S1:19062:5	O
4	NULOJIX.xml:S1:19068:1	O
:	NULOJIX.xml:S1:19069:1	O
Adverse	NULOJIX.xml:S1:19071:7	O
Reactions	NULOJIX.xml:S1:19079:9	O
Reported	NULOJIX.xml:S1:19089:8	O
by	NULOJIX.xml:S1:19098:2	O
10%	NULOJIX.xml:S1:19103:3	O
of	NULOJIX.xml:S1:19107:2	O
Patients	NULOJIX.xml:S1:19110:8	O
Treated	NULOJIX.xml:S1:19119:7	O
with	NULOJIX.xml:S1:19127:4	O
Either	NULOJIX.xml:S1:19132:6	O
the	NULOJIX.xml:S1:19139:3	O
NULOJIX	NULOJIX.xml:S1:19143:7	O
Recommended	NULOJIX.xml:S1:19151:11	O
Regimen	NULOJIX.xml:S1:19163:7	O
or	NULOJIX.xml:S1:19171:2	O
Control	NULOJIX.xml:S1:19174:7	O
in	NULOJIX.xml:S1:19182:2	O
Studies	NULOJIX.xml:S1:19185:7	O
1	NULOJIX.xml:S1:19193:1	O
and	NULOJIX.xml:S1:19195:3	O
2	NULOJIX.xml:S1:19199:1	O
Through	NULOJIX.xml:S1:19201:7	O
Three	NULOJIX.xml:S1:19209:5	O
Years	NULOJIX.xml:S1:19215:5	O
,	NULOJIX.xml:S1:19221:1	O

Adverse	NULOJIX.xml:S1:19227:7	O
Reaction	NULOJIX.xml:S1:19235:8	O
NULOJIX	NULOJIX.xml:S1:19275:7	O
Recommended	NULOJIX.xml:S1:19286:11	O
Regimen	NULOJIX.xml:S1:19298:7	O
N	NULOJIX.xml:S1:19309:1	O
401	NULOJIX.xml:S1:19311:3	O
Cyclosporine	NULOJIX.xml:S1:19325:12	O
N	NULOJIX.xml:S1:19341:1	O
405	NULOJIX.xml:S1:19343:3	O

All	NULOJIX.xml:S1:19363:3	O

randomized	NULOJIX.xml:S1:19367:10	O
and	NULOJIX.xml:S1:19378:3	O
transplanted	NULOJIX.xml:S1:19382:12	O
patients	NULOJIX.xml:S1:19395:8	O
in	NULOJIX.xml:S1:19404:2	O
Studies	NULOJIX.xml:S1:19407:7	O
1	NULOJIX.xml:S1:19415:1	O
and	NULOJIX.xml:S1:19417:3	O
2	NULOJIX.xml:S1:19421:1	O
.	NULOJIX.xml:S1:19422:1	O

Studies	NULOJIX.xml:S1:19427:7	O
1	NULOJIX.xml:S1:19435:1	O
and	NULOJIX.xml:S1:19437:3	O
2	NULOJIX.xml:S1:19441:1	O
were	NULOJIX.xml:S1:19443:4	O
not	NULOJIX.xml:S1:19448:3	O
designed	NULOJIX.xml:S1:19452:8	O
to	NULOJIX.xml:S1:19461:2	O
support	NULOJIX.xml:S1:19464:7	O
comparative	NULOJIX.xml:S1:19472:11	O
claims	NULOJIX.xml:S1:19484:6	O
for	NULOJIX.xml:S1:19491:3	O
NULOJIX	NULOJIX.xml:S1:19495:7	O
for	NULOJIX.xml:S1:19503:3	O
the	NULOJIX.xml:S1:19507:3	O
adverse	NULOJIX.xml:S1:19511:7	O
reactions	NULOJIX.xml:S1:19519:9	O
reported	NULOJIX.xml:S1:19529:8	O
in	NULOJIX.xml:S1:19538:2	O
this	NULOJIX.xml:S1:19541:4	O
table	NULOJIX.xml:S1:19546:5	O
.	NULOJIX.xml:S1:19551:1	O

Infections	NULOJIX.xml:S1:19561:10	O

and	NULOJIX.xml:S1:19572:3	O
Infestations	NULOJIX.xml:S1:19576:12	O

Urinary	NULOJIX.xml:S1:19674:7	B-AdverseReaction
tract	NULOJIX.xml:S1:19682:5	I-AdverseReaction
infection	NULOJIX.xml:S1:19688:9	I-AdverseReaction
37	NULOJIX.xml:S1:19718:2	O
36	NULOJIX.xml:S1:19747:2	O

Upper	NULOJIX.xml:S1:19783:5	B-AdverseReaction
respiratory	NULOJIX.xml:S1:19789:11	I-AdverseReaction
infection	NULOJIX.xml:S1:19801:9	I-AdverseReaction
15	NULOJIX.xml:S1:19827:2	O
16	NULOJIX.xml:S1:19856:2	O

Nasopharyngitis	NULOJIX.xml:S1:19892:15	B-AdverseReaction
13	NULOJIX.xml:S1:19936:2	O
16	NULOJIX.xml:S1:19965:2	O

Cytomegalovirus	NULOJIX.xml:S1:20001:15	B-AdverseReaction
infection	NULOJIX.xml:S1:20017:9	I-AdverseReaction
12	NULOJIX.xml:S1:20045:2	O
12	NULOJIX.xml:S1:20074:2	O

Influenza	NULOJIX.xml:S1:20110:9	B-AdverseReaction
11	NULOJIX.xml:S1:20154:2	O
8	NULOJIX.xml:S1:20183:1	O

Bronchitis	NULOJIX.xml:S1:20219:10	B-AdverseReaction
10	NULOJIX.xml:S1:20263:2	O
7	NULOJIX.xml:S1:20292:1	O

Gastrointestinal	NULOJIX.xml:S1:20324:16	O
Disorders	NULOJIX.xml:S1:20341:9	O

Diarrhea	NULOJIX.xml:S1:20437:8	B-AdverseReaction
39	NULOJIX.xml:S1:20481:2	O
36	NULOJIX.xml:S1:20510:2	O

Constipation	NULOJIX.xml:S1:20546:12	B-AdverseReaction
33	NULOJIX.xml:S1:20590:2	O
35	NULOJIX.xml:S1:20619:2	O

Nausea	NULOJIX.xml:S1:20655:6	B-AdverseReaction
24	NULOJIX.xml:S1:20699:2	O
27	NULOJIX.xml:S1:20728:2	O

Vomiting	NULOJIX.xml:S1:20764:8	B-AdverseReaction
22	NULOJIX.xml:S1:20808:2	O
20	NULOJIX.xml:S1:20837:2	O

Abdominal	NULOJIX.xml:S1:20873:9	B-AdverseReaction
pain	NULOJIX.xml:S1:20883:4	I-AdverseReaction
19	NULOJIX.xml:S1:20917:2	O
16	NULOJIX.xml:S1:20946:2	O

Abdominal	NULOJIX.xml:S1:20982:9	B-AdverseReaction
pain	NULOJIX.xml:S1:20992:4	I-AdverseReaction
upper	NULOJIX.xml:S1:20997:5	I-AdverseReaction
9	NULOJIX.xml:S1:21026:1	O
10	NULOJIX.xml:S1:21055:2	O

Metabolism	NULOJIX.xml:S1:21087:10	O
and	NULOJIX.xml:S1:21098:3	O
Nutrition	NULOJIX.xml:S1:21102:9	O
Disorders	NULOJIX.xml:S1:21112:9	O

Hyperkalemia	NULOJIX.xml:S1:21200:12	B-AdverseReaction
20	NULOJIX.xml:S1:21244:2	O
20	NULOJIX.xml:S1:21273:2	O

Hypokalemia	NULOJIX.xml:S1:21309:11	B-AdverseReaction
21	NULOJIX.xml:S1:21353:2	O
14	NULOJIX.xml:S1:21382:2	O

Hypophosphatemia	NULOJIX.xml:S1:21418:16	B-AdverseReaction
19	NULOJIX.xml:S1:21462:2	O
13	NULOJIX.xml:S1:21491:2	O

Dyslipidemia	NULOJIX.xml:S1:21527:12	B-AdverseReaction
19	NULOJIX.xml:S1:21571:2	O
24	NULOJIX.xml:S1:21600:2	O

Hyperglycemia	NULOJIX.xml:S1:21636:13	B-AdverseReaction
16	NULOJIX.xml:S1:21680:2	O
17	NULOJIX.xml:S1:21709:2	O

Hypocalcemia	NULOJIX.xml:S1:21745:12	B-AdverseReaction
13	NULOJIX.xml:S1:21789:2	O
11	NULOJIX.xml:S1:21818:2	O

Hypercholesterolemia	NULOJIX.xml:S1:21854:20	B-AdverseReaction
11	NULOJIX.xml:S1:21898:2	O
11	NULOJIX.xml:S1:21927:2	O

Hypomagnesemia	NULOJIX.xml:S1:21963:14	B-AdverseReaction
7	NULOJIX.xml:S1:22007:1	O
10	NULOJIX.xml:S1:22036:2	O

Hyperuricemia	NULOJIX.xml:S1:22072:13	B-AdverseReaction
5	NULOJIX.xml:S1:22116:1	O
12	NULOJIX.xml:S1:22145:2	O

Procedural	NULOJIX.xml:S1:22177:10	O
Complications	NULOJIX.xml:S1:22188:13	O

Graft	NULOJIX.xml:S1:22290:5	B-AdverseReaction
dysfunction	NULOJIX.xml:S1:22296:11	I-AdverseReaction
25	NULOJIX.xml:S1:22334:2	O
34	NULOJIX.xml:S1:22363:2	O

General	NULOJIX.xml:S1:22395:7	O
Disorders	NULOJIX.xml:S1:22403:9	O

Peripheral	NULOJIX.xml:S1:22508:10	B-AdverseReaction
edema	NULOJIX.xml:S1:22519:5	I-AdverseReaction
34	NULOJIX.xml:S1:22552:2	O
42	NULOJIX.xml:S1:22581:2	O

Pyrexia	NULOJIX.xml:S1:22617:7	B-AdverseReaction
28	NULOJIX.xml:S1:22661:2	O
26	NULOJIX.xml:S1:22690:2	O

Blood	NULOJIX.xml:S1:22722:5	O
and	NULOJIX.xml:S1:22728:3	O
Lymphatic	NULOJIX.xml:S1:22732:9	O
System	NULOJIX.xml:S1:22742:6	O
Disorders	NULOJIX.xml:S1:22749:9	O

Anemia	NULOJIX.xml:S1:22835:6	B-AdverseReaction
45	NULOJIX.xml:S1:22879:2	O
44	NULOJIX.xml:S1:22908:2	O

Leukopenia	NULOJIX.xml:S1:22944:10	B-AdverseReaction
20	NULOJIX.xml:S1:22988:2	O
23	NULOJIX.xml:S1:23017:2	O

Renal	NULOJIX.xml:S1:23049:5	O
and	NULOJIX.xml:S1:23055:3	O
Urinary	NULOJIX.xml:S1:23059:7	O
Disorders	NULOJIX.xml:S1:23067:9	O

Hematuria	NULOJIX.xml:S1:23162:9	B-AdverseReaction
16	NULOJIX.xml:S1:23206:2	O
18	NULOJIX.xml:S1:23235:2	O

Proteinuria	NULOJIX.xml:S1:23271:11	B-AdverseReaction
16	NULOJIX.xml:S1:23315:2	O
12	NULOJIX.xml:S1:23344:2	O

Dysuria	NULOJIX.xml:S1:23380:7	B-AdverseReaction
11	NULOJIX.xml:S1:23424:2	O
11	NULOJIX.xml:S1:23453:2	O

Renal	NULOJIX.xml:S1:23489:5	B-AdverseReaction
tubular	NULOJIX.xml:S1:23495:7	I-AdverseReaction
necrosis	NULOJIX.xml:S1:23503:8	I-AdverseReaction
9	NULOJIX.xml:S1:23533:1	O
13	NULOJIX.xml:S1:23562:2	O

Vascular	NULOJIX.xml:S1:23594:8	O
Disorders	NULOJIX.xml:S1:23603:9	O

Hypertension	NULOJIX.xml:S1:23707:12	B-AdverseReaction
32	NULOJIX.xml:S1:23751:2	O
37	NULOJIX.xml:S1:23780:2	O

Hypotension	NULOJIX.xml:S1:23816:11	B-AdverseReaction
18	NULOJIX.xml:S1:23860:2	O
12	NULOJIX.xml:S1:23889:2	O

Respiratory	NULOJIX.xml:S1:23921:11	O
,	NULOJIX.xml:S1:23932:1	O
Thoracic	NULOJIX.xml:S1:23934:8	O
,	NULOJIX.xml:S1:23942:1	O
and	NULOJIX.xml:S1:23944:3	O
Mediastinal	NULOJIX.xml:S1:23948:11	O
Disorders	NULOJIX.xml:S1:23960:9	O

Cough	NULOJIX.xml:S1:24038:5	B-AdverseReaction
24	NULOJIX.xml:S1:24082:2	O
18	NULOJIX.xml:S1:24111:2	O

Dyspnea	NULOJIX.xml:S1:24147:7	B-AdverseReaction
12	NULOJIX.xml:S1:24191:2	O
15	NULOJIX.xml:S1:24220:2	O

Investigations	NULOJIX.xml:S1:24252:14	O

Blood	NULOJIX.xml:S1:24365:5	B-AdverseReaction
creatinine	NULOJIX.xml:S1:24371:10	I-AdverseReaction
increased	NULOJIX.xml:S1:24382:9	I-AdverseReaction
15	NULOJIX.xml:S1:24409:2	O
20	NULOJIX.xml:S1:24438:2	O

Musculoskeletal	NULOJIX.xml:S1:24470:15	O
and	NULOJIX.xml:S1:24486:3	O
Connective	NULOJIX.xml:S1:24490:10	O
Tissue	NULOJIX.xml:S1:24501:6	O
Disorders	NULOJIX.xml:S1:24508:9	O

Arthralgia	NULOJIX.xml:S1:24586:10	B-AdverseReaction
17	NULOJIX.xml:S1:24630:2	O
13	NULOJIX.xml:S1:24659:2	O

Back	NULOJIX.xml:S1:24695:4	B-AdverseReaction
pain	NULOJIX.xml:S1:24700:4	I-AdverseReaction
13	NULOJIX.xml:S1:24739:2	O
13	NULOJIX.xml:S1:24768:2	O

Nervous	NULOJIX.xml:S1:24800:7	O
System	NULOJIX.xml:S1:24808:6	O
Disorders	NULOJIX.xml:S1:24815:9	O

Headache	NULOJIX.xml:S1:24913:8	B-AdverseReaction
21	NULOJIX.xml:S1:24957:2	O
18	NULOJIX.xml:S1:24986:2	O

Dizziness	NULOJIX.xml:S1:25022:9	B-AdverseReaction
9	NULOJIX.xml:S1:25066:1	O
10	NULOJIX.xml:S1:25095:2	O

Tremor	NULOJIX.xml:S1:25131:6	B-AdverseReaction
8	NULOJIX.xml:S1:25175:1	O
17	NULOJIX.xml:S1:25204:2	O

Skin	NULOJIX.xml:S1:25236:4	O
and	NULOJIX.xml:S1:25241:3	O
Subcutaneous	NULOJIX.xml:S1:25245:12	O
Tissue	NULOJIX.xml:S1:25258:6	O
Disorders	NULOJIX.xml:S1:25265:9	O

Acne	NULOJIX.xml:S1:25349:4	B-AdverseReaction
8	NULOJIX.xml:S1:25393:1	O
11	NULOJIX.xml:S1:25422:2	O

Psychiatric	NULOJIX.xml:S1:25454:11	O
Disorders	NULOJIX.xml:S1:25466:9	O

Insomnia	NULOJIX.xml:S1:25567:8	B-AdverseReaction
15	NULOJIX.xml:S1:25611:2	O
18	NULOJIX.xml:S1:25640:2	O

Anxiety	NULOJIX.xml:S1:25676:7	B-AdverseReaction
10	NULOJIX.xml:S1:25720:2	O
11	NULOJIX.xml:S1:25749:2	O

Selected	NULOJIX.xml:S1:25788:8	O
adverse	NULOJIX.xml:S1:25797:7	O
reactions	NULOJIX.xml:S1:25805:9	O
occurring	NULOJIX.xml:S1:25815:9	O
in	NULOJIX.xml:S1:25825:2	O
10%	NULOJIX.xml:S1:25829:3	O
from	NULOJIX.xml:S1:25833:4	O
NULOJIX	NULOJIX.xml:S1:25838:7	O
-	NULOJIX.xml:S1:25845:1	O
treated	NULOJIX.xml:S1:25846:7	O
patients	NULOJIX.xml:S1:25854:8	O
in	NULOJIX.xml:S1:25863:2	O
either	NULOJIX.xml:S1:25866:6	O
regimen	NULOJIX.xml:S1:25873:7	O
through	NULOJIX.xml:S1:25881:7	O
three	NULOJIX.xml:S1:25889:5	O
years	NULOJIX.xml:S1:25895:5	O
in	NULOJIX.xml:S1:25901:2	O
Studies	NULOJIX.xml:S1:25904:7	O
1	NULOJIX.xml:S1:25912:1	O
and	NULOJIX.xml:S1:25914:3	O
2	NULOJIX.xml:S1:25918:1	O
are	NULOJIX.xml:S1:25920:3	O
listed	NULOJIX.xml:S1:25924:6	O
below	NULOJIX.xml:S1:25931:5	O
:	NULOJIX.xml:S1:25936:1	O

Immune	NULOJIX.xml:S1:25944:6	O

System	NULOJIX.xml:S1:25951:6	O
Disorders	NULOJIX.xml:S1:25958:9	O
:	NULOJIX.xml:S1:25967:1	O
Guillain	NULOJIX.xml:S1:25970:8	B-AdverseReaction
-	NULOJIX.xml:S1:25978:1	I-AdverseReaction
Barre	NULOJIX.xml:S1:25979:5	I-AdverseReaction
syndrome	NULOJIX.xml:S1:25985:8	I-AdverseReaction

Infections	NULOJIX.xml:S1:26000:10	O
and	NULOJIX.xml:S1:26011:3	O
Infestations	NULOJIX.xml:S1:26015:12	O
:	NULOJIX.xml:S1:26027:1	O
see	NULOJIX.xml:S1:26030:3	O
Table	NULOJIX.xml:S1:26034:5	O
3	NULOJIX.xml:S1:26040:1	O

Gastrointestinal	NULOJIX.xml:S1:26048:16	O
Disorders	NULOJIX.xml:S1:26065:9	O
:	NULOJIX.xml:S1:26074:1	O
stomatitis	NULOJIX.xml:S1:26077:10	B-AdverseReaction
,	NULOJIX.xml:S1:26087:1	O
including	NULOJIX.xml:S1:26089:9	O
aphthous	NULOJIX.xml:S1:26099:8	B-AdverseReaction
stomatitis	NULOJIX.xml:S1:26108:10	I-AdverseReaction

Injury	NULOJIX.xml:S1:26125:6	O
,	NULOJIX.xml:S1:26131:1	O
Poisoning	NULOJIX.xml:S1:26133:9	O
,	NULOJIX.xml:S1:26142:1	O
and	NULOJIX.xml:S1:26144:3	O
Procedural	NULOJIX.xml:S1:26148:10	O
Complications	NULOJIX.xml:S1:26159:13	O
:	NULOJIX.xml:S1:26172:1	O
chronic	NULOJIX.xml:S1:26175:7	B-AdverseReaction
allograft	NULOJIX.xml:S1:26183:9	I-AdverseReaction
nephropathy	NULOJIX.xml:S1:26193:11	I-AdverseReaction
,	NULOJIX.xml:S1:26204:1	O
complications	NULOJIX.xml:S1:26206:13	B-AdverseReaction
of	NULOJIX.xml:S1:26220:2	I-AdverseReaction
transplanted	NULOJIX.xml:S1:26223:12	I-AdverseReaction
kidney	NULOJIX.xml:S1:26236:6	I-AdverseReaction
,	NULOJIX.xml:S1:26242:1	O
including	NULOJIX.xml:S1:26244:9	O
wound	NULOJIX.xml:S1:26254:5	B-AdverseReaction
dehiscence	NULOJIX.xml:S1:26260:10	I-AdverseReaction
,	NULOJIX.xml:S1:26270:1	O
arteriovenous	NULOJIX.xml:S1:26272:13	B-AdverseReaction
fistula	NULOJIX.xml:S1:26286:7	I-AdverseReaction
thrombosis	NULOJIX.xml:S1:26294:10	I-AdverseReaction

Blood	NULOJIX.xml:S1:26311:5	O
and	NULOJIX.xml:S1:26317:3	O
Lymphatic	NULOJIX.xml:S1:26321:9	O
System	NULOJIX.xml:S1:26331:6	O
Disorders	NULOJIX.xml:S1:26338:9	O
:	NULOJIX.xml:S1:26347:1	O
neutropenia	NULOJIX.xml:S1:26350:11	B-AdverseReaction

Renal	NULOJIX.xml:S1:26368:5	O
and	NULOJIX.xml:S1:26374:3	O
Urinary	NULOJIX.xml:S1:26378:7	O
Disorders	NULOJIX.xml:S1:26386:9	O
:	NULOJIX.xml:S1:26395:1	O
renal	NULOJIX.xml:S1:26398:5	B-AdverseReaction
impairment	NULOJIX.xml:S1:26404:10	I-AdverseReaction
,	NULOJIX.xml:S1:26414:1	O
including	NULOJIX.xml:S1:26416:9	O
acute	NULOJIX.xml:S1:26426:5	B-AdverseReaction
renal	NULOJIX.xml:S1:26432:5	I-AdverseReaction
failure	NULOJIX.xml:S1:26438:7	I-AdverseReaction
,	NULOJIX.xml:S1:26445:1	O
renal	NULOJIX.xml:S1:26447:5	B-AdverseReaction
artery	NULOJIX.xml:S1:26453:6	I-AdverseReaction
stenosis	NULOJIX.xml:S1:26460:8	I-AdverseReaction
,	NULOJIX.xml:S1:26468:1	O
urinary	NULOJIX.xml:S1:26470:7	B-AdverseReaction
incontinence	NULOJIX.xml:S1:26478:12	I-AdverseReaction
,	NULOJIX.xml:S1:26490:1	O
hydronephrosis	NULOJIX.xml:S1:26492:14	B-AdverseReaction

Vascular	NULOJIX.xml:S1:26513:8	O
Disorders	NULOJIX.xml:S1:26522:9	O
:	NULOJIX.xml:S1:26531:1	O
hematoma	NULOJIX.xml:S1:26534:8	B-AdverseReaction
,	NULOJIX.xml:S1:26542:1	O
lymphocele	NULOJIX.xml:S1:26544:10	B-AdverseReaction

Musculoskeletal	NULOJIX.xml:S1:26561:15	O
and	NULOJIX.xml:S1:26577:3	O
Connective	NULOJIX.xml:S1:26581:10	O
Tissue	NULOJIX.xml:S1:26592:6	O
Disorders	NULOJIX.xml:S1:26599:9	O
:	NULOJIX.xml:S1:26608:1	O
musculoskeletal	NULOJIX.xml:S1:26611:15	B-AdverseReaction
pain	NULOJIX.xml:S1:26627:4	I-AdverseReaction

Skin	NULOJIX.xml:S1:26638:4	O
and	NULOJIX.xml:S1:26643:3	O
Subcutaneous	NULOJIX.xml:S1:26647:12	O
Tissue	NULOJIX.xml:S1:26660:6	O
Disorders	NULOJIX.xml:S1:26667:9	O
:	NULOJIX.xml:S1:26676:1	O
alopecia	NULOJIX.xml:S1:26679:8	B-AdverseReaction
,	NULOJIX.xml:S1:26687:1	O
hyperhidrosis	NULOJIX.xml:S1:26689:13	B-AdverseReaction

Cardiac	NULOJIX.xml:S1:26709:7	O
Disorders	NULOJIX.xml:S1:26717:9	O
:	NULOJIX.xml:S1:26726:1	O
atrial	NULOJIX.xml:S1:26729:6	B-AdverseReaction
fibrillation	NULOJIX.xml:S1:26736:12	I-AdverseReaction
\n\n	NULOJIX.xml:S2:0:2	O
BOXED	NULOJIX.xml:S2:6:5	O
WARNING	NULOJIX.xml:S2:12:7	O
:	NULOJIX.xml:S2:19:1	O
WARNING	NULOJIX.xml:S2:21:7	O
:	NULOJIX.xml:S2:28:1	O
POST	NULOJIX.xml:S2:30:4	B-AdverseReaction
-	NULOJIX.xml:S2:34:1	I-AdverseReaction
TRANSPLANT	NULOJIX.xml:S2:35:10	I-AdverseReaction
LYMPHOPROLIFERATIVE	NULOJIX.xml:S2:46:19	I-AdverseReaction
DISORDER	NULOJIX.xml:S2:66:8	I-AdverseReaction
,	NULOJIX.xml:S2:74:1	O
OTHER	NULOJIX.xml:S2:76:5	O
MALIGNANCIES	NULOJIX.xml:S2:82:12	B-AdverseReaction
,	NULOJIX.xml:S2:94:1	O
AND	NULOJIX.xml:S2:96:3	O
SERIOUS	NULOJIX.xml:S2:100:7	B-Severity
INFECTIONS	NULOJIX.xml:S2:108:10	B-AdverseReaction
\n\n	NULOJIX.xml:S2:118:2	O
WARNING	NULOJIX.xml:S2:122:7	O
:	NULOJIX.xml:S2:129:1	O
POST	NULOJIX.xml:S2:131:4	B-AdverseReaction
-	NULOJIX.xml:S2:135:1	I-AdverseReaction
TRANSPLANT	NULOJIX.xml:S2:136:10	I-AdverseReaction
LYMPHOPROLIFERATIVE	NULOJIX.xml:S2:147:19	I-AdverseReaction
DISORDER	NULOJIX.xml:S2:167:8	I-AdverseReaction
,	NULOJIX.xml:S2:175:1	O
OTHER	NULOJIX.xml:S2:177:5	O
MALIGNANCIES	NULOJIX.xml:S2:183:12	B-AdverseReaction
,	NULOJIX.xml:S2:195:1	O
AND	NULOJIX.xml:S2:197:3	O
SERIOUS	NULOJIX.xml:S2:201:7	B-Severity
INFECTIONS	NULOJIX.xml:S2:209:10	B-AdverseReaction
\n\n	NULOJIX.xml:S2:219:2	O
Increased	NULOJIX.xml:S2:225:9	O
risk	NULOJIX.xml:S2:235:4	B-Factor
for	NULOJIX.xml:S2:240:3	O
developing	NULOJIX.xml:S2:244:10	O
post	NULOJIX.xml:S2:255:4	B-AdverseReaction
-	NULOJIX.xml:S2:259:1	I-AdverseReaction
transplant	NULOJIX.xml:S2:260:10	I-AdverseReaction
lymphoproliferative	NULOJIX.xml:S2:271:19	I-AdverseReaction
disorder	NULOJIX.xml:S2:291:8	I-AdverseReaction
(	NULOJIX.xml:S2:300:1	O
PTLD	NULOJIX.xml:S2:301:4	B-AdverseReaction
)	NULOJIX.xml:S2:305:1	O
,	NULOJIX.xml:S2:306:1	O
predominantly	NULOJIX.xml:S2:308:13	O
involving	NULOJIX.xml:S2:322:9	O
the	NULOJIX.xml:S2:332:3	O
central	NULOJIX.xml:S2:336:7	O
nervous	NULOJIX.xml:S2:344:7	O
system	NULOJIX.xml:S2:352:6	O
(	NULOJIX.xml:S2:359:1	O
CNS	NULOJIX.xml:S2:360:3	O
)	NULOJIX.xml:S2:363:1	O
.	NULOJIX.xml:S2:364:1	O

Recipients	NULOJIX.xml:S2:366:10	O
without	NULOJIX.xml:S2:377:7	O
immunity	NULOJIX.xml:S2:385:8	O
to	NULOJIX.xml:S2:394:2	O
Epstein	NULOJIX.xml:S2:397:7	O
-	NULOJIX.xml:S2:404:1	O
Barr	NULOJIX.xml:S2:405:4	O
virus	NULOJIX.xml:S2:410:5	O
(	NULOJIX.xml:S2:416:1	O
EBV	NULOJIX.xml:S2:417:3	O
)	NULOJIX.xml:S2:420:1	O
are	NULOJIX.xml:S2:422:3	O
at	NULOJIX.xml:S2:426:2	O
a	NULOJIX.xml:S2:429:1	O
particularly	NULOJIX.xml:S2:431:12	O
increased	NULOJIX.xml:S2:444:9	O
risk	NULOJIX.xml:S2:454:4	O
;	NULOJIX.xml:S2:458:1	O
therefore	NULOJIX.xml:S2:460:9	O
,	NULOJIX.xml:S2:469:1	O
use	NULOJIX.xml:S2:471:3	O
in	NULOJIX.xml:S2:475:2	O
EBV	NULOJIX.xml:S2:478:3	O
seropositive	NULOJIX.xml:S2:482:12	O
patients	NULOJIX.xml:S2:495:8	O
only	NULOJIX.xml:S2:504:4	O
.	NULOJIX.xml:S2:508:1	O

Do	NULOJIX.xml:S2:510:2	O
not	NULOJIX.xml:S2:513:3	O
use	NULOJIX.xml:S2:517:3	O
NULOJIX	NULOJIX.xml:S2:521:7	O
in	NULOJIX.xml:S2:529:2	O
transplant	NULOJIX.xml:S2:532:10	O
recipients	NULOJIX.xml:S2:543:10	O
who	NULOJIX.xml:S2:554:3	O
are	NULOJIX.xml:S2:558:3	O
EBV	NULOJIX.xml:S2:562:3	O
seronegative	NULOJIX.xml:S2:566:12	O
or	NULOJIX.xml:S2:579:2	O
with	NULOJIX.xml:S2:582:4	O
unknown	NULOJIX.xml:S2:587:7	O
EBV	NULOJIX.xml:S2:595:3	O
serostatus	NULOJIX.xml:S2:599:10	O
[	NULOJIX.xml:S2:610:1	O
see	NULOJIX.xml:S2:611:3	O
Contraindications	NULOJIX.xml:S2:619:17	O
(	NULOJIX.xml:S2:637:1	O
4	NULOJIX.xml:S2:638:1	O
)	NULOJIX.xml:S2:639:1	O
and	NULOJIX.xml:S2:645:3	O
Warnings	NULOJIX.xml:S2:653:8	O
and	NULOJIX.xml:S2:662:3	O
Precautions	NULOJIX.xml:S2:666:11	O
(	NULOJIX.xml:S2:678:1	O
5.1	NULOJIX.xml:S2:679:3	O
)	NULOJIX.xml:S2:682:1	O
]	NULOJIX.xml:S2:687:1	O
.	NULOJIX.xml:S2:688:1	O

Only	NULOJIX.xml:S2:698:4	O
physicians	NULOJIX.xml:S2:703:10	O
experienced	NULOJIX.xml:S2:714:11	O
in	NULOJIX.xml:S2:726:2	O
immunosuppressive	NULOJIX.xml:S2:729:17	O
therapy	NULOJIX.xml:S2:747:7	O
and	NULOJIX.xml:S2:755:3	O
management	NULOJIX.xml:S2:759:10	O
of	NULOJIX.xml:S2:770:2	O
kidney	NULOJIX.xml:S2:773:6	O
transplant	NULOJIX.xml:S2:780:10	O
patients	NULOJIX.xml:S2:791:8	O
should	NULOJIX.xml:S2:800:6	O
prescribe	NULOJIX.xml:S2:807:9	O
NULOJIX	NULOJIX.xml:S2:817:7	O
.	NULOJIX.xml:S2:824:1	O

Patients	NULOJIX.xml:S2:826:8	O
receiving	NULOJIX.xml:S2:835:9	O
the	NULOJIX.xml:S2:845:3	O
drug	NULOJIX.xml:S2:849:4	O
should	NULOJIX.xml:S2:854:6	O
be	NULOJIX.xml:S2:861:2	O
managed	NULOJIX.xml:S2:864:7	O
in	NULOJIX.xml:S2:872:2	O
facilities	NULOJIX.xml:S2:875:10	O
equipped	NULOJIX.xml:S2:886:8	O
and	NULOJIX.xml:S2:895:3	O
staffed	NULOJIX.xml:S2:899:7	O
with	NULOJIX.xml:S2:907:4	O
adequate	NULOJIX.xml:S2:912:8	O
laboratory	NULOJIX.xml:S2:921:10	O
and	NULOJIX.xml:S2:932:3	O
supportive	NULOJIX.xml:S2:936:10	O
medical	NULOJIX.xml:S2:947:7	O
resources	NULOJIX.xml:S2:955:9	O
.	NULOJIX.xml:S2:964:1	O

The	NULOJIX.xml:S2:966:3	O
physician	NULOJIX.xml:S2:970:9	O
responsible	NULOJIX.xml:S2:980:11	O
for	NULOJIX.xml:S2:992:3	O
maintenance	NULOJIX.xml:S2:996:11	O
therapy	NULOJIX.xml:S2:1008:7	O
should	NULOJIX.xml:S2:1016:6	O
have	NULOJIX.xml:S2:1023:4	O
complete	NULOJIX.xml:S2:1028:8	O
information	NULOJIX.xml:S2:1037:11	O
requisite	NULOJIX.xml:S2:1049:9	O
for	NULOJIX.xml:S2:1059:3	O
the	NULOJIX.xml:S2:1063:3	O
follow	NULOJIX.xml:S2:1067:6	O
-	NULOJIX.xml:S2:1073:1	O
up	NULOJIX.xml:S2:1074:2	O
of	NULOJIX.xml:S2:1077:2	O
the	NULOJIX.xml:S2:1080:3	O
patient	NULOJIX.xml:S2:1084:7	O
[	NULOJIX.xml:S2:1092:1	O
see	NULOJIX.xml:S2:1093:3	O
Warnings	NULOJIX.xml:S2:1101:8	O
and	NULOJIX.xml:S2:1110:3	O
Precautions	NULOJIX.xml:S2:1114:11	O
(	NULOJIX.xml:S2:1126:1	O
5.2	NULOJIX.xml:S2:1127:3	O
)	NULOJIX.xml:S2:1130:1	O
]	NULOJIX.xml:S2:1135:1	O
.	NULOJIX.xml:S2:1136:1	O

Increased	NULOJIX.xml:S2:1146:9	B-AdverseReaction
susceptibility	NULOJIX.xml:S2:1156:14	I-AdverseReaction
to	NULOJIX.xml:S2:1171:2	I-AdverseReaction
infection	NULOJIX.xml:S2:1174:9	I-AdverseReaction
and	NULOJIX.xml:S2:1184:3	O
the	NULOJIX.xml:S2:1188:3	O
possible	NULOJIX.xml:S2:1192:8	O
development	NULOJIX.xml:S2:1201:11	O
of	NULOJIX.xml:S2:1213:2	O
malignancies	NULOJIX.xml:S2:1216:12	B-AdverseReaction
may	NULOJIX.xml:S2:1229:3	B-Factor
result	NULOJIX.xml:S2:1233:6	O
from	NULOJIX.xml:S2:1240:4	O
immunosuppression	NULOJIX.xml:S2:1245:17	O
[	NULOJIX.xml:S2:1263:1	O
see	NULOJIX.xml:S2:1264:3	O
Warnings	NULOJIX.xml:S2:1272:8	O
and	NULOJIX.xml:S2:1281:3	O
Precautions	NULOJIX.xml:S2:1285:11	O
(	NULOJIX.xml:S2:1297:1	O
5.1	NULOJIX.xml:S2:1298:3	O
,	NULOJIX.xml:S2:1303:1	O
5.3	NULOJIX.xml:S2:1307:3	O
,	NULOJIX.xml:S2:1312:1	O
5.4	NULOJIX.xml:S2:1316:3	O
,	NULOJIX.xml:S2:1321:1	O
5.5	NULOJIX.xml:S2:1325:3	O
)	NULOJIX.xml:S2:1328:1	O
]	NULOJIX.xml:S2:1333:1	O
.	NULOJIX.xml:S2:1334:1	O

Use	NULOJIX.xml:S2:1344:3	O
in	NULOJIX.xml:S2:1348:2	O
liver	NULOJIX.xml:S2:1351:5	O
transplant	NULOJIX.xml:S2:1357:10	O
patients	NULOJIX.xml:S2:1368:8	O
is	NULOJIX.xml:S2:1377:2	O
not	NULOJIX.xml:S2:1380:3	O
recommended	NULOJIX.xml:S2:1384:11	O
due	NULOJIX.xml:S2:1396:3	O
to	NULOJIX.xml:S2:1400:2	O
an	NULOJIX.xml:S2:1403:2	O
increased	NULOJIX.xml:S2:1406:9	O
risk	NULOJIX.xml:S2:1416:4	O
of	NULOJIX.xml:S2:1421:2	O
graft	NULOJIX.xml:S2:1424:5	O
loss	NULOJIX.xml:S2:1430:4	O
and	NULOJIX.xml:S2:1435:3	O
death	NULOJIX.xml:S2:1439:5	O
[	NULOJIX.xml:S2:1445:1	O
see	NULOJIX.xml:S2:1446:3	O
Warnings	NULOJIX.xml:S2:1454:8	O
and	NULOJIX.xml:S2:1463:3	O
Precautions	NULOJIX.xml:S2:1467:11	O
(	NULOJIX.xml:S2:1479:1	O
5.6	NULOJIX.xml:S2:1480:3	O
)	NULOJIX.xml:S2:1483:1	O
]	NULOJIX.xml:S2:1488:1	O
.	NULOJIX.xml:S2:1489:1	O

EXCERPT	NULOJIX.xml:S2:1499:7	O
:	NULOJIX.xml:S2:1506:1	O
WARNING	NULOJIX.xml:S2:1510:7	O
:	NULOJIX.xml:S2:1517:1	O
POST	NULOJIX.xml:S2:1519:4	B-AdverseReaction
-	NULOJIX.xml:S2:1523:1	I-AdverseReaction
TRANSPLANT	NULOJIX.xml:S2:1524:10	I-AdverseReaction
LYMPHOPROLIFERATIVE	NULOJIX.xml:S2:1535:19	I-AdverseReaction
DISORDER	NULOJIX.xml:S2:1555:8	I-AdverseReaction
,	NULOJIX.xml:S2:1563:1	O
OTHER	NULOJIX.xml:S2:1565:5	O
MALIGNANCIES	NULOJIX.xml:S2:1571:12	B-AdverseReaction
,	NULOJIX.xml:S2:1583:1	O
AND	NULOJIX.xml:S2:1585:3	O
SERIOUS	NULOJIX.xml:S2:1589:7	B-Severity
INFECTIONS	NULOJIX.xml:S2:1597:10	B-AdverseReaction
\n\n\n\n	NULOJIX.xml:S2:1607:4	O
See	NULOJIX.xml:S2:1616:3	O
full	NULOJIX.xml:S2:1620:4	O
prescribing	NULOJIX.xml:S2:1625:11	O
information	NULOJIX.xml:S2:1637:11	O
for	NULOJIX.xml:S2:1649:3	O
complete	NULOJIX.xml:S2:1653:8	O
boxed	NULOJIX.xml:S2:1662:5	O
warning	NULOJIX.xml:S2:1668:7	O
.	NULOJIX.xml:S2:1675:1	O

Increased	NULOJIX.xml:S2:1688:9	O
risk	NULOJIX.xml:S2:1698:4	B-Factor
for	NULOJIX.xml:S2:1703:3	O
developing	NULOJIX.xml:S2:1707:10	O
post	NULOJIX.xml:S2:1718:4	B-AdverseReaction
-	NULOJIX.xml:S2:1722:1	I-AdverseReaction
transplant	NULOJIX.xml:S2:1723:10	I-AdverseReaction
lymphoproliferative	NULOJIX.xml:S2:1734:19	I-AdverseReaction
disorder	NULOJIX.xml:S2:1754:8	I-AdverseReaction
(	NULOJIX.xml:S2:1763:1	O
PTLD	NULOJIX.xml:S2:1764:4	B-AdverseReaction
)	NULOJIX.xml:S2:1768:1	O
,	NULOJIX.xml:S2:1769:1	O
predominantly	NULOJIX.xml:S2:1771:13	O
involving	NULOJIX.xml:S2:1785:9	O
the	NULOJIX.xml:S2:1795:3	O
central	NULOJIX.xml:S2:1799:7	O
nervous	NULOJIX.xml:S2:1807:7	O
system	NULOJIX.xml:S2:1815:6	O
(	NULOJIX.xml:S2:1822:1	O
CNS	NULOJIX.xml:S2:1823:3	O
)	NULOJIX.xml:S2:1826:1	O
.	NULOJIX.xml:S2:1827:1	O

Recipients	NULOJIX.xml:S2:1829:10	O
without	NULOJIX.xml:S2:1840:7	O
immunity	NULOJIX.xml:S2:1848:8	O
to	NULOJIX.xml:S2:1857:2	O
Epstein	NULOJIX.xml:S2:1860:7	O
-	NULOJIX.xml:S2:1867:1	O
Barr	NULOJIX.xml:S2:1868:4	O
virus	NULOJIX.xml:S2:1873:5	O
(	NULOJIX.xml:S2:1879:1	O
EBV	NULOJIX.xml:S2:1880:3	O
)	NULOJIX.xml:S2:1883:1	O
are	NULOJIX.xml:S2:1885:3	O
at	NULOJIX.xml:S2:1889:2	O
a	NULOJIX.xml:S2:1892:1	O
particularly	NULOJIX.xml:S2:1894:12	O
increased	NULOJIX.xml:S2:1907:9	O
risk	NULOJIX.xml:S2:1917:4	O
;	NULOJIX.xml:S2:1921:1	O
therefore	NULOJIX.xml:S2:1923:9	O
,	NULOJIX.xml:S2:1932:1	O
use	NULOJIX.xml:S2:1934:3	O
in	NULOJIX.xml:S2:1938:2	O
EBV	NULOJIX.xml:S2:1941:3	O
seropositive	NULOJIX.xml:S2:1945:12	O
patients	NULOJIX.xml:S2:1958:8	O
only	NULOJIX.xml:S2:1967:4	O
.	NULOJIX.xml:S2:1971:1	O

Do	NULOJIX.xml:S2:1973:2	O
not	NULOJIX.xml:S2:1976:3	O
use	NULOJIX.xml:S2:1980:3	O
NULOJIX	NULOJIX.xml:S2:1984:7	O
in	NULOJIX.xml:S2:1992:2	O
transplant	NULOJIX.xml:S2:1995:10	O
recipients	NULOJIX.xml:S2:2006:10	O
who	NULOJIX.xml:S2:2017:3	O
are	NULOJIX.xml:S2:2021:3	O
EBV	NULOJIX.xml:S2:2025:3	O
seronegative	NULOJIX.xml:S2:2029:12	O
or	NULOJIX.xml:S2:2042:2	O
with	NULOJIX.xml:S2:2045:4	O
unknown	NULOJIX.xml:S2:2050:7	O
serostatus	NULOJIX.xml:S2:2058:10	O
.	NULOJIX.xml:S2:2068:1	O

(	NULOJIX.xml:S2:2070:1	O
4	NULOJIX.xml:S2:2071:1	O
,	NULOJIX.xml:S2:2072:1	O
5.1	NULOJIX.xml:S2:2074:3	O
)	NULOJIX.xml:S2:2077:1	O
\n	NULOJIX.xml:S2:2079:1	O
Only	NULOJIX.xml:S2:2084:4	O
physicians	NULOJIX.xml:S2:2089:10	O
experienced	NULOJIX.xml:S2:2100:11	O
in	NULOJIX.xml:S2:2112:2	O
immunosuppressive	NULOJIX.xml:S2:2115:17	O
therapy	NULOJIX.xml:S2:2133:7	O
and	NULOJIX.xml:S2:2141:3	O
management	NULOJIX.xml:S2:2145:10	O
of	NULOJIX.xml:S2:2156:2	O
kidney	NULOJIX.xml:S2:2159:6	O
transplant	NULOJIX.xml:S2:2166:10	O
patients	NULOJIX.xml:S2:2177:8	O
should	NULOJIX.xml:S2:2186:6	O
prescribe	NULOJIX.xml:S2:2193:9	O
NULOJIX	NULOJIX.xml:S2:2203:7	O
.	NULOJIX.xml:S2:2210:1	O

(	NULOJIX.xml:S2:2212:1	O
5.2	NULOJIX.xml:S2:2213:3	O
)	NULOJIX.xml:S2:2216:1	O
\n	NULOJIX.xml:S2:2218:1	O
Increased	NULOJIX.xml:S2:2223:9	B-AdverseReaction
susceptibility	NULOJIX.xml:S2:2233:14	I-AdverseReaction
to	NULOJIX.xml:S2:2248:2	I-AdverseReaction
infection	NULOJIX.xml:S2:2251:9	I-AdverseReaction
and	NULOJIX.xml:S2:2261:3	O
the	NULOJIX.xml:S2:2265:3	O
possible	NULOJIX.xml:S2:2269:8	O
development	NULOJIX.xml:S2:2278:11	O
of	NULOJIX.xml:S2:2290:2	O
malignancies	NULOJIX.xml:S2:2293:12	B-AdverseReaction
may	NULOJIX.xml:S2:2306:3	B-Factor
result	NULOJIX.xml:S2:2310:6	O
from	NULOJIX.xml:S2:2317:4	O
immunosuppression	NULOJIX.xml:S2:2322:17	O
.	NULOJIX.xml:S2:2339:1	O

(	NULOJIX.xml:S2:2341:1	O
5.1	NULOJIX.xml:S2:2342:3	O
,	NULOJIX.xml:S2:2345:1	O
5.3	NULOJIX.xml:S2:2347:3	O
,	NULOJIX.xml:S2:2350:1	O
5.4	NULOJIX.xml:S2:2352:3	O
,	NULOJIX.xml:S2:2355:1	O
5.5	NULOJIX.xml:S2:2357:3	O
)	NULOJIX.xml:S2:2360:1	O
\n	NULOJIX.xml:S2:2362:1	O
Use	NULOJIX.xml:S2:2367:3	O
in	NULOJIX.xml:S2:2371:2	O
liver	NULOJIX.xml:S2:2374:5	O
transplant	NULOJIX.xml:S2:2380:10	O
patients	NULOJIX.xml:S2:2391:8	O
is	NULOJIX.xml:S2:2400:2	O
not	NULOJIX.xml:S2:2403:3	O
recommended	NULOJIX.xml:S2:2407:11	O
due	NULOJIX.xml:S2:2419:3	O
to	NULOJIX.xml:S2:2423:2	O
an	NULOJIX.xml:S2:2426:2	O
increased	NULOJIX.xml:S2:2429:9	O
risk	NULOJIX.xml:S2:2439:4	O
of	NULOJIX.xml:S2:2444:2	O
graft	NULOJIX.xml:S2:2447:5	O
loss	NULOJIX.xml:S2:2453:4	O
and	NULOJIX.xml:S2:2458:3	O
death	NULOJIX.xml:S2:2462:5	O
.	NULOJIX.xml:S2:2467:1	O

(	NULOJIX.xml:S2:2469:1	O
5.6	NULOJIX.xml:S2:2470:3	O
)	NULOJIX.xml:S2:2473:1	O
\n	NULOJIX.xml:S2:2475:1	O
5	NULOJIX.xml:S3:4:1	O
WARNINGS	NULOJIX.xml:S3:6:8	O
AND	NULOJIX.xml:S3:15:3	O
PRECAUTIONS	NULOJIX.xml:S3:19:11	O

EXCERPT	NULOJIX.xml:S3:37:7	O
:	NULOJIX.xml:S3:44:1	O
Post	NULOJIX.xml:S3:55:4	B-AdverseReaction
-	NULOJIX.xml:S3:59:1	I-AdverseReaction
Transplant	NULOJIX.xml:S3:60:10	I-AdverseReaction
Lymphoproliferative	NULOJIX.xml:S3:71:19	I-AdverseReaction
Disorder	NULOJIX.xml:S3:91:8	I-AdverseReaction
(	NULOJIX.xml:S3:100:1	O
PTLD	NULOJIX.xml:S3:101:4	B-AdverseReaction
)	NULOJIX.xml:S3:105:1	O
:	NULOJIX.xml:S3:107:1	O
increased	NULOJIX.xml:S3:109:9	O
risk	NULOJIX.xml:S3:119:4	B-Factor
,	NULOJIX.xml:S3:123:1	O
predominantly	NULOJIX.xml:S3:125:13	O
involving	NULOJIX.xml:S3:139:9	O
the	NULOJIX.xml:S3:149:3	O
CNS	NULOJIX.xml:S3:153:3	O
;	NULOJIX.xml:S3:156:1	O
monitor	NULOJIX.xml:S3:158:7	O
for	NULOJIX.xml:S3:166:3	O
new	NULOJIX.xml:S3:170:3	O
or	NULOJIX.xml:S3:174:2	O
worsening	NULOJIX.xml:S3:177:9	O
neurological	NULOJIX.xml:S3:187:12	O
,	NULOJIX.xml:S3:199:1	O
cognitive	NULOJIX.xml:S3:201:9	O
,	NULOJIX.xml:S3:210:1	O
or	NULOJIX.xml:S3:212:2	O
behavioral	NULOJIX.xml:S3:215:10	O
signs	NULOJIX.xml:S3:226:5	O
and	NULOJIX.xml:S3:232:3	O
symptoms	NULOJIX.xml:S3:236:8	O
.	NULOJIX.xml:S3:244:1	O

(	NULOJIX.xml:S3:247:1	O
Boxed	NULOJIX.xml:S3:248:5	O
Warning	NULOJIX.xml:S3:254:7	O
,	NULOJIX.xml:S3:263:1	O
4	NULOJIX.xml:S3:266:1	O
,	NULOJIX.xml:S3:269:1	O
5.1	NULOJIX.xml:S3:272:3	O
,	NULOJIX.xml:S3:277:1	O
5.6	NULOJIX.xml:S3:280:3	O
)	NULOJIX.xml:S3:283:1	O

Other	NULOJIX.xml:S3:295:5	O
malignancies	NULOJIX.xml:S3:301:12	B-AdverseReaction
:	NULOJIX.xml:S3:314:1	O
increased	NULOJIX.xml:S3:316:9	O
risk	NULOJIX.xml:S3:326:4	O
with	NULOJIX.xml:S3:331:4	O
all	NULOJIX.xml:S3:336:3	O
immunosuppressants	NULOJIX.xml:S3:340:18	B-DrugClass
;	NULOJIX.xml:S3:358:1	O
appears	NULOJIX.xml:S3:360:7	O
related	NULOJIX.xml:S3:368:7	O
to	NULOJIX.xml:S3:376:2	O
intensity	NULOJIX.xml:S3:379:9	O
and	NULOJIX.xml:S3:389:3	O
duration	NULOJIX.xml:S3:393:8	O
of	NULOJIX.xml:S3:402:2	O
use	NULOJIX.xml:S3:405:3	O
.	NULOJIX.xml:S3:408:1	O

Avoid	NULOJIX.xml:S3:410:5	O
prolonged	NULOJIX.xml:S3:416:9	O
exposure	NULOJIX.xml:S3:426:8	O
to	NULOJIX.xml:S3:435:2	O
UV	NULOJIX.xml:S3:438:2	O
light	NULOJIX.xml:S3:441:5	O
and	NULOJIX.xml:S3:447:3	O
sunlight	NULOJIX.xml:S3:451:8	O
.	NULOJIX.xml:S3:459:1	O

(	NULOJIX.xml:S3:462:1	O
5.3	NULOJIX.xml:S3:463:3	O
)	NULOJIX.xml:S3:466:1	O

Progressive	NULOJIX.xml:S3:478:11	B-AdverseReaction
Multifocal	NULOJIX.xml:S3:490:10	I-AdverseReaction
Leukoencephalopathy	NULOJIX.xml:S3:501:19	I-AdverseReaction
(	NULOJIX.xml:S3:521:1	O
PML	NULOJIX.xml:S3:522:3	B-AdverseReaction
)	NULOJIX.xml:S3:525:1	O
:	NULOJIX.xml:S3:527:1	O
increased	NULOJIX.xml:S3:529:9	O
risk	NULOJIX.xml:S3:539:4	B-Factor
;	NULOJIX.xml:S3:543:1	O
consider	NULOJIX.xml:S3:545:8	O
in	NULOJIX.xml:S3:554:2	O
the	NULOJIX.xml:S3:557:3	O
diagnosis	NULOJIX.xml:S3:561:9	O
of	NULOJIX.xml:S3:571:2	O
patients	NULOJIX.xml:S3:574:8	O
reporting	NULOJIX.xml:S3:583:9	O
new	NULOJIX.xml:S3:593:3	O
or	NULOJIX.xml:S3:597:2	O
worsening	NULOJIX.xml:S3:600:9	O
neurological	NULOJIX.xml:S3:610:12	O
,	NULOJIX.xml:S3:622:1	O
cognitive	NULOJIX.xml:S3:624:9	O
,	NULOJIX.xml:S3:633:1	O
or	NULOJIX.xml:S3:635:2	O
behavioral	NULOJIX.xml:S3:638:10	O
signs	NULOJIX.xml:S3:649:5	O
and	NULOJIX.xml:S3:655:3	O
symptoms	NULOJIX.xml:S3:659:8	O
.	NULOJIX.xml:S3:667:1	O

Recommended	NULOJIX.xml:S3:669:11	O
doses	NULOJIX.xml:S3:681:5	O
of	NULOJIX.xml:S3:687:2	O
immunosuppressants	NULOJIX.xml:S3:690:18	O
should	NULOJIX.xml:S3:709:6	O
not	NULOJIX.xml:S3:716:3	O
be	NULOJIX.xml:S3:720:2	O
exceeded	NULOJIX.xml:S3:723:8	O
.	NULOJIX.xml:S3:731:1	O

(	NULOJIX.xml:S3:734:1	O
5.4	NULOJIX.xml:S3:735:3	O
)	NULOJIX.xml:S3:738:1	O

Other	NULOJIX.xml:S3:750:5	O
serious	NULOJIX.xml:S3:756:7	B-Severity
infections	NULOJIX.xml:S3:764:10	B-AdverseReaction
:	NULOJIX.xml:S3:775:1	O
increased	NULOJIX.xml:S3:777:9	O
risk	NULOJIX.xml:S3:787:4	B-Factor
of	NULOJIX.xml:S3:792:2	O
bacterial	NULOJIX.xml:S3:795:9	B-AdverseReaction
,	NULOJIX.xml:S3:804:1	O
viral	NULOJIX.xml:S3:806:5	B-AdverseReaction
,	NULOJIX.xml:S3:811:1	O
fungal	NULOJIX.xml:S3:813:6	B-AdverseReaction
,	NULOJIX.xml:S3:819:1	O
and	NULOJIX.xml:S3:821:3	O
protozoal	NULOJIX.xml:S3:825:9	B-AdverseReaction
infections	NULOJIX.xml:S3:835:10	I-AdverseReaction
,	NULOJIX.xml:S3:845:1	O
including	NULOJIX.xml:S3:847:9	O
opportunistic	NULOJIX.xml:S3:857:13	B-AdverseReaction
infections	NULOJIX.xml:S3:871:10	I-AdverseReaction
and	NULOJIX.xml:S3:882:3	O
tuberculosis	NULOJIX.xml:S3:886:12	B-AdverseReaction
.	NULOJIX.xml:S3:898:1	O

Some	NULOJIX.xml:S3:900:4	O
infections	NULOJIX.xml:S3:905:10	B-AdverseReaction
were	NULOJIX.xml:S3:916:4	O
fatal	NULOJIX.xml:S3:921:5	B-AdverseReaction
.	NULOJIX.xml:S3:926:1	O

Polyoma	NULOJIX.xml:S3:928:7	B-AdverseReaction
virus	NULOJIX.xml:S3:936:5	I-AdverseReaction
-	NULOJIX.xml:S3:941:1	I-AdverseReaction
associated	NULOJIX.xml:S3:942:10	I-AdverseReaction
nephropathy	NULOJIX.xml:S3:953:11	I-AdverseReaction
can	NULOJIX.xml:S3:965:3	B-Factor
lead	NULOJIX.xml:S3:969:4	O
to	NULOJIX.xml:S3:974:2	O
kidney	NULOJIX.xml:S3:977:6	B-AdverseReaction
graft	NULOJIX.xml:S3:984:5	I-AdverseReaction
loss	NULOJIX.xml:S3:990:4	I-AdverseReaction
;	NULOJIX.xml:S3:994:1	O
consider	NULOJIX.xml:S3:996:8	O
reduction	NULOJIX.xml:S3:1005:9	O
in	NULOJIX.xml:S3:1015:2	O
immunosuppression	NULOJIX.xml:S3:1018:17	O
.	NULOJIX.xml:S3:1035:1	O

Evaluate	NULOJIX.xml:S3:1037:8	O
for	NULOJIX.xml:S3:1046:3	O
tuberculosis	NULOJIX.xml:S3:1050:12	O
and	NULOJIX.xml:S3:1063:3	O
initiate	NULOJIX.xml:S3:1067:8	O
treatment	NULOJIX.xml:S3:1076:9	O
for	NULOJIX.xml:S3:1086:3	O
latent	NULOJIX.xml:S3:1090:6	O
infection	NULOJIX.xml:S3:1097:9	O
prior	NULOJIX.xml:S3:1107:5	O
to	NULOJIX.xml:S3:1113:2	O
NULOJIX	NULOJIX.xml:S3:1116:7	O
use	NULOJIX.xml:S3:1124:3	O
.	NULOJIX.xml:S3:1127:1	O

Cytomegalovirus	NULOJIX.xml:S3:1129:15	O
and	NULOJIX.xml:S3:1145:3	O
pneumocystis	NULOJIX.xml:S3:1149:12	O
prophylaxis	NULOJIX.xml:S3:1162:11	O
are	NULOJIX.xml:S3:1174:3	O
recommended	NULOJIX.xml:S3:1178:11	O
after	NULOJIX.xml:S3:1190:5	O
transplantation	NULOJIX.xml:S3:1196:15	O
.	NULOJIX.xml:S3:1211:1	O

(	NULOJIX.xml:S3:1214:1	O
5.1	NULOJIX.xml:S3:1215:3	O
,	NULOJIX.xml:S3:1220:1	O
5.4	NULOJIX.xml:S3:1223:3	O
,	NULOJIX.xml:S3:1228:1	O
5.5	NULOJIX.xml:S3:1231:3	O
)	NULOJIX.xml:S3:1234:1	O

Liver	NULOJIX.xml:S3:1246:5	O
transplant	NULOJIX.xml:S3:1252:10	O
:	NULOJIX.xml:S3:1263:1	O
use	NULOJIX.xml:S3:1265:3	O
is	NULOJIX.xml:S3:1269:2	O
not	NULOJIX.xml:S3:1272:3	O
recommended	NULOJIX.xml:S3:1276:11	O
.	NULOJIX.xml:S3:1287:1	O

(	NULOJIX.xml:S3:1290:1	O
5.6	NULOJIX.xml:S3:1291:3	O
)	NULOJIX.xml:S3:1294:1	O

Acute	NULOJIX.xml:S3:1306:5	B-AdverseReaction
Rejection	NULOJIX.xml:S3:1312:9	I-AdverseReaction
and	NULOJIX.xml:S3:1322:3	O
Graft	NULOJIX.xml:S3:1326:5	I-AdverseReaction
Loss	NULOJIX.xml:S3:1332:4	I-AdverseReaction
with	NULOJIX.xml:S3:1337:4	O
Corticosteroid	NULOJIX.xml:S3:1342:14	O
Minimization	NULOJIX.xml:S3:1357:12	O
:	NULOJIX.xml:S3:1370:1	O
corticosteroid	NULOJIX.xml:S3:1372:14	O
utilization	NULOJIX.xml:S3:1387:11	O
should	NULOJIX.xml:S3:1399:6	O
be	NULOJIX.xml:S3:1406:2	O
consistent	NULOJIX.xml:S3:1409:10	O
with	NULOJIX.xml:S3:1420:4	O
the	NULOJIX.xml:S3:1425:3	O
NULOJIX	NULOJIX.xml:S3:1429:7	O
clinical	NULOJIX.xml:S3:1437:8	O
trial	NULOJIX.xml:S3:1446:5	O
experience	NULOJIX.xml:S3:1452:10	O
.	NULOJIX.xml:S3:1462:1	O

(	NULOJIX.xml:S3:1465:1	O
2.1	NULOJIX.xml:S3:1466:3	O
,	NULOJIX.xml:S3:1471:1	O
5.7	NULOJIX.xml:S3:1474:3	O
,	NULOJIX.xml:S3:1479:1	O
14.1	NULOJIX.xml:S3:1482:4	O
)	NULOJIX.xml:S3:1486:1	O

Immunizations	NULOJIX.xml:S3:1498:13	O
:	NULOJIX.xml:S3:1512:1	O
avoid	NULOJIX.xml:S3:1514:5	O
use	NULOJIX.xml:S3:1520:3	O
of	NULOJIX.xml:S3:1524:2	O
live	NULOJIX.xml:S3:1527:4	O
vaccines	NULOJIX.xml:S3:1532:8	O
during	NULOJIX.xml:S3:1541:6	O
treatment	NULOJIX.xml:S3:1548:9	O
.	NULOJIX.xml:S3:1557:1	O

(	NULOJIX.xml:S3:1560:1	O
5.8	NULOJIX.xml:S3:1561:3	O
)	NULOJIX.xml:S3:1564:1	O

5.1	NULOJIX.xml:S3:1580:3	O

Post	NULOJIX.xml:S3:1584:4	O

-	NULOJIX.xml:S3:1588:1	O
Transplant	NULOJIX.xml:S3:1589:10	O
Lymphoproliferative	NULOJIX.xml:S3:1600:19	O
Disorder	NULOJIX.xml:S3:1620:8	O

NULOJIX	NULOJIX.xml:S3:1634:7	O
-	NULOJIX.xml:S3:1641:1	O
treated	NULOJIX.xml:S3:1642:7	O
patients	NULOJIX.xml:S3:1650:8	O
have	NULOJIX.xml:S3:1659:4	O
an	NULOJIX.xml:S3:1664:2	O
increased	NULOJIX.xml:S3:1667:9	O
risk	NULOJIX.xml:S3:1677:4	B-Factor
for	NULOJIX.xml:S3:1682:3	O
developing	NULOJIX.xml:S3:1686:10	O
post	NULOJIX.xml:S3:1697:4	B-AdverseReaction
-	NULOJIX.xml:S3:1701:1	I-AdverseReaction
transplant	NULOJIX.xml:S3:1702:10	I-AdverseReaction
lymphoproliferative	NULOJIX.xml:S3:1713:19	I-AdverseReaction
disorder	NULOJIX.xml:S3:1733:8	I-AdverseReaction
(	NULOJIX.xml:S3:1742:1	O
PTLD	NULOJIX.xml:S3:1743:4	B-AdverseReaction
)	NULOJIX.xml:S3:1747:1	O
,	NULOJIX.xml:S3:1748:1	O
predominantly	NULOJIX.xml:S3:1750:13	O
involving	NULOJIX.xml:S3:1764:9	O
the	NULOJIX.xml:S3:1774:3	O
CNS	NULOJIX.xml:S3:1778:3	O
,	NULOJIX.xml:S3:1781:1	O
compared	NULOJIX.xml:S3:1783:8	O
to	NULOJIX.xml:S3:1792:2	O
patients	NULOJIX.xml:S3:1795:8	O
on	NULOJIX.xml:S3:1804:2	O
a	NULOJIX.xml:S3:1807:1	O
cyclosporine	NULOJIX.xml:S3:1809:12	O
-	NULOJIX.xml:S3:1821:1	O
based	NULOJIX.xml:S3:1822:5	O
regimen	NULOJIX.xml:S3:1828:7	O
[	NULOJIX.xml:S3:1836:1	O
see	NULOJIX.xml:S3:1837:3	O
Adverse	NULOJIX.xml:S3:1843:7	O
Reactions	NULOJIX.xml:S3:1851:9	O
(	NULOJIX.xml:S3:1861:1	O
6.1	NULOJIX.xml:S3:1862:3	O
)	NULOJIX.xml:S3:1865:1	O
and	NULOJIX.xml:S3:1870:3	O
Table	NULOJIX.xml:S3:1874:5	O
2	NULOJIX.xml:S3:1880:1	O
]	NULOJIX.xml:S3:1883:1	O
.	NULOJIX.xml:S3:1884:1	O

As	NULOJIX.xml:S3:1886:2	O
the	NULOJIX.xml:S3:1889:3	O
total	NULOJIX.xml:S3:1893:5	O
burden	NULOJIX.xml:S3:1899:6	O
of	NULOJIX.xml:S3:1906:2	O
immunosuppression	NULOJIX.xml:S3:1909:17	O
is	NULOJIX.xml:S3:1927:2	O
a	NULOJIX.xml:S3:1930:1	O
risk	NULOJIX.xml:S3:1932:4	O
factor	NULOJIX.xml:S3:1937:6	O
for	NULOJIX.xml:S3:1944:3	O
PTLD	NULOJIX.xml:S3:1948:4	O
,	NULOJIX.xml:S3:1952:1	O
higher	NULOJIX.xml:S3:1954:6	O
than	NULOJIX.xml:S3:1961:4	O
the	NULOJIX.xml:S3:1966:3	O
recommended	NULOJIX.xml:S3:1970:11	O
doses	NULOJIX.xml:S3:1982:5	O
or	NULOJIX.xml:S3:1988:2	O
more	NULOJIX.xml:S3:1991:4	O
frequent	NULOJIX.xml:S3:1996:8	O
dosing	NULOJIX.xml:S3:2005:6	O
of	NULOJIX.xml:S3:2012:2	O
NULOJIX	NULOJIX.xml:S3:2015:7	O
and	NULOJIX.xml:S3:2023:3	O
higher	NULOJIX.xml:S3:2027:6	O
than	NULOJIX.xml:S3:2034:4	O
recommended	NULOJIX.xml:S3:2039:11	O
doses	NULOJIX.xml:S3:2051:5	O
of	NULOJIX.xml:S3:2057:2	O
concomitant	NULOJIX.xml:S3:2060:11	O
immunosuppressive	NULOJIX.xml:S3:2072:17	O
agents	NULOJIX.xml:S3:2090:6	O
are	NULOJIX.xml:S3:2097:3	O
not	NULOJIX.xml:S3:2101:3	O
recommended	NULOJIX.xml:S3:2105:11	O
[	NULOJIX.xml:S3:2117:1	O
see	NULOJIX.xml:S3:2118:3	O
Dosage	NULOJIX.xml:S3:2124:6	O
and	NULOJIX.xml:S3:2131:3	O
Administration	NULOJIX.xml:S3:2135:14	O
(	NULOJIX.xml:S3:2150:1	O
2.1	NULOJIX.xml:S3:2151:3	O
)	NULOJIX.xml:S3:2154:1	O
and	NULOJIX.xml:S3:2159:3	O
Warnings	NULOJIX.xml:S3:2165:8	O
and	NULOJIX.xml:S3:2174:3	O
Precautions	NULOJIX.xml:S3:2178:11	O
(	NULOJIX.xml:S3:2190:1	O
5.6	NULOJIX.xml:S3:2191:3	O
)	NULOJIX.xml:S3:2194:1	O
]	NULOJIX.xml:S3:2199:1	O
.	NULOJIX.xml:S3:2200:1	O

Physicians	NULOJIX.xml:S3:2202:10	O
should	NULOJIX.xml:S3:2213:6	O
consider	NULOJIX.xml:S3:2220:8	O
PTLD	NULOJIX.xml:S3:2229:4	O
in	NULOJIX.xml:S3:2234:2	O
patients	NULOJIX.xml:S3:2237:8	O
reporting	NULOJIX.xml:S3:2246:9	O
new	NULOJIX.xml:S3:2256:3	O
or	NULOJIX.xml:S3:2260:2	O
worsening	NULOJIX.xml:S3:2263:9	O
neurological	NULOJIX.xml:S3:2273:12	O
,	NULOJIX.xml:S3:2285:1	O
cognitive	NULOJIX.xml:S3:2287:9	O
,	NULOJIX.xml:S3:2296:1	O
or	NULOJIX.xml:S3:2298:2	O
behavioral	NULOJIX.xml:S3:2301:10	O
signs	NULOJIX.xml:S3:2312:5	O
or	NULOJIX.xml:S3:2318:2	O
symptoms	NULOJIX.xml:S3:2321:8	O
.	NULOJIX.xml:S3:2329:1	O

EBV	NULOJIX.xml:S3:2338:3	O
Serostatus	NULOJIX.xml:S3:2342:10	O

The	NULOJIX.xml:S3:2358:3	O
risk	NULOJIX.xml:S3:2362:4	B-Factor
of	NULOJIX.xml:S3:2367:2	O
PTLD	NULOJIX.xml:S3:2370:4	B-AdverseReaction
was	NULOJIX.xml:S3:2375:3	O
higher	NULOJIX.xml:S3:2379:6	O
in	NULOJIX.xml:S3:2386:2	O
EBV	NULOJIX.xml:S3:2389:3	O
seronegative	NULOJIX.xml:S3:2393:12	O
patients	NULOJIX.xml:S3:2406:8	O
compared	NULOJIX.xml:S3:2415:8	O
to	NULOJIX.xml:S3:2424:2	O
EBV	NULOJIX.xml:S3:2427:3	O
seropositive	NULOJIX.xml:S3:2431:12	O
patients	NULOJIX.xml:S3:2444:8	O
.	NULOJIX.xml:S3:2452:1	O

EBV	NULOJIX.xml:S3:2454:3	O
seropositive	NULOJIX.xml:S3:2458:12	O
patients	NULOJIX.xml:S3:2471:8	O
are	NULOJIX.xml:S3:2480:3	O
defined	NULOJIX.xml:S3:2484:7	O
as	NULOJIX.xml:S3:2492:2	O
having	NULOJIX.xml:S3:2495:6	O
evidence	NULOJIX.xml:S3:2502:8	O
of	NULOJIX.xml:S3:2511:2	O
acquired	NULOJIX.xml:S3:2514:8	O
immunity	NULOJIX.xml:S3:2523:8	O
shown	NULOJIX.xml:S3:2532:5	O
by	NULOJIX.xml:S3:2538:2	O
the	NULOJIX.xml:S3:2541:3	O
presence	NULOJIX.xml:S3:2545:8	O
of	NULOJIX.xml:S3:2554:2	O
IgG	NULOJIX.xml:S3:2557:3	O
antibodies	NULOJIX.xml:S3:2561:10	O
to	NULOJIX.xml:S3:2572:2	O
viral	NULOJIX.xml:S3:2575:5	O
capsid	NULOJIX.xml:S3:2581:6	O
antigen	NULOJIX.xml:S3:2588:7	O
(	NULOJIX.xml:S3:2596:1	O
VCA	NULOJIX.xml:S3:2597:3	O
)	NULOJIX.xml:S3:2600:1	O
and	NULOJIX.xml:S3:2602:3	O
EBV	NULOJIX.xml:S3:2606:3	O
nuclear	NULOJIX.xml:S3:2610:7	O
antigen	NULOJIX.xml:S3:2618:7	O
(	NULOJIX.xml:S3:2626:1	O
EBNA	NULOJIX.xml:S3:2627:4	O
)	NULOJIX.xml:S3:2631:1	O
.	NULOJIX.xml:S3:2632:1	O

Epstein	NULOJIX.xml:S3:2638:7	O
-	NULOJIX.xml:S3:2645:1	O
Barr	NULOJIX.xml:S3:2646:4	O
virus	NULOJIX.xml:S3:2651:5	O
serology	NULOJIX.xml:S3:2657:8	O
should	NULOJIX.xml:S3:2666:6	O
be	NULOJIX.xml:S3:2673:2	O
ascertained	NULOJIX.xml:S3:2676:11	O
before	NULOJIX.xml:S3:2688:6	O
starting	NULOJIX.xml:S3:2695:8	O
administration	NULOJIX.xml:S3:2704:14	O
of	NULOJIX.xml:S3:2719:2	O
NULOJIX	NULOJIX.xml:S3:2722:7	O
,	NULOJIX.xml:S3:2729:1	O
and	NULOJIX.xml:S3:2731:3	O
only	NULOJIX.xml:S3:2735:4	O
patients	NULOJIX.xml:S3:2740:8	O
who	NULOJIX.xml:S3:2749:3	O
are	NULOJIX.xml:S3:2753:3	O
EBV	NULOJIX.xml:S3:2757:3	O
seropositive	NULOJIX.xml:S3:2761:12	O
should	NULOJIX.xml:S3:2774:6	O
receive	NULOJIX.xml:S3:2781:7	O
NULOJIX	NULOJIX.xml:S3:2789:7	O
.	NULOJIX.xml:S3:2796:1	O

Transplant	NULOJIX.xml:S3:2798:10	O
recipients	NULOJIX.xml:S3:2809:10	O
who	NULOJIX.xml:S3:2820:3	O
are	NULOJIX.xml:S3:2824:3	O
EBV	NULOJIX.xml:S3:2828:3	O
seronegative	NULOJIX.xml:S3:2832:12	O
,	NULOJIX.xml:S3:2844:1	O
or	NULOJIX.xml:S3:2846:2	O
with	NULOJIX.xml:S3:2849:4	O
unknown	NULOJIX.xml:S3:2854:7	O
serostatus	NULOJIX.xml:S3:2862:10	O
,	NULOJIX.xml:S3:2872:1	O
should	NULOJIX.xml:S3:2874:6	O
not	NULOJIX.xml:S3:2881:3	O
receive	NULOJIX.xml:S3:2885:7	O
NULOJIX	NULOJIX.xml:S3:2893:7	O
[	NULOJIX.xml:S3:2901:1	O
see	NULOJIX.xml:S3:2902:3	O
Boxed	NULOJIX.xml:S3:2908:5	O
Warning	NULOJIX.xml:S3:2914:7	O
and	NULOJIX.xml:S3:2925:3	O
Contraindications	NULOJIX.xml:S3:2931:17	O
(	NULOJIX.xml:S3:2949:1	O
4	NULOJIX.xml:S3:2950:1	O
)	NULOJIX.xml:S3:2951:1	O
]	NULOJIX.xml:S3:2956:1	O
.	NULOJIX.xml:S3:2957:1	O

Other	NULOJIX.xml:S3:2966:5	O
Risk	NULOJIX.xml:S3:2972:4	O
Factors	NULOJIX.xml:S3:2977:7	O

Other	NULOJIX.xml:S3:2990:5	O
known	NULOJIX.xml:S3:2996:5	O
risk	NULOJIX.xml:S3:3002:4	O
factors	NULOJIX.xml:S3:3007:7	O
for	NULOJIX.xml:S3:3015:3	O
PTLD	NULOJIX.xml:S3:3019:4	O
include	NULOJIX.xml:S3:3024:7	O
cytomegalovirus	NULOJIX.xml:S3:3032:15	O
(	NULOJIX.xml:S3:3048:1	O
CMV	NULOJIX.xml:S3:3049:3	O
)	NULOJIX.xml:S3:3052:1	O
infection	NULOJIX.xml:S3:3054:9	O
and	NULOJIX.xml:S3:3064:3	O
T	NULOJIX.xml:S3:3068:1	O
-	NULOJIX.xml:S3:3069:1	O
cell	NULOJIX.xml:S3:3070:4	O
-	NULOJIX.xml:S3:3074:1	O
depleting	NULOJIX.xml:S3:3075:9	O
therapy	NULOJIX.xml:S3:3085:7	O
.	NULOJIX.xml:S3:3092:1	O

T	NULOJIX.xml:S3:3094:1	O
-	NULOJIX.xml:S3:3095:1	O
cell	NULOJIX.xml:S3:3096:4	O
-	NULOJIX.xml:S3:3100:1	O
depleting	NULOJIX.xml:S3:3101:9	O
therapies	NULOJIX.xml:S3:3111:9	O
to	NULOJIX.xml:S3:3121:2	O
treat	NULOJIX.xml:S3:3124:5	O
acute	NULOJIX.xml:S3:3130:5	O
rejection	NULOJIX.xml:S3:3136:9	O
should	NULOJIX.xml:S3:3146:6	O
be	NULOJIX.xml:S3:3153:2	O
used	NULOJIX.xml:S3:3156:4	O
cautiously	NULOJIX.xml:S3:3161:10	O
.	NULOJIX.xml:S3:3171:1	O

CMV	NULOJIX.xml:S3:3173:3	O
prophylaxis	NULOJIX.xml:S3:3177:11	O
is	NULOJIX.xml:S3:3189:2	O
recommended	NULOJIX.xml:S3:3192:11	O
for	NULOJIX.xml:S3:3204:3	O
at	NULOJIX.xml:S3:3208:2	O
least	NULOJIX.xml:S3:3211:5	O
3	NULOJIX.xml:S3:3217:1	O
months	NULOJIX.xml:S3:3219:6	O
after	NULOJIX.xml:S3:3226:5	O
transplantation	NULOJIX.xml:S3:3232:15	O
[	NULOJIX.xml:S3:3248:1	O
see	NULOJIX.xml:S3:3249:3	O
Warnings	NULOJIX.xml:S3:3255:8	O
and	NULOJIX.xml:S3:3264:3	O
Precautions	NULOJIX.xml:S3:3268:11	O
(	NULOJIX.xml:S3:3280:1	O
5.5	NULOJIX.xml:S3:3281:3	O
)	NULOJIX.xml:S3:3284:1	O
]	NULOJIX.xml:S3:3289:1	O
.	NULOJIX.xml:S3:3290:1	O

Patients	NULOJIX.xml:S3:3296:8	O
who	NULOJIX.xml:S3:3305:3	O
are	NULOJIX.xml:S3:3309:3	O
EBV	NULOJIX.xml:S3:3313:3	O
seropositive	NULOJIX.xml:S3:3317:12	O
and	NULOJIX.xml:S3:3330:3	O
CMV	NULOJIX.xml:S3:3334:3	O
seronegative	NULOJIX.xml:S3:3338:12	O
may	NULOJIX.xml:S3:3351:3	O
be	NULOJIX.xml:S3:3355:2	O
at	NULOJIX.xml:S3:3358:2	O
increased	NULOJIX.xml:S3:3361:9	O
risk	NULOJIX.xml:S3:3371:4	O
for	NULOJIX.xml:S3:3376:3	O
PTLD	NULOJIX.xml:S3:3380:4	O
compared	NULOJIX.xml:S3:3385:8	O
to	NULOJIX.xml:S3:3394:2	O
patients	NULOJIX.xml:S3:3397:8	O
who	NULOJIX.xml:S3:3406:3	O
are	NULOJIX.xml:S3:3410:3	O
EBV	NULOJIX.xml:S3:3414:3	O
seropositive	NULOJIX.xml:S3:3418:12	O
and	NULOJIX.xml:S3:3431:3	O
CMV	NULOJIX.xml:S3:3435:3	O
seropositive	NULOJIX.xml:S3:3439:12	O
[	NULOJIX.xml:S3:3452:1	O
see	NULOJIX.xml:S3:3453:3	O
Adverse	NULOJIX.xml:S3:3459:7	O
Reactions	NULOJIX.xml:S3:3467:9	O
(	NULOJIX.xml:S3:3477:1	O
6.1	NULOJIX.xml:S3:3478:3	O
)	NULOJIX.xml:S3:3481:1	O
]	NULOJIX.xml:S3:3486:1	O
.	NULOJIX.xml:S3:3487:1	O

Since	NULOJIX.xml:S3:3489:5	O
CMV	NULOJIX.xml:S3:3495:3	O
seronegative	NULOJIX.xml:S3:3499:12	O
patients	NULOJIX.xml:S3:3512:8	O
are	NULOJIX.xml:S3:3521:3	O
at	NULOJIX.xml:S3:3525:2	O
increased	NULOJIX.xml:S3:3528:9	O
risk	NULOJIX.xml:S3:3538:4	O
for	NULOJIX.xml:S3:3543:3	O
CMV	NULOJIX.xml:S3:3547:3	O
disease	NULOJIX.xml:S3:3551:7	O
(	NULOJIX.xml:S3:3559:1	O
a	NULOJIX.xml:S3:3560:1	O
known	NULOJIX.xml:S3:3562:5	O
risk	NULOJIX.xml:S3:3568:4	O
factor	NULOJIX.xml:S3:3573:6	O
for	NULOJIX.xml:S3:3580:3	O
PTLD	NULOJIX.xml:S3:3584:4	O
)	NULOJIX.xml:S3:3588:1	O
,	NULOJIX.xml:S3:3589:1	O
the	NULOJIX.xml:S3:3591:3	O
clinical	NULOJIX.xml:S3:3595:8	O
significance	NULOJIX.xml:S3:3604:12	O
of	NULOJIX.xml:S3:3617:2	O
CMV	NULOJIX.xml:S3:3620:3	O
serology	NULOJIX.xml:S3:3624:8	O
for	NULOJIX.xml:S3:3633:3	O
PTLD	NULOJIX.xml:S3:3637:4	O
remains	NULOJIX.xml:S3:3642:7	O
to	NULOJIX.xml:S3:3650:2	O
be	NULOJIX.xml:S3:3653:2	O
determined	NULOJIX.xml:S3:3656:10	O
;	NULOJIX.xml:S3:3666:1	O
however	NULOJIX.xml:S3:3668:7	O
,	NULOJIX.xml:S3:3675:1	O
these	NULOJIX.xml:S3:3677:5	O
findings	NULOJIX.xml:S3:3683:8	O
should	NULOJIX.xml:S3:3692:6	O
be	NULOJIX.xml:S3:3699:2	O
considered	NULOJIX.xml:S3:3702:10	O
when	NULOJIX.xml:S3:3713:4	O
prescribing	NULOJIX.xml:S3:3718:11	O
NULOJIX	NULOJIX.xml:S3:3730:7	O
.	NULOJIX.xml:S3:3737:1	O

5.2	NULOJIX.xml:S3:3746:3	O
Management	NULOJIX.xml:S3:3750:10	O
of	NULOJIX.xml:S3:3761:2	O
Immunosuppression	NULOJIX.xml:S3:3764:17	O

Only	NULOJIX.xml:S3:3787:4	O
physicians	NULOJIX.xml:S3:3792:10	O
experienced	NULOJIX.xml:S3:3803:11	O
in	NULOJIX.xml:S3:3815:2	O
management	NULOJIX.xml:S3:3818:10	O
of	NULOJIX.xml:S3:3829:2	O
systemic	NULOJIX.xml:S3:3832:8	O
immunosuppressant	NULOJIX.xml:S3:3841:17	O
therapy	NULOJIX.xml:S3:3859:7	O
in	NULOJIX.xml:S3:3867:2	O
transplantation	NULOJIX.xml:S3:3870:15	O
should	NULOJIX.xml:S3:3886:6	O
prescribe	NULOJIX.xml:S3:3893:9	O
NULOJIX	NULOJIX.xml:S3:3903:7	O
.	NULOJIX.xml:S3:3910:1	O

Patients	NULOJIX.xml:S3:3912:8	O
receiving	NULOJIX.xml:S3:3921:9	O
the	NULOJIX.xml:S3:3931:3	O
drug	NULOJIX.xml:S3:3935:4	O
should	NULOJIX.xml:S3:3940:6	O
be	NULOJIX.xml:S3:3947:2	O
managed	NULOJIX.xml:S3:3950:7	O
in	NULOJIX.xml:S3:3958:2	O
facilities	NULOJIX.xml:S3:3961:10	O
equipped	NULOJIX.xml:S3:3972:8	O
and	NULOJIX.xml:S3:3981:3	O
staffed	NULOJIX.xml:S3:3985:7	O
with	NULOJIX.xml:S3:3993:4	O
adequate	NULOJIX.xml:S3:3998:8	O
laboratory	NULOJIX.xml:S3:4007:10	O
and	NULOJIX.xml:S3:4018:3	O
supportive	NULOJIX.xml:S3:4022:10	O
medical	NULOJIX.xml:S3:4033:7	O
resources	NULOJIX.xml:S3:4041:9	O
.	NULOJIX.xml:S3:4050:1	O

The	NULOJIX.xml:S3:4052:3	O
physician	NULOJIX.xml:S3:4056:9	O
responsible	NULOJIX.xml:S3:4066:11	O
for	NULOJIX.xml:S3:4078:3	O
the	NULOJIX.xml:S3:4082:3	O
maintenance	NULOJIX.xml:S3:4086:11	O
therapy	NULOJIX.xml:S3:4098:7	O
should	NULOJIX.xml:S3:4106:6	O
have	NULOJIX.xml:S3:4113:4	O
complete	NULOJIX.xml:S3:4118:8	O
information	NULOJIX.xml:S3:4127:11	O
requisite	NULOJIX.xml:S3:4139:9	O
for	NULOJIX.xml:S3:4149:3	O
the	NULOJIX.xml:S3:4153:3	O
follow	NULOJIX.xml:S3:4157:6	O
-	NULOJIX.xml:S3:4163:1	O
up	NULOJIX.xml:S3:4164:2	O
of	NULOJIX.xml:S3:4167:2	O
the	NULOJIX.xml:S3:4170:3	O
patient	NULOJIX.xml:S3:4174:7	O
[	NULOJIX.xml:S3:4182:1	O
see	NULOJIX.xml:S3:4183:3	O
Boxed	NULOJIX.xml:S3:4189:5	O
Warning	NULOJIX.xml:S3:4195:7	O
]	NULOJIX.xml:S3:4206:1	O
.	NULOJIX.xml:S3:4207:1	O

5.3	NULOJIX.xml:S3:4216:3	O
Other	NULOJIX.xml:S3:4220:5	O
Malignancies	NULOJIX.xml:S3:4226:12	O

Patients	NULOJIX.xml:S3:4244:8	O
receiving	NULOJIX.xml:S3:4253:9	O
immunosuppressants	NULOJIX.xml:S3:4263:18	O
,	NULOJIX.xml:S3:4281:1	O
including	NULOJIX.xml:S3:4283:9	O
NULOJIX	NULOJIX.xml:S3:4293:7	O
,	NULOJIX.xml:S3:4300:1	O
are	NULOJIX.xml:S3:4302:3	O
at	NULOJIX.xml:S3:4306:2	O
increased	NULOJIX.xml:S3:4309:9	O
risk	NULOJIX.xml:S3:4319:4	O
of	NULOJIX.xml:S3:4324:2	O
developing	NULOJIX.xml:S3:4327:10	O
malignancies	NULOJIX.xml:S3:4338:12	B-AdverseReaction
,	NULOJIX.xml:S3:4350:1	O
in	NULOJIX.xml:S3:4352:2	O
addition	NULOJIX.xml:S3:4355:8	O
to	NULOJIX.xml:S3:4364:2	O
PTLD	NULOJIX.xml:S3:4367:4	B-AdverseReaction
,	NULOJIX.xml:S3:4371:1	O
including	NULOJIX.xml:S3:4373:9	O
the	NULOJIX.xml:S3:4383:3	O
skin	NULOJIX.xml:S3:4387:4	I-AdverseReaction
[	NULOJIX.xml:S3:4392:1	O
see	NULOJIX.xml:S3:4393:3	O
Boxed	NULOJIX.xml:S3:4399:5	O
Warning	NULOJIX.xml:S3:4405:7	O
and	NULOJIX.xml:S3:4416:3	O
Warnings	NULOJIX.xml:S3:4422:8	O
and	NULOJIX.xml:S3:4431:3	O
Precautions	NULOJIX.xml:S3:4435:11	O
(	NULOJIX.xml:S3:4447:1	O
5.1	NULOJIX.xml:S3:4448:3	O
)	NULOJIX.xml:S3:4451:1	O
]	NULOJIX.xml:S3:4456:1	O
.	NULOJIX.xml:S3:4457:1	O

Exposure	NULOJIX.xml:S3:4459:8	O
to	NULOJIX.xml:S3:4468:2	O
sunlight	NULOJIX.xml:S3:4471:8	O
and	NULOJIX.xml:S3:4480:3	O
ultraviolet	NULOJIX.xml:S3:4484:11	O
(	NULOJIX.xml:S3:4496:1	O
UV	NULOJIX.xml:S3:4497:2	O
)	NULOJIX.xml:S3:4499:1	O
light	NULOJIX.xml:S3:4501:5	O
should	NULOJIX.xml:S3:4507:6	O
be	NULOJIX.xml:S3:4514:2	O
limited	NULOJIX.xml:S3:4517:7	O
by	NULOJIX.xml:S3:4525:2	O
wearing	NULOJIX.xml:S3:4528:7	O
protective	NULOJIX.xml:S3:4536:10	O
clothing	NULOJIX.xml:S3:4547:8	O
and	NULOJIX.xml:S3:4556:3	O
using	NULOJIX.xml:S3:4560:5	O
a	NULOJIX.xml:S3:4566:1	O
sunscreen	NULOJIX.xml:S3:4568:9	O
with	NULOJIX.xml:S3:4578:4	O
a	NULOJIX.xml:S3:4583:1	O
high	NULOJIX.xml:S3:4585:4	O
protection	NULOJIX.xml:S3:4590:10	O
factor	NULOJIX.xml:S3:4601:6	O
.	NULOJIX.xml:S3:4607:1	O

5.4	NULOJIX.xml:S3:4616:3	O
Progressive	NULOJIX.xml:S3:4620:11	O
Multifocal	NULOJIX.xml:S3:4632:10	O
Leukoencephalopathy	NULOJIX.xml:S3:4643:19	O

Progressive	NULOJIX.xml:S3:4668:11	O
multifocal	NULOJIX.xml:S3:4680:10	O
leukoencephalopathy	NULOJIX.xml:S3:4691:19	O
(	NULOJIX.xml:S3:4711:1	O
PML	NULOJIX.xml:S3:4712:3	O
)	NULOJIX.xml:S3:4715:1	O
is	NULOJIX.xml:S3:4717:2	O
an	NULOJIX.xml:S3:4720:2	O
often	NULOJIX.xml:S3:4723:5	O
rapidly	NULOJIX.xml:S3:4729:7	O
progressive	NULOJIX.xml:S3:4737:11	O
and	NULOJIX.xml:S3:4749:3	O
fatal	NULOJIX.xml:S3:4753:5	O
opportunistic	NULOJIX.xml:S3:4759:13	O
infection	NULOJIX.xml:S3:4773:9	O
of	NULOJIX.xml:S3:4783:2	O
the	NULOJIX.xml:S3:4786:3	O
CNS	NULOJIX.xml:S3:4790:3	O
that	NULOJIX.xml:S3:4794:4	O
is	NULOJIX.xml:S3:4799:2	O
caused	NULOJIX.xml:S3:4802:6	O
by	NULOJIX.xml:S3:4809:2	O
the	NULOJIX.xml:S3:4812:3	O
JC	NULOJIX.xml:S3:4816:2	O
virus	NULOJIX.xml:S3:4819:5	O
,	NULOJIX.xml:S3:4824:1	O
a	NULOJIX.xml:S3:4826:1	O
human	NULOJIX.xml:S3:4828:5	O
polyoma	NULOJIX.xml:S3:4834:7	O
virus	NULOJIX.xml:S3:4842:5	O
.	NULOJIX.xml:S3:4847:1	O

In	NULOJIX.xml:S3:4849:2	O
clinical	NULOJIX.xml:S3:4852:8	O
trials	NULOJIX.xml:S3:4861:6	O
with	NULOJIX.xml:S3:4868:4	O
NULOJIX	NULOJIX.xml:S3:4873:7	O
,	NULOJIX.xml:S3:4880:1	O
two	NULOJIX.xml:S3:4882:3	O
cases	NULOJIX.xml:S3:4886:5	O
of	NULOJIX.xml:S3:4892:2	O
PML	NULOJIX.xml:S3:4895:3	B-AdverseReaction
were	NULOJIX.xml:S3:4899:4	O
reported	NULOJIX.xml:S3:4904:8	O
in	NULOJIX.xml:S3:4913:2	O
patients	NULOJIX.xml:S3:4916:8	O
receiving	NULOJIX.xml:S3:4925:9	O
NULOJIX	NULOJIX.xml:S3:4935:7	O
at	NULOJIX.xml:S3:4943:2	O
higher	NULOJIX.xml:S3:4946:6	O
cumulative	NULOJIX.xml:S3:4953:10	O
doses	NULOJIX.xml:S3:4964:5	O
and	NULOJIX.xml:S3:4970:3	O
more	NULOJIX.xml:S3:4974:4	O
frequently	NULOJIX.xml:S3:4979:10	O
than	NULOJIX.xml:S3:4990:4	O
the	NULOJIX.xml:S3:4995:3	O
recommended	NULOJIX.xml:S3:4999:11	O
regimen	NULOJIX.xml:S3:5011:7	O
,	NULOJIX.xml:S3:5018:1	O
along	NULOJIX.xml:S3:5020:5	O
with	NULOJIX.xml:S3:5026:4	O
mycophenolate	NULOJIX.xml:S3:5031:13	O
mofetil	NULOJIX.xml:S3:5045:7	O
(	NULOJIX.xml:S3:5053:1	O
MMF	NULOJIX.xml:S3:5054:3	O
)	NULOJIX.xml:S3:5057:1	O
and	NULOJIX.xml:S3:5059:3	O
corticosteroids	NULOJIX.xml:S3:5063:15	O
;	NULOJIX.xml:S3:5078:1	O
one	NULOJIX.xml:S3:5080:3	O
case	NULOJIX.xml:S3:5084:4	O
occurred	NULOJIX.xml:S3:5089:8	O
in	NULOJIX.xml:S3:5098:2	O
a	NULOJIX.xml:S3:5101:1	O
kidney	NULOJIX.xml:S3:5103:6	O
transplant	NULOJIX.xml:S3:5110:10	O
recipient	NULOJIX.xml:S3:5121:9	O
and	NULOJIX.xml:S3:5131:3	O
the	NULOJIX.xml:S3:5135:3	O
second	NULOJIX.xml:S3:5139:6	O
case	NULOJIX.xml:S3:5146:4	O
occurred	NULOJIX.xml:S3:5151:8	O
in	NULOJIX.xml:S3:5160:2	O
a	NULOJIX.xml:S3:5163:1	O
liver	NULOJIX.xml:S3:5165:5	O
transplant	NULOJIX.xml:S3:5171:10	O
recipient	NULOJIX.xml:S3:5182:9	O
[	NULOJIX.xml:S3:5192:1	O
see	NULOJIX.xml:S3:5193:3	O
Warnings	NULOJIX.xml:S3:5199:8	O
and	NULOJIX.xml:S3:5208:3	O
Precautions	NULOJIX.xml:S3:5212:11	O
(	NULOJIX.xml:S3:5224:1	O
5.6	NULOJIX.xml:S3:5225:3	O
)	NULOJIX.xml:S3:5228:1	O
]	NULOJIX.xml:S3:5233:1	O
.	NULOJIX.xml:S3:5234:1	O

As	NULOJIX.xml:S3:5236:2	O
PML	NULOJIX.xml:S3:5239:3	O
has	NULOJIX.xml:S3:5243:3	O
been	NULOJIX.xml:S3:5247:4	O
associated	NULOJIX.xml:S3:5252:10	O
with	NULOJIX.xml:S3:5263:4	O
high	NULOJIX.xml:S3:5268:4	O
levels	NULOJIX.xml:S3:5273:6	O
of	NULOJIX.xml:S3:5280:2	O
overall	NULOJIX.xml:S3:5283:7	O
immunosuppression	NULOJIX.xml:S3:5291:17	O
,	NULOJIX.xml:S3:5308:1	O
the	NULOJIX.xml:S3:5310:3	O
recommended	NULOJIX.xml:S3:5314:11	O
doses	NULOJIX.xml:S3:5326:5	O
and	NULOJIX.xml:S3:5332:3	O
frequency	NULOJIX.xml:S3:5336:9	O
of	NULOJIX.xml:S3:5346:2	O
NULOJIX	NULOJIX.xml:S3:5349:7	O
and	NULOJIX.xml:S3:5357:3	O
concomitant	NULOJIX.xml:S3:5361:11	O
immunosuppressives	NULOJIX.xml:S3:5373:18	O
,	NULOJIX.xml:S3:5391:1	O
including	NULOJIX.xml:S3:5393:9	O
MMF	NULOJIX.xml:S3:5403:3	O
,	NULOJIX.xml:S3:5406:1	O
should	NULOJIX.xml:S3:5408:6	O
not	NULOJIX.xml:S3:5415:3	O
be	NULOJIX.xml:S3:5419:2	O
exceeded	NULOJIX.xml:S3:5422:8	O
.	NULOJIX.xml:S3:5430:1	O

Physicians	NULOJIX.xml:S3:5436:10	O
should	NULOJIX.xml:S3:5447:6	O
consider	NULOJIX.xml:S3:5454:8	O
PML	NULOJIX.xml:S3:5463:3	O
in	NULOJIX.xml:S3:5467:2	O
the	NULOJIX.xml:S3:5470:3	O
differential	NULOJIX.xml:S3:5474:12	O
diagnosis	NULOJIX.xml:S3:5487:9	O
in	NULOJIX.xml:S3:5497:2	O
patients	NULOJIX.xml:S3:5500:8	O
with	NULOJIX.xml:S3:5509:4	O
new	NULOJIX.xml:S3:5514:3	O
or	NULOJIX.xml:S3:5518:2	O
worsening	NULOJIX.xml:S3:5521:9	O
neurological	NULOJIX.xml:S3:5531:12	O
,	NULOJIX.xml:S3:5543:1	O
cognitive	NULOJIX.xml:S3:5545:9	O
,	NULOJIX.xml:S3:5554:1	O
or	NULOJIX.xml:S3:5556:2	O
behavioral	NULOJIX.xml:S3:5559:10	O
signs	NULOJIX.xml:S3:5570:5	O
or	NULOJIX.xml:S3:5576:2	O
symptoms	NULOJIX.xml:S3:5579:8	O
.	NULOJIX.xml:S3:5587:1	O

PML	NULOJIX.xml:S3:5589:3	O
is	NULOJIX.xml:S3:5593:2	O
usually	NULOJIX.xml:S3:5596:7	O
diagnosed	NULOJIX.xml:S3:5604:9	O
by	NULOJIX.xml:S3:5614:2	O
brain	NULOJIX.xml:S3:5617:5	O
imaging	NULOJIX.xml:S3:5623:7	O
,	NULOJIX.xml:S3:5630:1	O
cerebrospinal	NULOJIX.xml:S3:5632:13	O
fluid	NULOJIX.xml:S3:5646:5	O
(	NULOJIX.xml:S3:5652:1	O
CSF	NULOJIX.xml:S3:5653:3	O
)	NULOJIX.xml:S3:5656:1	O
testing	NULOJIX.xml:S3:5658:7	O
for	NULOJIX.xml:S3:5666:3	O
JC	NULOJIX.xml:S3:5670:2	O
viral	NULOJIX.xml:S3:5673:5	O
DNA	NULOJIX.xml:S3:5679:3	O
by	NULOJIX.xml:S3:5683:2	O
polymerase	NULOJIX.xml:S3:5686:10	O
chain	NULOJIX.xml:S3:5697:5	O
reaction	NULOJIX.xml:S3:5703:8	O
(	NULOJIX.xml:S3:5712:1	O
PCR	NULOJIX.xml:S3:5713:3	O
)	NULOJIX.xml:S3:5716:1	O
,	NULOJIX.xml:S3:5717:1	O
and	NULOJIX.xml:S3:5719:3	O
or	NULOJIX.xml:S3:5723:2	O
brain	NULOJIX.xml:S3:5726:5	O
biopsy	NULOJIX.xml:S3:5732:6	O
.	NULOJIX.xml:S3:5738:1	O

Consultation	NULOJIX.xml:S3:5740:12	O
with	NULOJIX.xml:S3:5753:4	O
a	NULOJIX.xml:S3:5758:1	O
specialist	NULOJIX.xml:S3:5760:10	O
(	NULOJIX.xml:S3:5771:1	O
e	NULOJIX.xml:S3:5772:1	O
.	NULOJIX.xml:S3:5773:1	O
g	NULOJIX.xml:S3:5774:1	O
.	NULOJIX.xml:S3:5775:1	O
,	NULOJIX.xml:S3:5776:1	O
neurologist	NULOJIX.xml:S3:5778:11	O
and	NULOJIX.xml:S3:5790:3	O
or	NULOJIX.xml:S3:5794:2	O
infectious	NULOJIX.xml:S3:5797:10	O
disease	NULOJIX.xml:S3:5808:7	O
)	NULOJIX.xml:S3:5815:1	O
should	NULOJIX.xml:S3:5817:6	O
be	NULOJIX.xml:S3:5824:2	O
considered	NULOJIX.xml:S3:5827:10	O
for	NULOJIX.xml:S3:5838:3	O
any	NULOJIX.xml:S3:5842:3	O
suspected	NULOJIX.xml:S3:5846:9	O
or	NULOJIX.xml:S3:5856:2	O
confirmed	NULOJIX.xml:S3:5859:9	O
cases	NULOJIX.xml:S3:5869:5	O
of	NULOJIX.xml:S3:5875:2	O
PML	NULOJIX.xml:S3:5878:3	O
.	NULOJIX.xml:S3:5881:1	O

If	NULOJIX.xml:S3:5887:2	O
PML	NULOJIX.xml:S3:5890:3	O
is	NULOJIX.xml:S3:5894:2	O
diagnosed	NULOJIX.xml:S3:5897:9	O
,	NULOJIX.xml:S3:5906:1	O
consideration	NULOJIX.xml:S3:5908:13	O
should	NULOJIX.xml:S3:5922:6	O
be	NULOJIX.xml:S3:5929:2	O
given	NULOJIX.xml:S3:5932:5	O
to	NULOJIX.xml:S3:5938:2	O
reduction	NULOJIX.xml:S3:5941:9	O
or	NULOJIX.xml:S3:5951:2	O
withdrawal	NULOJIX.xml:S3:5954:10	O
of	NULOJIX.xml:S3:5965:2	O
immunosuppression	NULOJIX.xml:S3:5968:17	O
taking	NULOJIX.xml:S3:5986:6	O
into	NULOJIX.xml:S3:5993:4	O
account	NULOJIX.xml:S3:5998:7	O
the	NULOJIX.xml:S3:6006:3	O
risk	NULOJIX.xml:S3:6010:4	O
to	NULOJIX.xml:S3:6015:2	O
the	NULOJIX.xml:S3:6018:3	O
allograft	NULOJIX.xml:S3:6022:9	O
.	NULOJIX.xml:S3:6031:1	O

5.5	NULOJIX.xml:S3:6040:3	O
Other	NULOJIX.xml:S3:6044:5	O
Serious	NULOJIX.xml:S3:6050:7	O
Infections	NULOJIX.xml:S3:6058:10	O

Patients	NULOJIX.xml:S3:6074:8	O
receiving	NULOJIX.xml:S3:6083:9	O
immunosuppressants	NULOJIX.xml:S3:6093:18	O
,	NULOJIX.xml:S3:6111:1	O
including	NULOJIX.xml:S3:6113:9	O
NULOJIX	NULOJIX.xml:S3:6123:7	O
,	NULOJIX.xml:S3:6130:1	O
are	NULOJIX.xml:S3:6132:3	O
at	NULOJIX.xml:S3:6136:2	O
increased	NULOJIX.xml:S3:6139:9	O
risk	NULOJIX.xml:S3:6149:4	B-Factor
of	NULOJIX.xml:S3:6154:2	O
developing	NULOJIX.xml:S3:6157:10	O
bacterial	NULOJIX.xml:S3:6168:9	B-AdverseReaction
,	NULOJIX.xml:S3:6177:1	O
viral	NULOJIX.xml:S3:6179:5	B-AdverseReaction
(	NULOJIX.xml:S3:6185:1	O
cytomegalovirus	NULOJIX.xml:S3:6186:15	B-AdverseReaction
[	NULOJIX.xml:S3:6202:1	O
CMV	NULOJIX.xml:S3:6203:3	B-AdverseReaction
]	NULOJIX.xml:S3:6206:1	O
and	NULOJIX.xml:S3:6208:3	O
herpes	NULOJIX.xml:S3:6212:6	B-AdverseReaction
)	NULOJIX.xml:S3:6218:1	O
,	NULOJIX.xml:S3:6219:1	O
fungal	NULOJIX.xml:S3:6221:6	B-AdverseReaction
,	NULOJIX.xml:S3:6227:1	O
and	NULOJIX.xml:S3:6229:3	O
protozoal	NULOJIX.xml:S3:6233:9	B-AdverseReaction
infections	NULOJIX.xml:S3:6243:10	I-AdverseReaction
,	NULOJIX.xml:S3:6253:1	O
including	NULOJIX.xml:S3:6255:9	O
opportunistic	NULOJIX.xml:S3:6265:13	B-AdverseReaction
infections	NULOJIX.xml:S3:6279:10	I-AdverseReaction
.	NULOJIX.xml:S3:6289:1	O

These	NULOJIX.xml:S3:6291:5	O
infections	NULOJIX.xml:S3:6297:10	B-AdverseReaction
may	NULOJIX.xml:S3:6308:3	O
lead	NULOJIX.xml:S3:6312:4	O
to	NULOJIX.xml:S3:6317:2	O
serious	NULOJIX.xml:S3:6320:7	B-Severity
,	NULOJIX.xml:S3:6327:1	O
including	NULOJIX.xml:S3:6329:9	O
fatal	NULOJIX.xml:S3:6339:5	B-AdverseReaction
,	NULOJIX.xml:S3:6344:1	O
outcomes	NULOJIX.xml:S3:6346:8	O
[	NULOJIX.xml:S3:6355:1	O
see	NULOJIX.xml:S3:6356:3	O
Boxed	NULOJIX.xml:S3:6362:5	O
Warning	NULOJIX.xml:S3:6368:7	O
and	NULOJIX.xml:S3:6379:3	O
Adverse	NULOJIX.xml:S3:6385:7	O
Reactions	NULOJIX.xml:S3:6393:9	O
(	NULOJIX.xml:S3:6403:1	O
6.1	NULOJIX.xml:S3:6404:3	O
)	NULOJIX.xml:S3:6407:1	O
]	NULOJIX.xml:S3:6412:1	O
.	NULOJIX.xml:S3:6413:1	O

Prophylaxis	NULOJIX.xml:S3:6419:11	O
for	NULOJIX.xml:S3:6431:3	O
cytomegalovirus	NULOJIX.xml:S3:6435:15	O
is	NULOJIX.xml:S3:6451:2	O
recommended	NULOJIX.xml:S3:6454:11	O
for	NULOJIX.xml:S3:6466:3	O
at	NULOJIX.xml:S3:6470:2	O
least	NULOJIX.xml:S3:6473:5	O
3	NULOJIX.xml:S3:6479:1	O
months	NULOJIX.xml:S3:6481:6	O
after	NULOJIX.xml:S3:6488:5	O
transplantation	NULOJIX.xml:S3:6494:15	O
.	NULOJIX.xml:S3:6509:1	O

Prophylaxis	NULOJIX.xml:S3:6511:11	O
for	NULOJIX.xml:S3:6523:3	O
Pneumocystis	NULOJIX.xml:S3:6527:12	O
jiroveci	NULOJIX.xml:S3:6540:8	O
is	NULOJIX.xml:S3:6550:2	O
recommended	NULOJIX.xml:S3:6553:11	O
after	NULOJIX.xml:S3:6565:5	O
transplantation	NULOJIX.xml:S3:6571:15	O
.	NULOJIX.xml:S3:6586:1	O

Tuberculosis	NULOJIX.xml:S3:6595:12	O

Tuberculosis	NULOJIX.xml:S3:6613:12	B-AdverseReaction
was	NULOJIX.xml:S3:6626:3	O
more	NULOJIX.xml:S3:6630:4	O
frequently	NULOJIX.xml:S3:6635:10	O
observed	NULOJIX.xml:S3:6646:8	O
in	NULOJIX.xml:S3:6655:2	O
patients	NULOJIX.xml:S3:6658:8	O
receiving	NULOJIX.xml:S3:6667:9	O
NULOJIX	NULOJIX.xml:S3:6677:7	O
than	NULOJIX.xml:S3:6685:4	O
cyclosporine	NULOJIX.xml:S3:6690:12	O
in	NULOJIX.xml:S3:6703:2	O
clinical	NULOJIX.xml:S3:6706:8	O
trials	NULOJIX.xml:S3:6715:6	O
[	NULOJIX.xml:S3:6722:1	O
see	NULOJIX.xml:S3:6723:3	O
Adverse	NULOJIX.xml:S3:6729:7	O
Reactions	NULOJIX.xml:S3:6737:9	O
(	NULOJIX.xml:S3:6747:1	O
6.1	NULOJIX.xml:S3:6748:3	O
)	NULOJIX.xml:S3:6751:1	O
]	NULOJIX.xml:S3:6756:1	O
.	NULOJIX.xml:S3:6757:1	O

Patients	NULOJIX.xml:S3:6759:8	O
should	NULOJIX.xml:S3:6768:6	O
be	NULOJIX.xml:S3:6775:2	O
evaluated	NULOJIX.xml:S3:6778:9	O
for	NULOJIX.xml:S3:6788:3	O
tuberculosis	NULOJIX.xml:S3:6792:12	O
and	NULOJIX.xml:S3:6805:3	O
tested	NULOJIX.xml:S3:6809:6	O
for	NULOJIX.xml:S3:6816:3	O
latent	NULOJIX.xml:S3:6820:6	O
infection	NULOJIX.xml:S3:6827:9	O
prior	NULOJIX.xml:S3:6837:5	O
to	NULOJIX.xml:S3:6843:2	O
initiating	NULOJIX.xml:S3:6846:10	O
NULOJIX	NULOJIX.xml:S3:6857:7	O
.	NULOJIX.xml:S3:6864:1	O

Treatment	NULOJIX.xml:S3:6866:9	O
of	NULOJIX.xml:S3:6876:2	O
latent	NULOJIX.xml:S3:6879:6	O
tuberculosis	NULOJIX.xml:S3:6886:12	O
infection	NULOJIX.xml:S3:6899:9	O
should	NULOJIX.xml:S3:6909:6	O
be	NULOJIX.xml:S3:6916:2	O
initiated	NULOJIX.xml:S3:6919:9	O
prior	NULOJIX.xml:S3:6929:5	O
to	NULOJIX.xml:S3:6935:2	O
NULOJIX	NULOJIX.xml:S3:6938:7	O
use	NULOJIX.xml:S3:6946:3	O
.	NULOJIX.xml:S3:6949:1	O

Polyoma	NULOJIX.xml:S3:6958:7	O
Virus	NULOJIX.xml:S3:6966:5	O
Nephropathy	NULOJIX.xml:S3:6972:11	O

In	NULOJIX.xml:S3:6989:2	O
addition	NULOJIX.xml:S3:6992:8	O
to	NULOJIX.xml:S3:7001:2	O
cases	NULOJIX.xml:S3:7004:5	O
of	NULOJIX.xml:S3:7010:2	O
JC	NULOJIX.xml:S3:7013:2	B-AdverseReaction
virus	NULOJIX.xml:S3:7016:5	I-AdverseReaction
-	NULOJIX.xml:S3:7021:1	O
associated	NULOJIX.xml:S3:7022:10	O
PML	NULOJIX.xml:S3:7033:3	B-AdverseReaction
[	NULOJIX.xml:S3:7037:1	O
see	NULOJIX.xml:S3:7038:3	O
Warnings	NULOJIX.xml:S3:7044:8	O
and	NULOJIX.xml:S3:7053:3	O
Precautions	NULOJIX.xml:S3:7057:11	O
(	NULOJIX.xml:S3:7069:1	O
5.4	NULOJIX.xml:S3:7070:3	O
)	NULOJIX.xml:S3:7073:1	O
]	NULOJIX.xml:S3:7078:1	O
,	NULOJIX.xml:S3:7079:1	O
cases	NULOJIX.xml:S3:7081:5	O
of	NULOJIX.xml:S3:7087:2	O
polyoma	NULOJIX.xml:S3:7090:7	B-AdverseReaction
virus	NULOJIX.xml:S3:7098:5	I-AdverseReaction
-	NULOJIX.xml:S3:7103:1	I-AdverseReaction
associated	NULOJIX.xml:S3:7104:10	I-AdverseReaction
nephropathy	NULOJIX.xml:S3:7115:11	I-AdverseReaction
(	NULOJIX.xml:S3:7127:1	O
PVAN	NULOJIX.xml:S3:7128:4	B-AdverseReaction
)	NULOJIX.xml:S3:7132:1	O
,	NULOJIX.xml:S3:7133:1	O
mostly	NULOJIX.xml:S3:7135:6	O
due	NULOJIX.xml:S3:7142:3	O
to	NULOJIX.xml:S3:7146:2	O
BK	NULOJIX.xml:S3:7149:2	B-AdverseReaction
virus	NULOJIX.xml:S3:7152:5	I-AdverseReaction
infection	NULOJIX.xml:S3:7158:9	I-AdverseReaction
,	NULOJIX.xml:S3:7167:1	O
have	NULOJIX.xml:S3:7169:4	O
been	NULOJIX.xml:S3:7174:4	O
reported	NULOJIX.xml:S3:7179:8	O
.	NULOJIX.xml:S3:7187:1	O

PVAN	NULOJIX.xml:S3:7189:4	B-AdverseReaction
is	NULOJIX.xml:S3:7194:2	O
associated	NULOJIX.xml:S3:7197:10	O
with	NULOJIX.xml:S3:7208:4	O
serious	NULOJIX.xml:S3:7213:7	O
outcomes	NULOJIX.xml:S3:7221:8	O
;	NULOJIX.xml:S3:7229:1	O
including	NULOJIX.xml:S3:7231:9	O
deteriorating	NULOJIX.xml:S3:7241:13	B-AdverseReaction
renal	NULOJIX.xml:S3:7255:5	I-AdverseReaction
function	NULOJIX.xml:S3:7261:8	I-AdverseReaction
and	NULOJIX.xml:S3:7270:3	O
kidney	NULOJIX.xml:S3:7274:6	B-AdverseReaction
graft	NULOJIX.xml:S3:7281:5	I-AdverseReaction
loss	NULOJIX.xml:S3:7287:4	I-AdverseReaction
[	NULOJIX.xml:S3:7292:1	O
see	NULOJIX.xml:S3:7293:3	O
Adverse	NULOJIX.xml:S3:7299:7	O
Reactions	NULOJIX.xml:S3:7307:9	O
(	NULOJIX.xml:S3:7317:1	O
6.1	NULOJIX.xml:S3:7318:3	O
)	NULOJIX.xml:S3:7321:1	O
]	NULOJIX.xml:S3:7326:1	O
.	NULOJIX.xml:S3:7327:1	O

Patient	NULOJIX.xml:S3:7329:7	O
monitoring	NULOJIX.xml:S3:7337:10	O
may	NULOJIX.xml:S3:7348:3	O
help	NULOJIX.xml:S3:7352:4	O
detect	NULOJIX.xml:S3:7357:6	O
patients	NULOJIX.xml:S3:7364:8	O
at	NULOJIX.xml:S3:7373:2	O
risk	NULOJIX.xml:S3:7376:4	O
for	NULOJIX.xml:S3:7381:3	O
PVAN	NULOJIX.xml:S3:7385:4	O
.	NULOJIX.xml:S3:7389:1	O

Reductions	NULOJIX.xml:S3:7391:10	O
in	NULOJIX.xml:S3:7402:2	O
immunosuppression	NULOJIX.xml:S3:7405:17	O
should	NULOJIX.xml:S3:7423:6	O
be	NULOJIX.xml:S3:7430:2	O
considered	NULOJIX.xml:S3:7433:10	O
for	NULOJIX.xml:S3:7444:3	O
patients	NULOJIX.xml:S3:7448:8	O
who	NULOJIX.xml:S3:7457:3	O
develop	NULOJIX.xml:S3:7461:7	O
evidence	NULOJIX.xml:S3:7469:8	O
of	NULOJIX.xml:S3:7478:2	O
PVAN	NULOJIX.xml:S3:7481:4	O
.	NULOJIX.xml:S3:7485:1	O

Physicians	NULOJIX.xml:S3:7487:10	O
should	NULOJIX.xml:S3:7498:6	O
also	NULOJIX.xml:S3:7505:4	O
consider	NULOJIX.xml:S3:7510:8	O
the	NULOJIX.xml:S3:7519:3	O
risk	NULOJIX.xml:S3:7523:4	O
that	NULOJIX.xml:S3:7528:4	O
reduced	NULOJIX.xml:S3:7533:7	O
immunosuppression	NULOJIX.xml:S3:7541:17	O
represents	NULOJIX.xml:S3:7559:10	O
to	NULOJIX.xml:S3:7570:2	O
the	NULOJIX.xml:S3:7573:3	O
functioning	NULOJIX.xml:S3:7577:11	O
allograft	NULOJIX.xml:S3:7589:9	O
.	NULOJIX.xml:S3:7598:1	O

5.6	NULOJIX.xml:S3:7607:3	O
Liver	NULOJIX.xml:S3:7611:5	O
Transplant	NULOJIX.xml:S3:7617:10	O

Use	NULOJIX.xml:S3:7633:3	O
of	NULOJIX.xml:S3:7637:2	O
NULOJIX	NULOJIX.xml:S3:7640:7	O
in	NULOJIX.xml:S3:7648:2	O
liver	NULOJIX.xml:S3:7651:5	O
transplant	NULOJIX.xml:S3:7657:10	O
patients	NULOJIX.xml:S3:7668:8	O
is	NULOJIX.xml:S3:7677:2	O
not	NULOJIX.xml:S3:7680:3	O
recommended	NULOJIX.xml:S3:7684:11	O
[	NULOJIX.xml:S3:7696:1	O
see	NULOJIX.xml:S3:7697:3	O
Boxed	NULOJIX.xml:S3:7703:5	O
Warning	NULOJIX.xml:S3:7709:7	O
]	NULOJIX.xml:S3:7720:1	O
.	NULOJIX.xml:S3:7721:1	O

In	NULOJIX.xml:S3:7723:2	O
a	NULOJIX.xml:S3:7726:1	O
clinical	NULOJIX.xml:S3:7728:8	O
trial	NULOJIX.xml:S3:7737:5	O
of	NULOJIX.xml:S3:7743:2	O
liver	NULOJIX.xml:S3:7746:5	O
transplant	NULOJIX.xml:S3:7752:10	O
patients	NULOJIX.xml:S3:7763:8	O
,	NULOJIX.xml:S3:7771:1	O
use	NULOJIX.xml:S3:7773:3	O
of	NULOJIX.xml:S3:7777:2	O
NULOJIX	NULOJIX.xml:S3:7780:7	O
regimens	NULOJIX.xml:S3:7788:8	O
with	NULOJIX.xml:S3:7797:4	O
more	NULOJIX.xml:S3:7802:4	O
frequent	NULOJIX.xml:S3:7807:8	O
administration	NULOJIX.xml:S3:7816:14	O
of	NULOJIX.xml:S3:7831:2	O
belatacept	NULOJIX.xml:S3:7834:10	O
than	NULOJIX.xml:S3:7845:4	O
any	NULOJIX.xml:S3:7850:3	O
of	NULOJIX.xml:S3:7854:2	O
those	NULOJIX.xml:S3:7857:5	O
studied	NULOJIX.xml:S3:7863:7	O
in	NULOJIX.xml:S3:7871:2	O
kidney	NULOJIX.xml:S3:7874:6	O
transplant	NULOJIX.xml:S3:7881:10	O
,	NULOJIX.xml:S3:7891:1	O
along	NULOJIX.xml:S3:7893:5	O
with	NULOJIX.xml:S3:7899:4	O
mycophenolate	NULOJIX.xml:S3:7904:13	O
mofetil	NULOJIX.xml:S3:7918:7	O
(	NULOJIX.xml:S3:7926:1	O
MMF	NULOJIX.xml:S3:7927:3	O
)	NULOJIX.xml:S3:7930:1	O
and	NULOJIX.xml:S3:7932:3	O
corticosteroids	NULOJIX.xml:S3:7936:15	O
,	NULOJIX.xml:S3:7951:1	O
was	NULOJIX.xml:S3:7953:3	O
associated	NULOJIX.xml:S3:7957:10	O
with	NULOJIX.xml:S3:7968:4	O
a	NULOJIX.xml:S3:7973:1	O
higher	NULOJIX.xml:S3:7975:6	O
rate	NULOJIX.xml:S3:7982:4	O
of	NULOJIX.xml:S3:7987:2	O
graft	NULOJIX.xml:S3:7990:5	B-AdverseReaction
loss	NULOJIX.xml:S3:7996:4	I-AdverseReaction
and	NULOJIX.xml:S3:8001:3	O
death	NULOJIX.xml:S3:8005:5	B-AdverseReaction
compared	NULOJIX.xml:S3:8011:8	O
to	NULOJIX.xml:S3:8020:2	O
the	NULOJIX.xml:S3:8023:3	O
tacrolimus	NULOJIX.xml:S3:8027:10	O
control	NULOJIX.xml:S3:8038:7	O
arms	NULOJIX.xml:S3:8046:4	O
.	NULOJIX.xml:S3:8050:1	O

In	NULOJIX.xml:S3:8052:2	O
addition	NULOJIX.xml:S3:8055:8	O
,	NULOJIX.xml:S3:8063:1	O
two	NULOJIX.xml:S3:8065:3	O
cases	NULOJIX.xml:S3:8069:5	O
of	NULOJIX.xml:S3:8075:2	O
PTLD	NULOJIX.xml:S3:8078:4	B-AdverseReaction
involving	NULOJIX.xml:S3:8083:9	O
the	NULOJIX.xml:S3:8093:3	O
liver	NULOJIX.xml:S3:8097:5	O
allograft	NULOJIX.xml:S3:8103:9	O
(	NULOJIX.xml:S3:8113:1	O
one	NULOJIX.xml:S3:8114:3	O
fatal	NULOJIX.xml:S3:8118:5	B-AdverseReaction
)	NULOJIX.xml:S3:8123:1	O
and	NULOJIX.xml:S3:8125:3	O
one	NULOJIX.xml:S3:8129:3	O
fatal	NULOJIX.xml:S3:8133:5	B-AdverseReaction
case	NULOJIX.xml:S3:8139:4	O
of	NULOJIX.xml:S3:8144:2	O
PML	NULOJIX.xml:S3:8147:3	B-AdverseReaction
were	NULOJIX.xml:S3:8151:4	O
observed	NULOJIX.xml:S3:8156:8	O
among	NULOJIX.xml:S3:8165:5	O
the	NULOJIX.xml:S3:8171:3	O
147	NULOJIX.xml:S3:8175:3	O
patients	NULOJIX.xml:S3:8179:8	O
randomized	NULOJIX.xml:S3:8188:10	O
to	NULOJIX.xml:S3:8199:2	O
NULOJIX	NULOJIX.xml:S3:8202:7	O
.	NULOJIX.xml:S3:8209:1	O

The	NULOJIX.xml:S3:8211:3	O
two	NULOJIX.xml:S3:8215:3	O
cases	NULOJIX.xml:S3:8219:5	O
of	NULOJIX.xml:S3:8225:2	O
PTLD	NULOJIX.xml:S3:8228:4	B-AdverseReaction
were	NULOJIX.xml:S3:8233:4	O
reported	NULOJIX.xml:S3:8238:8	O
among	NULOJIX.xml:S3:8247:5	O
the	NULOJIX.xml:S3:8253:3	O
140	NULOJIX.xml:S3:8257:3	O
EBV	NULOJIX.xml:S3:8261:3	O
seropositive	NULOJIX.xml:S3:8265:12	O
patients	NULOJIX.xml:S3:8278:8	O
(	NULOJIX.xml:S3:8287:1	O
1.4%	NULOJIX.xml:S3:8288:4	O
)	NULOJIX.xml:S3:8292:1	O
.	NULOJIX.xml:S3:8293:1	O

The	NULOJIX.xml:S3:8295:3	O
fatal	NULOJIX.xml:S3:8299:5	B-AdverseReaction
case	NULOJIX.xml:S3:8305:4	O
of	NULOJIX.xml:S3:8310:2	O
PML	NULOJIX.xml:S3:8313:3	B-AdverseReaction
was	NULOJIX.xml:S3:8317:3	O
reported	NULOJIX.xml:S3:8321:8	O
in	NULOJIX.xml:S3:8330:2	O
a	NULOJIX.xml:S3:8333:1	O
patient	NULOJIX.xml:S3:8335:7	O
receiving	NULOJIX.xml:S3:8343:9	O
higher	NULOJIX.xml:S3:8353:6	O
than	NULOJIX.xml:S3:8360:4	O
recommended	NULOJIX.xml:S3:8365:11	O
doses	NULOJIX.xml:S3:8377:5	O
of	NULOJIX.xml:S3:8383:2	O
NULOJIX	NULOJIX.xml:S3:8386:7	O
and	NULOJIX.xml:S3:8394:3	O
MMF	NULOJIX.xml:S3:8398:3	O
[	NULOJIX.xml:S3:8402:1	O
see	NULOJIX.xml:S3:8403:3	O
Warnings	NULOJIX.xml:S3:8409:8	O
and	NULOJIX.xml:S3:8418:3	O
Precautions	NULOJIX.xml:S3:8422:11	O
(	NULOJIX.xml:S3:8434:1	O
5.4	NULOJIX.xml:S3:8435:3	O
)	NULOJIX.xml:S3:8438:1	O
]	NULOJIX.xml:S3:8443:1	O
.	NULOJIX.xml:S3:8444:1	O

5.7	NULOJIX.xml:S3:8453:3	O
Acute	NULOJIX.xml:S3:8457:5	O
Rejection	NULOJIX.xml:S3:8463:9	O
and	NULOJIX.xml:S3:8473:3	O
Graft	NULOJIX.xml:S3:8477:5	B-AdverseReaction
Loss	NULOJIX.xml:S3:8483:4	O
with	NULOJIX.xml:S3:8488:4	O
Corticosteroid	NULOJIX.xml:S3:8493:14	O
Minimization	NULOJIX.xml:S3:8508:12	O

In	NULOJIX.xml:S3:8526:2	O
postmarketing	NULOJIX.xml:S3:8529:13	O
experience	NULOJIX.xml:S3:8543:10	O
,	NULOJIX.xml:S3:8553:1	O
use	NULOJIX.xml:S3:8555:3	O
of	NULOJIX.xml:S3:8559:2	O
NULOJIX	NULOJIX.xml:S3:8562:7	O
in	NULOJIX.xml:S3:8570:2	O
conjunction	NULOJIX.xml:S3:8573:11	O
with	NULOJIX.xml:S3:8585:4	O
basiliximab	NULOJIX.xml:S3:8590:11	O
induction	NULOJIX.xml:S3:8602:9	O
,	NULOJIX.xml:S3:8611:1	O
MMF	NULOJIX.xml:S3:8613:3	O
,	NULOJIX.xml:S3:8616:1	O
and	NULOJIX.xml:S3:8618:3	O
corticosteroid	NULOJIX.xml:S3:8622:14	O
minimization	NULOJIX.xml:S3:8637:12	O
to	NULOJIX.xml:S3:8650:2	O
5	NULOJIX.xml:S3:8653:1	O
mg	NULOJIX.xml:S3:8655:2	O
per	NULOJIX.xml:S3:8658:3	O
day	NULOJIX.xml:S3:8662:3	O
between	NULOJIX.xml:S3:8666:7	O
Day	NULOJIX.xml:S3:8674:3	O
3	NULOJIX.xml:S3:8678:1	O
and	NULOJIX.xml:S3:8680:3	O
Week	NULOJIX.xml:S3:8684:4	O
6	NULOJIX.xml:S3:8689:1	O
post	NULOJIX.xml:S3:8691:4	B-AdverseReaction
-	NULOJIX.xml:S3:8695:1	I-AdverseReaction
transplant	NULOJIX.xml:S3:8696:10	I-AdverseReaction
was	NULOJIX.xml:S3:8707:3	O
associated	NULOJIX.xml:S3:8711:10	O
with	NULOJIX.xml:S3:8722:4	O
an	NULOJIX.xml:S3:8727:2	O
increased	NULOJIX.xml:S3:8730:9	O
rate	NULOJIX.xml:S3:8740:4	O
and	NULOJIX.xml:S3:8745:3	O
grade	NULOJIX.xml:S3:8749:5	O
of	NULOJIX.xml:S3:8755:2	O
acute	NULOJIX.xml:S3:8758:5	I-AdverseReaction
rejection	NULOJIX.xml:S3:8764:9	I-AdverseReaction
,	NULOJIX.xml:S3:8773:1	O
particularly	NULOJIX.xml:S3:8775:12	O
Grade	NULOJIX.xml:S3:8788:5	B-Severity
III	NULOJIX.xml:S3:8794:3	I-Severity
rejection	NULOJIX.xml:S3:8798:9	O
.	NULOJIX.xml:S3:8807:1	O

These	NULOJIX.xml:S3:8809:5	O
Grade	NULOJIX.xml:S3:8815:5	B-Severity
III	NULOJIX.xml:S3:8821:3	I-Severity
rejections	NULOJIX.xml:S3:8825:10	I-AdverseReaction
occurred	NULOJIX.xml:S3:8836:8	O
in	NULOJIX.xml:S3:8845:2	O
patients	NULOJIX.xml:S3:8848:8	O
with	NULOJIX.xml:S3:8857:4	O
4	NULOJIX.xml:S3:8862:1	O
to	NULOJIX.xml:S3:8864:2	O
6	NULOJIX.xml:S3:8867:1	O
HLA	NULOJIX.xml:S3:8869:3	O
mismatches	NULOJIX.xml:S3:8873:10	O
.	NULOJIX.xml:S3:8883:1	O

Graft	NULOJIX.xml:S3:8885:5	B-AdverseReaction
loss	NULOJIX.xml:S3:8891:4	I-AdverseReaction
was	NULOJIX.xml:S3:8896:3	O
a	NULOJIX.xml:S3:8900:1	O
consequence	NULOJIX.xml:S3:8902:11	O
of	NULOJIX.xml:S3:8914:2	O
Grade	NULOJIX.xml:S3:8917:5	B-Severity
III	NULOJIX.xml:S3:8923:3	I-Severity
rejection	NULOJIX.xml:S3:8927:9	I-AdverseReaction
in	NULOJIX.xml:S3:8937:2	O
some	NULOJIX.xml:S3:8940:4	O
patients	NULOJIX.xml:S3:8945:8	O
.	NULOJIX.xml:S3:8953:1	O

Corticosteroid	NULOJIX.xml:S3:8959:14	O
utilization	NULOJIX.xml:S3:8974:11	O
should	NULOJIX.xml:S3:8986:6	O
be	NULOJIX.xml:S3:8993:2	O
consistent	NULOJIX.xml:S3:8996:10	O
with	NULOJIX.xml:S3:9007:4	O
the	NULOJIX.xml:S3:9012:3	O
NULOJIX	NULOJIX.xml:S3:9016:7	O
clinical	NULOJIX.xml:S3:9024:8	O
trial	NULOJIX.xml:S3:9033:5	O
experience	NULOJIX.xml:S3:9039:10	O
[	NULOJIX.xml:S3:9050:1	O
see	NULOJIX.xml:S3:9051:3	O
Dosage	NULOJIX.xml:S3:9057:6	O
and	NULOJIX.xml:S3:9064:3	O
Administration	NULOJIX.xml:S3:9068:14	O
(	NULOJIX.xml:S3:9083:1	O
2.1	NULOJIX.xml:S3:9084:3	O
)	NULOJIX.xml:S3:9087:1	O
and	NULOJIX.xml:S3:9092:3	O
Clinical	NULOJIX.xml:S3:9098:8	O
Studies	NULOJIX.xml:S3:9107:7	O
(	NULOJIX.xml:S3:9115:1	O
14.1	NULOJIX.xml:S3:9116:4	O
)	NULOJIX.xml:S3:9120:1	O
]	NULOJIX.xml:S3:9125:1	O
.	NULOJIX.xml:S3:9126:1	O

5.8	NULOJIX.xml:S3:9135:3	O
Immunizations	NULOJIX.xml:S3:9139:13	O

The	NULOJIX.xml:S3:9158:3	O
use	NULOJIX.xml:S3:9162:3	O
of	NULOJIX.xml:S3:9166:2	O
live	NULOJIX.xml:S3:9169:4	O
vaccines	NULOJIX.xml:S3:9174:8	O
should	NULOJIX.xml:S3:9183:6	O
be	NULOJIX.xml:S3:9190:2	O
avoided	NULOJIX.xml:S3:9193:7	O
during	NULOJIX.xml:S3:9201:6	O
treatment	NULOJIX.xml:S3:9208:9	O
with	NULOJIX.xml:S3:9218:4	O
NULOJIX	NULOJIX.xml:S3:9223:7	O
,	NULOJIX.xml:S3:9230:1	O
including	NULOJIX.xml:S3:9232:9	O
but	NULOJIX.xml:S3:9242:3	O
not	NULOJIX.xml:S3:9246:3	O
limited	NULOJIX.xml:S3:9250:7	O
to	NULOJIX.xml:S3:9258:2	O
the	NULOJIX.xml:S3:9261:3	O
following	NULOJIX.xml:S3:9265:9	O
:	NULOJIX.xml:S3:9274:1	O
intranasal	NULOJIX.xml:S3:9276:10	O
influenza	NULOJIX.xml:S3:9287:9	O
,	NULOJIX.xml:S3:9296:1	O
measles	NULOJIX.xml:S3:9298:7	O
,	NULOJIX.xml:S3:9305:1	O
mumps	NULOJIX.xml:S3:9307:5	O
,	NULOJIX.xml:S3:9312:1	O
rubella	NULOJIX.xml:S3:9314:7	O
,	NULOJIX.xml:S3:9321:1	O
oral	NULOJIX.xml:S3:9323:4	O
polio	NULOJIX.xml:S3:9328:5	O
,	NULOJIX.xml:S3:9333:1	O
BCG	NULOJIX.xml:S3:9335:3	O
,	NULOJIX.xml:S3:9338:1	O
yellow	NULOJIX.xml:S3:9340:6	O
fever	NULOJIX.xml:S3:9347:5	O
,	NULOJIX.xml:S3:9352:1	O
varicella	NULOJIX.xml:S3:9354:9	O
,	NULOJIX.xml:S3:9363:1	O
and	NULOJIX.xml:S3:9365:3	O
TY21a	NULOJIX.xml:S3:9369:5	O
typhoid	NULOJIX.xml:S3:9375:7	O
vaccines	NULOJIX.xml:S3:9383:8	O
.	NULOJIX.xml:S3:9391:1	O
